Current awareness: Pharmacoepidemiology and drug safety
Identifieur interne : 002792 ( Istex/Corpus ); précédent : 002791; suivant : 002793Current awareness: Pharmacoepidemiology and drug safety
Auteurs :Source :
- Pharmacoepidemiology and Drug Safety [ 1053-8569 ] ; 2008-04.
Abstract
In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 20 sections: 1 Reviews; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.
Url:
DOI: 10.1002/pds.1485
Links to Exploration step
ISTEX:EC2952E26CD15CA219654F0C5AB72A0C4E7223DDLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Current awareness: Pharmacoepidemiology and drug safety</title></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:EC2952E26CD15CA219654F0C5AB72A0C4E7223DD</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1002/pds.1485</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-M51NF9R3-6/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">002792</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002792</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Current awareness: Pharmacoepidemiology and drug safety</title></analytic><monogr></monogr><series><title level="j" type="main">Pharmacoepidemiology and Drug Safety</title><title level="j" type="alt">PHARMACOEPIDEMIOLOGY AND DRUG SAFETY</title><idno type="ISSN">1053-8569</idno><idno type="eISSN">1099-1557</idno><imprint><biblScope unit="vol">17</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="i">i</biblScope><biblScope unit="page" to="xvi">xvi</biblScope><biblScope unit="page-count">16</biblScope><publisher>John Wiley & Sons, Ltd.</publisher><pubPlace>Chichester, UK</pubPlace><date type="published" when="2008-04">2008-04</date></imprint><idno type="ISSN">1053-8569</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1053-8569</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 20 sections: 1 Reviews; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.</div></front></TEI><istex><corpusName>wiley</corpusName><keywords><teeft><json:string>univ</json:string><json:string>clin</json:string><json:string>hosp</json:string><json:string>pharmacoepidemiol</json:string><json:string>pharmacoepidemiol drug</json:string><json:string>pharmacol</json:string><json:string>dermatol</json:string><json:string>pharmacoepidemiology</json:string><json:string>inst</json:string><json:string>oncol</json:string><json:string>serv</json:string><json:string>drug safety</json:string><json:string>neurol</json:string><json:string>ophthalmol</json:string><json:string>hlth</json:string><json:string>pharm</json:string><json:string>psychiat</json:string><json:string>gastroenterol</json:string><json:string>allergy</json:string><json:string>john wiley son</json:string><json:string>clin pharmacol</json:string><json:string>nephrol</json:string><json:string>dept</json:string><json:string>suppl</json:string><json:string>copyright</json:string><json:string>current awareness</json:string><json:string>dept dermatol</json:string><json:string>acad</json:string><json:string>curr</json:string><json:string>cardiol</json:string><json:string>english abstract</json:string><json:string>toxicity</json:string><json:string>clin psychiatry</json:string><json:string>surg</json:string><json:string>immunol</json:string><json:string>rheumatol</json:string><json:string>opin</json:string><json:string>randomized</json:string><json:string>singapore</json:string><json:string>canc</json:string><json:string>antipsychotic</json:string><json:string>pharmacotherapy</json:string><json:string>hematol</json:string><json:string>epidemiol</json:string><json:string>antidepressant</json:string><json:string>coll</json:string><json:string>toxicol</json:string><json:string>hepatol</json:string><json:string>rheumatology</json:string><json:string>endocrinol</json:string><json:string>pediatr</json:string><json:string>gynecol</json:string><json:string>nephropathy</json:string><json:string>childrens</json:string><json:string>acta</json:string><json:string>pharmacother</json:string><json:string>case report</json:string><json:string>vaccine</json:string><json:string>groningen</json:string><json:string>dept psychiat</json:string><json:string>tolerability</json:string><json:string>emerg</json:string><json:string>dept ophthalmol</json:string><json:string>pract</json:string><json:string>interferon</json:string><json:string>cardiovasc</json:string><json:string>acad dermatol venereol</json:string><json:string>venereol</json:string><json:string>obstet</json:string><json:string>assoc</json:string><json:string>hypersensitivity</json:string><json:string>adverse drug reaction</json:string><json:string>clin espan</json:string><json:string>dept rheumatol</json:string><json:string>adverse effect</json:string><json:string>dept neurol</json:string><json:string>nephrol dial transplant</json:string><json:string>syndrome</json:string><json:string>psychiatry</json:string><json:string>breast cancer</json:string><json:string>monatsschr kinderheilk</json:string><json:string>clinical practice</json:string><json:string>univ hosp</json:string><json:string>clin oncol</json:string><json:string>clin pract</json:string><json:string>renal</json:string><json:string>inhibitor</json:string><json:string>cardiovascular</json:string><json:string>side effect</json:string><json:string>systematic review</json:string><json:string>dept internal</json:string><json:string>dept pharm</json:string><json:string>coronary heart disease</json:string><json:string>dept nephrol</json:string><json:string>adverse event</json:string><json:string>curr opin allergy clin immunol</json:string><json:string>holcombe blvd</json:string><json:string>dept cardiol</json:string><json:string>cardiovasc toxicol</json:string><json:string>chronic hepatitis</json:string><json:string>cardiac</json:string><json:string>atypical</json:string><json:string>acta ophthalmol scand</json:string><json:string>antimicrob agent chemother</json:string><json:string>adverse reaction</json:string><json:string>risk factor</json:string><json:string>multiple myeloma</json:string><json:string>clin electrophysiol</json:string><json:string>dept clin pharmacol</json:string><json:string>dept gastroenterol</json:string><json:string>dept emergency</json:string><json:string>bipolar disorder</json:string><json:string>pegylated interferon</json:string><json:string>aliment pharmacol</json:string><json:string>gastroenterol hepatol</json:string><json:string>washington univ</json:string><json:string>dept pediat</json:string><json:string>brit columbia</json:string><json:string>arch pediatr</json:string><json:string>pain symptom</json:string><json:string>dept psychiat behav</json:string><json:string>dept pharmacol</json:string><json:string>clin breast cancer</json:string><json:string>univ palermo</json:string><json:string>anesth reanim</json:string><json:string>atypical antipsychotic</json:string><json:string>postmenopausal woman</json:string><json:string>blvd hopital</json:string><json:string>diabetic patient</json:string><json:string>emory univ</json:string><json:string>stanford univ</json:string><json:string>congenital malformation</json:string><json:string>overactive bladder syndrome</json:string><json:string>sulfonylurea therapy</json:string><json:string>ontario</json:string><json:string>cedar sinai</json:string><json:string>bull acad natl</json:string><json:string>cornell univ</json:string><json:string>london wc1n</json:string><json:string>anthracycline cardiotoxicity</json:string><json:string>membranous nephropathy</json:string><json:string>drug interaction</json:string><json:string>coll pharm</json:string><json:string>univ maryland</json:string><json:string>allergy asthma immunol</json:string><json:string>dept pathol</json:string><json:string>atypical neuroleptic</json:string><json:string>coronary heart disease outcome</json:string><json:string>healthy volunteer</json:string><json:string>antidiabetic agent</json:string><json:string>erasmus univ</json:string><json:string>clin trial</json:string><json:string>siriraj hosp</json:string><json:string>adverse drug event</json:string><json:string>interferon treatment</json:string><json:string>magn reson imaging</json:string><json:string>inst clin pharmacol</json:string><json:string>serv dermatol</json:string><json:string>slone epidemiol</json:string><json:string>dermatological agent</json:string><json:string>univ bonn</json:string><json:string>sigmund freud</json:string><json:string>ajou univ</json:string><json:string>wonchon dong</json:string><json:string>renal safety</json:string><json:string>clin drug</json:string><json:string>antidepressant treatment</json:string><json:string>diabetes obes metab</json:string><json:string>metastatic breast cancer</json:string><json:string>high incidence</json:string><json:string>boston univ</json:string><json:string>blood pressure</json:string><json:string>pulmonary hypertension</json:string><json:string>univ munich</json:string><json:string>yale univ</json:string><json:string>movement disorder unit</json:string><json:string>congestive heart failure</json:string><json:string>kaiser permanente</json:string><json:string>cutaneous vasculitis</json:string><json:string>hyperammonemic encephalopathy</json:string><json:string>safety study</json:string><json:string>important source</json:string><json:string>arch allergy immunol</json:string><json:string>silver spring</json:string><json:string>acta gastroenterol belg</json:string><json:string>neurol neurosurg psychiatry</json:string><json:string>pilot study</json:string><json:string>emergency department</json:string><json:string>royal victoria hosp</json:string><json:string>curr pharm</json:string><json:string>univ otago</json:string><json:string>loma linda univ</json:string><json:string>loma linda</json:string><json:string>antiretroviral regimen</json:string><json:string>laar mafj</json:string><json:string>vrije univ amsterdam</json:string><json:string>hydroxychloroquine dosage</json:string><json:string>lean body mass</json:string><json:string>arch ophthalmol</json:string><json:string>graefes arch clin</json:string><json:string>univ pittsburgh</json:string><json:string>cataract refract surg</json:string><json:string>aspirin withdrawal</json:string><json:string>invasive procedure</json:string><json:string>nonsteroidal drug</json:string><json:string>clin gastroenterol hepatol</json:string><json:string>pharmacovigilance informat medicament</json:string><json:string>tardive dyskinesia</json:string><json:string>psychopharmacol clin</json:string><json:string>chronic insomnia</json:string><json:string>neuroleptic malignant syndrome</json:string><json:string>clin neuropharmacol</json:string><json:string>crossover study</json:string><json:string>blockley hall</json:string><json:string>clin epidemiol</json:string><json:string>cholinesterase inhibitor</json:string><json:string>antipsychotic medication</json:string><json:string>rheumatoid arthritis</json:string><json:string>royal london hosp</json:string><json:string>charite univ</json:string><json:string>selective serotonin reuptake inhibitor</json:string><json:string>blvd tonnelle</json:string><json:string>metabolic syndrome</json:string><json:string>antipsychotic drug</json:string><json:string>univ messina</json:string><json:string>tumour necrosis factor</json:string><json:string>mclean hosp</json:string><json:string>univ arkansas</json:string><json:string>aromatase inhibitor</json:string><json:string>hematol oncol clin</json:string><json:string>trivalent meningococcal polysaccharide vaccine</json:string><json:string>hosp ramon</json:string><json:string>univ texas</json:string><json:string>dept leukemia</json:string><json:string>renal function</json:string><json:string>focal segmental glomerulosclerosis</json:string><json:string>intrathecal liposomal cytarabine</json:string><json:string>pediatr blood cancer</json:string><json:string>wilford hall usaf</json:string><json:string>little rock</json:string><json:string>cardiac safety</json:string><json:string>dept anesthesiol</json:string><json:string>masseter spasm</json:string><json:string>succinylcholine administration</json:string><json:string>oral contraceptive pill</json:string><json:string>univ aberdeen</json:string><json:string>inflammatory bowel disease</json:string><json:string>inflamm bowel</json:string><json:string>obstet gynecol reprod biol</json:string><json:string>health solution</json:string><json:string>triangle park</json:string><json:string>renal insufficiency</json:string><json:string>contrast medium administration trial</json:string><json:string>randomized comparison</json:string><json:string>preventive strategy</json:string><json:string>childrens hosp</json:string><json:string>elderly patient</json:string><json:string>acute myocardial infarction</json:string><json:string>incretin therapy</json:string><json:string>safety risk</json:string><json:string>contrast agent</json:string><json:string>dept microbiol</json:string></teeft></keywords><articleId><json:string>PDS1485</json:string></articleId><arkIstex>ark:/67375/WNG-M51NF9R3-6</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>bibliography</json:string></originalGenre><abstract>In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 20 sections: 1 Reviews; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.</abstract><qualityIndicators><score>8.788</score><pdfWordCount>16740</pdfWordCount><pdfCharCount>104761</pdfCharCount><pdfVersion>1.4</pdfVersion><pdfPageCount>16</pdfPageCount><pdfPageSize>566.937 x 737.005 pts</pdfPageSize><pdfWordsPerPage>1046</pdfWordsPerPage><pdfText>true</pdfText><refBibsNative>true</refBibsNative><abstractWordCount>149</abstractWordCount><abstractCharCount>1064</abstractCharCount><keywordCount>0</keywordCount></qualityIndicators><title>Current awareness: Pharmacoepidemiology and drug safety</title><corporate><json:item><name>John Wiley & Sons, Ltd.</name></json:item></corporate><genre><json:string>other</json:string></genre><host><title>Pharmacoepidemiology and Drug Safety</title><language><json:string>unknown</json:string></language><doi><json:string>10.1002/(ISSN)1099-1557</json:string></doi><issn><json:string>1053-8569</json:string></issn><eissn><json:string>1099-1557</json:string></eissn><publisherId><json:string>PDS</json:string></publisherId><volume>17</volume><issue>4</issue><pages><first>i</first><last>xvi</last><total>16</total></pages><genre><json:string>journal</json:string></genre><subject><json:item><value>Current Awareness</value></json:item><json:item><value>Current Awareness</value></json:item></subject></host><namedEntities><unitex><date><json:string>6-11-1</json:string><json:string>1-16-20</json:string><json:string>7-3-1</json:string><json:string>2003</json:string><json:string>2008</json:string></date><geogName></geogName><orgName><json:string>Denmark Hill, London SE</json:string><json:string>African-American Heart Failure Trial</json:string><json:string>Hebrew University</json:string><json:string>Department Human Pathol Med Oncol</json:string><json:string>SCERHDD</json:string><json:string>A Crucell Co</json:string><json:string>US/FDA, Ctr Biol Evaluation</json:string><json:string>Cornell Medical Center</json:string><json:string>ANRS CO</json:string><json:string>Presbyterian Hospital, Division Hematol</json:string><json:string>US/FDA, Office Surveillance</json:string><json:string>GlaxoSmithKline Inc</json:string><json:string>Dev Inc</json:string><json:string>SUNY Downstate Medical Center</json:string><json:string>Department Pharmacol, FR</json:string><json:string>Siriraj Hospital, Bangkok, Thailand</json:string><json:string>Am Board Fam Med</json:string><json:string>Denver, Co</json:string><json:string>Little France Crescent, Edinburgh EH</json:string><json:string>Sons, Ltd.</json:string><json:string>Renji Hospital, Department Gastroenterology, CN</json:string><json:string>Biotech</json:string><json:string>MD Anderson Cancer Center</json:string><json:string>Stiller CO</json:string><json:string>Hospital Clinic, Movement Disorders Unit, BR</json:string><json:string>Thomas Street Health Center</json:string><json:string>Singapore Gen Hosp, Dept Neurol, Outram Rd, SG</json:string><json:string>Hill Top Res Inc</json:string><json:string>Children's Hospital Orange County, Department Pharm</json:string><json:string>Cordis Corp</json:string><json:string>Natl Univ Singapore Hosp, Div Endocrinol</json:string><json:string>Childrens Hospital, Institute Endocrinology</json:string><json:string>Hospital Rd, Sydney, NSW</json:string><json:string>UK and USA</json:string><json:string>Singapore, Rep Singapore</json:string><json:string>Himalaya Drug Co</json:string><json:string>Sons, Ltd</json:string><json:string>Beth Israel Deaconess Med Ctr</json:string><json:string>Duke University</json:string><json:string>West National Ave, Milwaukee, Wi</json:string><json:string>Hospital Universidad Marques Valdecilla, Seccion Endocrinol, Santander, Spain</json:string><json:string>South Carolina Emergency Room Hospital Discharge Database</json:string><json:string>Hospital Pharm</json:string><json:string>Department Dermatol Venerol</json:string><json:string>Research Triangle Park, North Carolina</json:string><json:string>Falade CO</json:string><json:string>State University</json:string><json:string>Abbott Laboratories</json:string><json:string>Asahi Kasei Pharma Corporation</json:string><json:string>Natl Taiwan Univ Hosp, Dept Dermatol</json:string><json:string>US/FDA, Div Neurol Prod</json:string><json:string>Department Emergency Medicine, Box</json:string><json:string>Womens Hospital, Division Gastroenterology Hepatology</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Ann Pharmacother</json:string><json:string>Div Epidemiol</json:string><json:string>Div Infect</json:string><json:string>Mori M. Gunma</json:string><json:string>A. Hosp</json:string><json:string>M. Gen</json:string><json:string>Caroline St</json:string><json:string>M. Med</json:string><json:string>Tom Baker</json:string><json:string>Queen Elizabeth</json:string><json:string>Div Rheumatol</json:string><json:string>La Pitie-Salpetriere</json:string><json:string>Eugene Millon</json:string><json:string>Ann Fr</json:string><json:string>Van de Laar</json:string><json:string>C. Rambam</json:string><json:string>Stanislas Torrents</json:string><json:string>Ambroise Pare</json:string><json:string>Antoine Lacassagne</json:string><json:string>K. Minst</json:string><json:string>M. Martini</json:string><json:string>El Ain</json:string><json:string>Gen Practice</json:string><json:string>N. Dept</json:string><json:string>CHU Nancy</json:string><json:string>Div Gasteroenterol</json:string><json:string>Systematic</json:string><json:string>Lila Weston</json:string><json:string>Duke Univ</json:string><json:string>Sinai Sch</json:string><json:string>Nancy Univ</json:string><json:string>Rosalia de Castro</json:string><json:string>Div Lower</json:string><json:string>Jamieson L. Broadmoor</json:string><json:string>G. Ospedale</json:string><json:string>Anne Hosp</json:string><json:string>E. Hosp</json:string><json:string>J. Krankenanstalt</json:string><json:string>Ben Salem</json:string><json:string>Gen Valle</json:string><json:string>Fred Hutchinson</json:string><json:string>Thomas Dr</json:string><json:string>Mae Sot</json:string><json:string>Div Gen</json:string><json:string>Sante Publ</json:string><json:string>CHU Angers</json:string><json:string>Div Med</json:string><json:string>Italia Meridionale</json:string><json:string>W. Klin</json:string><json:string>X. Hosp</json:string><json:string>M. University</json:string><json:string>Frederick Ave</json:string><json:string>Elizabeth St</json:string><json:string>Ann Oncol</json:string><json:string>Van Staa</json:string><json:string>Werner Fromm</json:string><json:string>John Wiley</json:string><json:string>Meir Med</json:string><json:string>Luther King</json:string><json:string>Erwin Rd</json:string><json:string>I. Hosp</json:string><json:string>B. Paul</json:string><json:string>B. Univ</json:string><json:string>Jean Moulin</json:string><json:string>Luna I. Royal</json:string><json:string>CHU Vaudois</json:string><json:string>S. Univ</json:string><json:string>La Fe</json:string><json:string>Ave Appia</json:string><json:string>Kendall St</json:string><json:string>Kent Ridge</json:string><json:string>Van Giezen</json:string><json:string>Jose Ramon</json:string><json:string>Ave Nth</json:string><json:string>La Coruna</json:string><json:string>M. Fac</json:string><json:string>Div Cardiol</json:string><json:string>J. Address</json:string><json:string>A. Hop</json:string><json:string>Ave Sth</json:string><json:string>Div Res</json:string><json:string>La Maddalena</json:string><json:string>Washington Ave</json:string><json:string>Washington Univ</json:string><json:string>W. Univ</json:string><json:string>Hamilton Gen</json:string><json:string>Sotero</json:string><json:string>S. Takeda</json:string><json:string>Ave Valombrose</json:string><json:string>John Umstead</json:string><json:string>CHU Jean</json:string><json:string>Div Hematol</json:string><json:string>Beverly Blvd</json:string><json:string>Med</json:string><json:string>A. Butler</json:string><json:string>Fortune M. Univ</json:string><json:string>Selly Oak</json:string><json:string>Dept Preventive</json:string><json:string>Sigmund Freud</json:string><json:string>S. Uludag</json:string><json:string>Ben Hamida</json:string><json:string>James Cook</json:string><json:string>Gen Intern</json:string><json:string>Vital GmbH</json:string><json:string>Yusuf S. Univ</json:string><json:string>Victoria Hosp</json:string><json:string>J. Univ</json:string><json:string>Edouard Herriot</json:string><json:string>Preliminary</json:string><json:string>P. Med</json:string><json:string>SUNY Hlth</json:string><json:string>R. Med</json:string><json:string>M. Klinikum</json:string><json:string>S. Murdoch</json:string><json:string>Ann Intern</json:string><json:string>T. Rikshospitalet</json:string><json:string>Sinai Med</json:string><json:string>S. Hosp</json:string><json:string>L. Univ</json:string><json:string>Ctr</json:string><json:string>Van Dieren</json:string><json:string>F. Dumlupinar</json:string><json:string>Virginia Commonwealth</json:string><json:string>M. Charite</json:string><json:string>Henry Ford</json:string><json:string>Linda Univ</json:string><json:string>Nathan Shock</json:string><json:string>Maria Claret</json:string><json:string>Ramiro Barcelos</json:string><json:string>Div Gastroenterol</json:string><json:string>Henri Huchard</json:string><json:string>Jonathan Lucas</json:string><json:string>N. Univ</json:string><json:string>Rev</json:string><json:string>Via Massarenti</json:string><json:string>Anderson St</json:string><json:string>B. Ctr</json:string><json:string>Kane D. Freeman</json:string><json:string>N. Prince</json:string><json:string>Liron M. Address</json:string><json:string>R. Ctr</json:string><json:string>E. Inst</json:string><json:string>Y. Nara</json:string><json:string>Paris Descartes</json:string><json:string>P. Univ</json:string><json:string>Dr</json:string><json:string>J. Johns</json:string><json:string>I. Charles</json:string><json:string>J. Tufts</json:string><json:string>C. Address</json:string><json:string>Prasad Ctr</json:string><json:string>K. Address</json:string><json:string>S. Address</json:string><json:string>Razi Ave</json:string><json:string>R. Univ</json:string><json:string>S. Royal</json:string><json:string>Internet</json:string><json:string>B. Karolinska</json:string><json:string>Winter St</json:string><json:string>Gen Psychiat</json:string><json:string>Shan Sth</json:string><json:string>S. L Sacco</json:string><json:string>King Edward</json:string><json:string>St</json:string><json:string>Div Cardiovasc</json:string><json:string>C. Midwestern</json:string><json:string>Smith N. Sourasky</json:string><json:string>Gottlieb T. Concord</json:string><json:string>W. Cantonal</json:string><json:string>Clark St</json:string><json:string>Heydenrich</json:string><json:string>T. Univ</json:string><json:string>S. Norwegian</json:string><json:string>Davis Jewish</json:string><json:string>Ave Marques</json:string><json:string>S. Cornell</json:string><json:string>Herbert Hellmann</json:string><json:string>von Haunerschen</json:string><json:string>La Jolla</json:string><json:string>G. Caswell</json:string><json:string>Van Tulder</json:string><json:string>Subotica</json:string><json:string>S. Grp</json:string><json:string>A. Jagiellonian</json:string><json:string>E. Univ</json:string><json:string>Seng Hosp</json:string><json:string>B. Hop</json:string><json:string>Div Endocrinol</json:string><json:string>F. Hop</json:string><json:string>Perry Parkway</json:string><json:string>Tennessee State</json:string><json:string>La Sapienza</json:string><json:string>T. Ege</json:string><json:string>A. Hafez</json:string><json:string>C. Marmara</json:string><json:string>Dana Farber</json:string><json:string>Ann Acad</json:string><json:string>M. Toho</json:string><json:string>G. Univ</json:string><json:string>Smith B. Univ</json:string><json:string>Via Venezian</json:string><json:string>Victor Segalen</json:string><json:string>Nat Clin</json:string><json:string>S. Cent</json:string><json:string>London Hosp</json:string><json:string>Office Tower</json:string><json:string>A. Akdeniz</json:string><json:string>Andreas Sygros</json:string><json:string>Gen Hosp</json:string><json:string>Ann Emerg</json:string><json:string>Dev Biol</json:string><json:string>Alden Dr</json:string><json:string>Carlton St</json:string><json:string>Critical</json:string><json:string>Taylor St</json:string></persName><placeName><json:string>Naples</json:string><json:string>Santander</json:string><json:string>PY</json:string><json:string>Groningen</json:string><json:string>Santa Creu</json:string><json:string>Durham</json:string><json:string>Portsmouth</json:string><json:string>Shiraz</json:string><json:string>Aberdeen</json:string><json:string>Colditz</json:string><json:string>Leiden</json:string><json:string>Geneva</json:string><json:string>Wakefield</json:string><json:string>Stanford</json:string><json:string>Bochum</json:string><json:string>Chapeltown</json:string><json:string>Southend on Sea</json:string><json:string>Winnipeg</json:string><json:string>Calgary</json:string><json:string>Buffalo</json:string><json:string>Berlin</json:string><json:string>Christchurch</json:string><json:string>Tel Aviv</json:string><json:string>Tehran</json:string><json:string>Brisbane</json:string><json:string>Ankara</json:string><json:string>Birmingham</json:string><json:string>Puzih City</json:string><json:string>San Diego</json:string><json:string>Cuenca</json:string><json:string>Paris</json:string><json:string>Fukui</json:string><json:string>Rochester</json:string><json:string>Middlesbrough</json:string><json:string>Bristol</json:string><json:string>Sfax</json:string><json:string>Southampton</json:string><json:string>Bangalore</json:string><json:string>Miami</json:string><json:string>Los Velez</json:string><json:string>Switzerland</json:string><json:string>Crewe</json:string><json:string>Palermo</json:string><json:string>Poznan</json:string><json:string>Szczecin</json:string><json:string>Columbia</json:string><json:string>Germany</json:string><json:string>Hagen</json:string><json:string>Newcastle upon Tyne</json:string><json:string>Greece</json:string><json:string>San Antonio</json:string><json:string>Blackburn</json:string><json:string>Dresden</json:string><json:string>Kiel</json:string><json:string>Caen</json:string><json:string>Munich</json:string><json:string>St Julien</json:string><json:string>Zaragoza</json:string><json:string>Edmonton</json:string><json:string>Ethiopia</json:string><json:string>St Columbas</json:string><json:string>Brescia</json:string><json:string>Australia</json:string><json:string>Hartford</json:string><json:string>Heidelberg</json:string><json:string>Bursa</json:string><json:string>Bern</json:string><json:string>Casablanca</json:string><json:string>Chile</json:string><json:string>Charleston</json:string><json:string>Korea</json:string><json:string>New Delhi</json:string><json:string>Teratogenicity</json:string><json:string>Seoul</json:string><json:string>Columbus</json:string><json:string>Poland</json:string><json:string>Brazil</json:string><json:string>Georgetown</json:string><json:string>St Gallen</json:string><json:string>Santos</json:string><json:string>Albacete</json:string><json:string>Norway</json:string><json:string>Bangkok</json:string><json:string>Milwaukee</json:string><json:string>Austria</json:string><json:string>Pittsburgh</json:string><json:string>Antalya</json:string><json:string>Washington</json:string><json:string>Toxicity</json:string><json:string>Serbia</json:string><json:string>Curitiba</json:string><json:string>St Isabel</json:string><json:string>Turkey</json:string><json:string>Leitersdorf</json:string><json:string>Richmond</json:string><json:string>Mannheim</json:string><json:string>Wolverhampton</json:string><json:string>Nashville</json:string><json:string>Wilmington</json:string><json:string>Dorchester</json:string><json:string>Taiwan</json:string><json:string>Edinburgh</json:string><json:string>Swansea</json:string><json:string>Genoa</json:string><json:string>St Francis</json:string><json:string>New Orleans</json:string><json:string>Nice</json:string><json:string>DC</json:string><json:string>Oslo</json:string><json:string>Santiago de Compostela</json:string><json:string>Belgrade</json:string><json:string>Oakland</json:string><json:string>Enschede</json:string><json:string>Houston</json:string><json:string>Stuttgart</json:string><json:string>Erlangen</json:string><json:string>Cardiff</json:string><json:string>Rimini</json:string><json:string>St Lukes</json:string><json:string>NC</json:string><json:string>Jaen</json:string><json:string>Bremen</json:string><json:string>Palo Alto</json:string><json:string>SC</json:string><json:string>Nottingham</json:string><json:string>Zhengzhou</json:string><json:string>Hampshire</json:string><json:string>Madrid</json:string><json:string>Cologne</json:string><json:string>New York City</json:string><json:string>Newport</json:string><json:string>St Anne</json:string><json:string>Soest</json:string><json:string>East Brunswick</json:string><json:string>India</json:string><json:string>Seattle</json:string><json:string>Bologna</json:string><json:string>Haifa</json:string><json:string>Tunisia</json:string><json:string>China</json:string><json:string>Nijmegen</json:string><json:string>St Pauls</json:string><json:string>Vancouver</json:string><json:string>Santiago</json:string><json:string>Belfast</json:string><json:string>Toronto</json:string><json:string>Atlanta</json:string><json:string>Ibadan</json:string><json:string>Hebron</json:string><json:string>Milan</json:string><json:string>Los Angeles</json:string><json:string>USA</json:string><json:string>Athens</json:string><json:string>Japan</json:string><json:string>Jerusalem</json:string><json:string>Strasbourg</json:string><json:string>Wales</json:string><json:string>Nigeria</json:string><json:string>Baltimore</json:string><json:string>Czech Republic</json:string><json:string>Leeds</json:string><json:string>Vienna</json:string><json:string>Liverpool</json:string><json:string>Manchester</json:string><json:string>Novara</json:string><json:string>Ferrara</json:string><json:string>Basel</json:string><json:string>San Francisco</json:string><json:string>Kolkata</json:string><json:string>Puri</json:string><json:string>Waterford</json:string><json:string>San Antoni</json:string><json:string>Amsterdam</json:string><json:string>Auckland</json:string><json:string>Toulouse</json:string><json:string>New Zealand</json:string><json:string>Frankfurt</json:string><json:string>Rome</json:string><json:string>Tokyo</json:string><json:string>St Antoine</json:string><json:string>Chicago</json:string><json:string>Patras</json:string><json:string>Murcia</json:string><json:string>San Lorenzo</json:string><json:string>Israel</json:string><json:string>York</json:string><json:string>St Michaels</json:string><json:string>Ottawa</json:string><json:string>Kansas City</json:string><json:string>MA</json:string><json:string>Lausanne</json:string><json:string>Burkina Faso</json:string><json:string>Stockholm</json:string><json:string>Croatia</json:string><json:string>NJ</json:string><json:string>Quebec</json:string><json:string>Cheltenham</json:string><json:string>FL</json:string><json:string>Copenhagen</json:string><json:string>Kampala</json:string><json:string>Morioka</json:string><json:string>Tampa</json:string><json:string>Cambridge</json:string><json:string>Sousse</json:string><json:string>Indianapolis</json:string><json:string>Italy</json:string><json:string>Istanbul</json:string><json:string>Detroit</json:string><json:string>Sweden</json:string><json:string>Zagreb</json:string><json:string>Taipei</json:string><json:string>Spain</json:string><json:string>Glendale</json:string><json:string>Oviedo</json:string><json:string>Mainz</json:string><json:string>Iran</json:string><json:string>Zurich</json:string><json:string>Neurotoxicity</json:string><json:string>Malaga</json:string><json:string>Lyon</json:string><json:string>Lincoln</json:string><json:string>Belgium</json:string><json:string>Netherlands</json:string><json:string>Osaka</json:string><json:string>Tours</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>Department Leukemia, 1515</json:string><json:string>ALZA Corp, 1900</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/WNG-M51NF9R3-6</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - pharmacology & pharmacy</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - pharmacology & pharmacy</json:string></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Pharmacology (medical)</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Epidemiology</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string></inist></categories><publicationDate>2008</publicationDate><copyrightDate>2008</copyrightDate><doi><json:string>10.1002/pds.1485</json:string></doi><id>EC2952E26CD15CA219654F0C5AB72A0C4E7223DD</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-M51NF9R3-6/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-M51NF9R3-6/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/WNG-M51NF9R3-6/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">Current awareness: Pharmacoepidemiology and drug safety</title><title level="a" type="short" xml:lang="en">Current Awareness</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>John Wiley & Sons, Ltd.</publisher><pubPlace>Chichester, UK</pubPlace><availability><licence>Copyright © 2008 John Wiley & Sons, Ltd.</licence></availability><date type="published" when="2008-04"></date></publicationStmt><notesStmt><note type="content-type" subtype="other" source="bibliography" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-7474895G-0">other</note><note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="other"><analytic><title level="a" type="main">Current awareness: Pharmacoepidemiology and drug safety</title><title level="a" type="short" xml:lang="en">Current Awareness</title><author xml:id="author-0000"><author><orgName>John Wiley & Sons, Ltd.</orgName></author></author><idno type="istex">EC2952E26CD15CA219654F0C5AB72A0C4E7223DD</idno><idno type="ark">ark:/67375/WNG-M51NF9R3-6</idno><idno type="DOI">10.1002/pds.1485</idno><idno type="unit">PDS1485</idno><idno type="toTypesetVersion">file:PDS.PDS1485.pdf</idno></analytic><monogr><title level="j" type="main">Pharmacoepidemiology and Drug Safety</title><title level="j" type="alt">PHARMACOEPIDEMIOLOGY AND DRUG SAFETY</title><idno type="pISSN">1053-8569</idno><idno type="eISSN">1099-1557</idno><idno type="book-DOI">10.1002/(ISSN)1099-1557</idno><idno type="book-part-DOI">10.1002/pds.v17:4</idno><idno type="product">PDS</idno><imprint><biblScope unit="vol">17</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="i">i</biblScope><biblScope unit="page" to="xvi">xvi</biblScope><biblScope unit="page-count">16</biblScope><publisher>John Wiley & Sons, Ltd.</publisher><pubPlace>Chichester, UK</pubPlace><date type="published" when="2008-04"></date></imprint></monogr></biblStruct></sourceDesc></fileDesc><encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef><appInfo><application ident="pub2tei" version="1.0.10" when="2019-12-20"><label>pub2TEI-ISTEX</label><desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
<ref target="http://www.tei-c.org/">We use TEI</ref></desc></application></appInfo></encodingDesc><profileDesc><abstract xml:lang="en" style="main"><head>Abstract</head><p>In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 20 sections: 1 Reviews; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted. </p></abstract><textClass><keywords rend="articleCategory"><term>Current Awareness</term></keywords><keywords rend="tocHeading1"><term>Current Awareness</term></keywords></textClass><langUsage><language ident="en"></language></langUsage></profileDesc><revisionDesc><change when="2019-12-20" who="#istex" xml:id="pub2tei">formatting</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-M51NF9R3-6/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>John Wiley & Sons, Ltd.</publisherName><publisherLoc>Chichester, UK</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1099-1557</doi><issn type="print">1053-8569</issn><issn type="electronic">1099-1557</issn><idGroup><id type="product" value="PDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="PHARMACOEPIDEMIOLOGY AND DRUG SAFETY">Pharmacoepidemiology and Drug Safety</title><title type="short">Pharmacoepidem. Drug Safe.</title></titleGroup></publicationMeta><publicationMeta level="part" position="40"><doi origin="wiley" registered="yes">10.1002/pds.v17:4</doi><numberingGroup><numbering type="journalVolume" number="17">17</numbering><numbering type="journalIssue">4</numbering></numberingGroup><coverDate startDate="2008-04">April 2008</coverDate></publicationMeta><publicationMeta level="unit" type="bibliography" position="999" status="forIssue"><doi origin="wiley" registered="yes">10.1002/pds.1485</doi><idGroup><id type="unit" value="PDS1485"></id></idGroup><countGroup><count type="pageTotal" number="16"></count></countGroup><titleGroup><title type="articleCategory">Current Awareness</title><title type="tocHeading1">Current Awareness</title></titleGroup><copyright ownership="publisher">Copyright © 2008 John Wiley & Sons, Ltd.</copyright><eventGroup><event type="firstOnline" date="2008-03-26"></event><event type="publishedOnlineFinalForm" date="2008-03-26"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4.7 mode:FullText source:FullText result:FullText" date="2011-02-24"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-06"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-11-03"></event></eventGroup><numberingGroup><numbering type="pageFirst">i</numbering><numbering type="pageLast">xvi</numbering></numberingGroup><linkGroup><link type="toTypesetVersion" href="file:PDS.PDS1485.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="0"></count><count type="referenceTotal" number="456"></count></countGroup><titleGroup><title type="main" xml:lang="en">Current awareness: Pharmacoepidemiology and drug safety</title><title type="short" xml:lang="en">Current Awareness</title></titleGroup><creators><creator xml:id="au1" creatorRole="author"><groupName>John Wiley & Sons, Ltd.</groupName></creator></creators><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 20 sections: 1 Reviews; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted. </p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Current awareness: Pharmacoepidemiology and drug safety</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Current Awareness</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Current awareness: Pharmacoepidemiology and drug safety</title></titleInfo><name type="corporate"><namePart>John Wiley & Sons, Ltd.</namePart></name><typeOfResource>text</typeOfResource><genre type="other" displayLabel="bibliography" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-7474895G-0">other</genre><originInfo><publisher>John Wiley & Sons, Ltd.</publisher><place><placeTerm type="text">Chichester, UK</placeTerm></place><dateIssued encoding="w3cdtf">2008-04</dateIssued><copyrightDate encoding="w3cdtf">2008</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><extent unit="figures">0</extent><extent unit="tables">0</extent><extent unit="references">456</extent></physicalDescription><abstract lang="en">In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 20 sections: 1 Reviews; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.</abstract><relatedItem type="host"><titleInfo><title>Pharmacoepidemiology and Drug Safety</title></titleInfo><titleInfo type="abbreviated"><title>Pharmacoepidem. Drug Safe.</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><subject><genre>article-category</genre><topic>Current Awareness</topic><topic>Current Awareness</topic></subject><identifier type="ISSN">1053-8569</identifier><identifier type="eISSN">1099-1557</identifier><identifier type="DOI">10.1002/(ISSN)1099-1557</identifier><identifier type="PublisherID">PDS</identifier><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>17</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>i</start><end>xvi</end><total>16</total></extent></part></relatedItem><relatedItem type="references" displayLabel="cit1"><titleInfo><title>1. Reviews</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit2"><titleInfo><title>Heparin induced thrombocytopenia: Diagnosis and management update</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ahmed I, Majeed A, Powell R. Heparin induced thrombocytopenia: Diagnosis and management update. Postgrad Med J (2007); 83: 575.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>83</number></detail><extent unit="pages"><start>575</start></extent></part><relatedItem type="host"><titleInfo><title>Postgrad Med J</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>83</number></detail><extent unit="pages"><start>575</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit3"><titleInfo><title>Neurotoxicity of bortezomib therapy in multiple myeloma: A single‐center experience and review of the literature</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Badros A, Goloubeva O, Dalai JS, Can L, Thompson J, Rapoport AP, Heyman M, Akpek G, Fenton RG. Neurotoxicity of bortezomib therapy in multiple myeloma: A single‐center experience and review of the literature. Cancer (2007); 110: 1042.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>110</number></detail><extent unit="pages"><start>1042</start></extent></part><relatedItem type="host"><titleInfo><title>Cancer</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>110</number></detail><extent unit="pages"><start>1042</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit4"><titleInfo><title>Immunogenicity of infliximab: How to handle the problem?</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Baert F, De Vos M, Louis E, Vermeire S. Immunogenicity of infliximab: How to handle the problem?. Acta Gastroenterol Belg (2007); 70: 163.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>70</number></detail><extent unit="pages"><start>163</start></extent></part><relatedItem type="host"><titleInfo><title>Acta Gastroenterol Belg</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>70</number></detail><extent unit="pages"><start>163</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit5"><titleInfo><title>Ecological studies of antidepressant treatment and suicidal risks</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Baldessarini RJ, Tondo L, Strombom IM, Dominguez S, Fawcett J, Licinio J, Oquendo MA, Tollefson GD, Valuck RJ, Tohen M. Ecological studies of antidepressant treatment and suicidal risks. Harv Rev Psychiatry (2007); 15: 133.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><extent unit="pages"><start>133</start></extent></part><relatedItem type="host"><titleInfo><title>Harv Rev Psychiatry</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><extent unit="pages"><start>133</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit6"><titleInfo><title>Cardiac safety of liposomal anthracyclines</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Batist G. Cardiac safety of liposomal anthracyclines. Cardiovasc Toxicol (2007); 7: 72.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>72</start></extent></part><relatedItem type="host"><titleInfo><title>Cardiovasc Toxicol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>72</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit7"><titleInfo><title>Efficacy and safety of adjunctive zonisamide therapy for refractory partial seizures</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Baulac M, Leppik IE. Efficacy and safety of adjunctive zonisamide therapy for refractory partial seizures. Epilepsy Res (2007); 75: 75.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>75</number></detail><extent unit="pages"><start>75</start></extent></part><relatedItem type="host"><titleInfo><title>Epilepsy Res</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>75</number></detail><extent unit="pages"><start>75</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit8"><titleInfo><title>Interactions between protease inhibitors and acid‐reducing agents: A systematic review</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Beique L, Giguere P, La Porte C, Angel J. Interactions between protease inhibitors and acid‐reducing agents: A systematic review. HIV Med (2007); 8: 335.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>335</start></extent></part><relatedItem type="host"><titleInfo><title>HIV Med</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>335</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit9"><titleInfo><title>Effects of pioglitazone on lipid and lipoprotein metabolism</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Betteridge DJ. Effects of pioglitazone on lipid and lipoprotein metabolism. Diabetes Obes Metab (2007); 9: 640.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>640</start></extent></part><relatedItem type="host"><titleInfo><title>Diabetes Obes Metab</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>640</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit10"><titleInfo><title>Drug‐induced liver injury: Review article</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bleibel W, Kim S, D'Silva K, Lemmer ER. Drug‐induced liver injury: Review article. Dig Dis Sci (2007); 52: 2463.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>52</number></detail><extent unit="pages"><start>2463</start></extent></part><relatedItem type="host"><titleInfo><title>Dig Dis Sci</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>52</number></detail><extent unit="pages"><start>2463</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit11"><titleInfo><title>Proton pump inhibitors and the kidney: Critical review</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Brewster UC, Perazella MA. Proton pump inhibitors and the kidney: Critical review. Clin Nephrol (2007); 68: 65.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>68</number></detail><extent unit="pages"><start>65</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Nephrol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>68</number></detail><extent unit="pages"><start>65</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit12"><titleInfo><title>Glucocorticoid‐induced osteoporosis: Pathophysiology and therapy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid‐induced osteoporosis: Pathophysiology and therapy. Osteoporos Int (2007); 18: 1319.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>1319</start></extent></part><relatedItem type="host"><titleInfo><title>Osteoporos Int</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>1319</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit13"><titleInfo><title>Severe cutaneous adverse reactions to drugs</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Chia FL, Leong KP. Severe cutaneous adverse reactions to drugs. Curr Opin Allergy Clin Immunol (2007); 7: 304.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>304</start></extent></part><relatedItem type="host"><titleInfo><title>Curr Opin Allergy Clin Immunol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>304</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit14"><titleInfo><title>Treatment of bipolar disorder during pregnancy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Cohen LS. Treatment of bipolar disorder during pregnancy. J Clin Psychiatry (2007); 68: 4.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>68</number></detail><extent unit="pages"><start>4</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Psychiatry</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>68</number></detail><extent unit="pages"><start>4</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit15"><titleInfo><title>Low molecular weight heparin and bleeding in patients with chronic renal failure</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Crowther M, Lim W. Low molecular weight heparin and bleeding in patients with chronic renal failure. Curr Opin Pulm Med (2007); 13: 409.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>409</start></extent></part><relatedItem type="host"><titleInfo><title>Curr Opin Pulm Med</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>409</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit16"><titleInfo><title>Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Davis RL, Rubanowice D, McPhillips H, Raebel MA, Andrade SE, Smith D, Yood MU, Platt R. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiol Drug Saf (2007); 16: 1086.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1086</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1086</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit17"><titleInfo><title>Genotyping the risk of anthracycline‐induced cardiotoxicity</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Deng SW, Wojnowski L. Genotyping the risk of anthracycline‐induced cardiotoxicity. Cardiovasc Toxicol (2007); 7: 129.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>129</start></extent></part><relatedItem type="host"><titleInfo><title>Cardiovasc Toxicol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>129</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit18"><titleInfo><title>Drug‐induced pancreatitis: A practical review</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Dhir R, Brown DK, Olden KW. Drug‐induced pancreatitis: A practical review. Drugs Today (Barc) (2007); 43: 499.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>43</number></detail><extent unit="pages"><start>499</start></extent></part><relatedItem type="host"><titleInfo><title>Drugs Today (Barc)</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>43</number></detail><extent unit="pages"><start>499</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit19"><titleInfo><title>Anthracycline cardiotoxicity in breast cancer patients: Synergism with trastuzumab and taxanes</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gianni L, Salvatorelli E, Minotti G. Anthracycline cardiotoxicity in breast cancer patients: Synergism with trastuzumab and taxanes. Cardiovasc Toxicol (2007); 7: 67.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>67</start></extent></part><relatedItem type="host"><titleInfo><title>Cardiovasc Toxicol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>67</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit20"><titleInfo><title>Recombinant factor VIIa: Safety and efficacy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Goodnougha LT, Shander AS. Recombinant factor VIIa: Safety and efficacy. Curr Opin Hematol (2007); 14: 504.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><extent unit="pages"><start>504</start></extent></part><relatedItem type="host"><titleInfo><title>Curr Opin Hematol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><extent unit="pages"><start>504</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit21"><titleInfo><title>Adverse effects of antipsychotics as outcome measures</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hamer S, Haddad PM. Adverse effects of antipsychotics as outcome measures. Br J Psychiatry (2007); 191: S64.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>191</number></detail><extent unit="pages"><start>S64</start></extent></part><relatedItem type="host"><titleInfo><title>Br J Psychiatry</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>191</number></detail><extent unit="pages"><start>S64</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit22"><titleInfo><title>The broad spectrum of statin myopathy: From myalgia to rhabdomyolysis</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Harper CR, Jacobson TA. The broad spectrum of statin myopathy: From myalgia to rhabdomyolysis. Curr Opin Lipidol (2007); 18: 401.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>401</start></extent></part><relatedItem type="host"><titleInfo><title>Curr Opin Lipidol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>401</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit23"><titleInfo><title>Current safety and tolerability issues in men with erectile dysfunction receiving PDE5 inhibitors</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hellstrom WJG. Current safety and tolerability issues in men with erectile dysfunction receiving PDE5 inhibitors. Int J Clin Pract (2007); 61: 1547.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>61</number></detail><extent unit="pages"><start>1547</start></extent></part><relatedItem type="host"><titleInfo><title>Int J Clin Pract</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>61</number></detail><extent unit="pages"><start>1547</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit24"><titleInfo><title>Oral hypoglycaemic agents for diabetes in pregnancy ‐ An appraisal of the current evidence for oral anti‐diabetic drug use in pregnancy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ho FLW, Liew CF, Cunanan EC, Lee KO. Oral hypoglycaemic agents for diabetes in pregnancy ‐ An appraisal of the current evidence for oral anti‐diabetic drug use in pregnancy. Ann Acad Med Singapore (2007); 36: 672.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>36</number></detail><extent unit="pages"><start>672</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Acad Med Singapore</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>36</number></detail><extent unit="pages"><start>672</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit25"><titleInfo><title>Reproductive biology and psychotropic treatments in premenopausal women with bipolar disorder</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Joffe H. Reproductive biology and psychotropic treatments in premenopausal women with bipolar disorder. J Clin Psychiatry (2007); 68: 10.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>68</number></detail><extent unit="pages"><start>10</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Psychiatry</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>68</number></detail><extent unit="pages"><start>10</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit26"><titleInfo><title>Dexrazoxane for anthracycline extravasation</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Langer SW. Dexrazoxane for anthracycline extravasation. Expert Rev Anticancer Ther (2007); 7: 1081.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>1081</start></extent></part><relatedItem type="host"><titleInfo><title>Expert Rev Anticancer Ther</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>1081</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit27"><titleInfo><title>Efficacy and safety of intravenous bisphosphonates in patients with bone metastases caused by metastatic breast cancer</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lipton A. Efficacy and safety of intravenous bisphosphonates in patients with bone metastases caused by metastatic breast cancer. Clin Breast Cancer (2007); 7: S14.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>S14</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Breast Cancer</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>S14</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit28"><titleInfo><title>Nonimmediate reactions to betalactams</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lopez S, Blanca‐Lopez N, Cornejo‐Garcia JA, Canto G, Torres MJ, Mayorga C, Blanca M. Nonimmediate reactions to betalactams. Curr Opin Allergy Clin Immunol (2007); 7: 310.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>310</start></extent></part><relatedItem type="host"><titleInfo><title>Curr Opin Allergy Clin Immunol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>310</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit29"><titleInfo><title>A systematic review on the application of pharmacoepidemiology in assessing prescription drug‐related adverse events in pediatrics</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Luo XM, Cappelleri JC, Frush K. A systematic review on the application of pharmacoepidemiology in assessing prescription drug‐related adverse events in pediatrics. Curr Med Res Opin (2007); 23: 1015.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>1015</start></extent></part><relatedItem type="host"><titleInfo><title>Curr Med Res Opin</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>1015</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit30"><titleInfo><title>MS treatment: Postmarketing studies</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Montalban X. MS treatment: Postmarketing studies. J Neurol Sci (2007); 259: 42.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>259</number></detail><extent unit="pages"><start>42</start></extent></part><relatedItem type="host"><titleInfo><title>J Neurol Sci</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>259</number></detail><extent unit="pages"><start>42</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit31"><titleInfo><title>Efficacy and safety of dihydroartemisinin‐piperaquine</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Myint HY, Ashley EA, Day NPJ, Nosten F, White NJ. Efficacy and safety of dihydroartemisinin‐piperaquine. Trans R Soc Trop Med Hyg (2007); 101: 858.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>101</number></detail><extent unit="pages"><start>858</start></extent></part><relatedItem type="host"><titleInfo><title>Trans R Soc Trop Med Hyg</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>101</number></detail><extent unit="pages"><start>858</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit32"><titleInfo><title>Linezolid‐associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Narita M, Tsuji BT, Yu VL. Linezolid‐associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. Pharmacotherapy (2007); 27: 1189.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>1189</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacotherapy</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>1189</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit33"><titleInfo><title>EAACI/GA2LEN guideline: Aspirin provocation tests for diagnosis of aspirin hypersensitivity</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Nizankowska‐Mogilnicka E, Bochenek G, Mastalerz L, Swierczynska M, Picado C, Scadding G, Kowalski ML, Setkowicz M, Ring J, Brockow K, Bachert C, Wohrl S, Dahlen B, Szczeklik A. EAACI/GA2LEN guideline: Aspirin provocation tests for diagnosis of aspirin hypersensitivity. Allergy (2007); 62: 1111.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>62</number></detail><extent unit="pages"><start>1111</start></extent></part><relatedItem type="host"><titleInfo><title>Allergy</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>62</number></detail><extent unit="pages"><start>1111</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit34"><titleInfo><title>Drug hypersensitivity in HIV</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Phillips E, Mallal S. Drug hypersensitivity in HIV. Curr Opin Allergy Clin Immunol (2007); 7: 324.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>324</start></extent></part><relatedItem type="host"><titleInfo><title>Curr Opin Allergy Clin Immunol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>324</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit35"><titleInfo><title>Pharmacoenvironmentology ‐ A component of pharmacovigilance</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Rahman SZ, Khan RA, Gupta V, Uddin M. Pharmacoenvironmentology ‐ A component of pharmacovigilance. Environ Health (2007); 6: 20.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>6</number></detail><extent unit="pages"><start>20</start></extent></part><relatedItem type="host"><titleInfo><title>Environ Health</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>6</number></detail><extent unit="pages"><start>20</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit36"><titleInfo><title>Dietary restrictions and drug interactions, with monoamine oxidase inhibitors: The state of the art</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Rapaport MH. Dietary restrictions and drug interactions, with monoamine oxidase inhibitors: The state of the art. J Clin Psychiatry (2007); 68: 42.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>68</number></detail><extent unit="pages"><start>42</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Psychiatry</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>68</number></detail><extent unit="pages"><start>42</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit37"><titleInfo><title>Is bisphosphonate‐associated osteonecrosis of the jaw caused by soft tissue toxicity?</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Reid IR, Bolland MJ, Grey AB. Is bisphosphonate‐associated osteonecrosis of the jaw caused by soft tissue toxicity?. Bone (2007); 41: 318.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>318</start></extent></part><relatedItem type="host"><titleInfo><title>Bone</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>318</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit38"><titleInfo><title>Recent advances in the diagnosis of drug allergy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Romano A, Demoly P. Recent advances in the diagnosis of drug allergy. Curr Opin Allergy Clin Immunol (2007); 7: 299.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>299</start></extent></part><relatedItem type="host"><titleInfo><title>Curr Opin Allergy Clin Immunol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>299</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit39"><titleInfo><title>Preventing adverse drug events in hospital practice: An overview</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Rommers MK, Teepe‐Twiss IM, Guchelaar HJ. Preventing adverse drug events in hospital practice: An overview. Pharmacoepidemiol Drug Saf (2007); 16: 1129.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1129</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1129</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit40"><titleInfo><title>Safety and tolerability of antidepressants: Weighing the impact on treatment decisions</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Schatzberg AF. Safety and tolerability of antidepressants: Weighing the impact on treatment decisions. J Clin Psychiatry (2007); 68: 26.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>68</number></detail><extent unit="pages"><start>26</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Psychiatry</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>68</number></detail><extent unit="pages"><start>26</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit41"><titleInfo><title>Alefacept: Its safety profile, off‐label uses, and potential as part of combination therapies for psoriasis</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Scheinfeld N. Alefacept: Its safety profile, off‐label uses, and potential as part of combination therapies for psoriasis. J Dermatol Treat (2007); 18: 197.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>197</start></extent></part><relatedItem type="host"><titleInfo><title>J Dermatol Treat</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>197</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit42"><titleInfo><title>Anthracycline cardiotoxicity in long‐term survivors of childhood cancer</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Scully RE, Lipschultz SE. Anthracycline cardiotoxicity in long‐term survivors of childhood cancer. Cardiovasc Toxicol (2007); 7: 122.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>122</start></extent></part><relatedItem type="host"><titleInfo><title>Cardiovasc Toxicol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>122</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit43"><titleInfo><title>Acute phosphate nephropathy ‐ An emerging issue</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sica DA, Carl D, Zfass AM. Acute phosphate nephropathy ‐ An emerging issue. Am J Gastroenterol (2007); 102: 1844.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>102</number></detail><extent unit="pages"><start>1844</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Gastroenterol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>102</number></detail><extent unit="pages"><start>1844</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit44"><titleInfo><title>Systematic review: Proton pump inhibitor‐associated acute interstitial nephritis</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sierra F, Suarez M, Rey M, Vela MF. Systematic review: Proton pump inhibitor‐associated acute interstitial nephritis. Aliment Pharmacol Ther (2007); 26: 545.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>545</start></extent></part><relatedItem type="host"><titleInfo><title>Aliment Pharmacol Ther</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>545</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit45"><titleInfo><title>How to advise aspirin use in patients who need NSAIDs</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sopena F, Lanas A. How to advise aspirin use in patients who need NSAIDs. Curr Pharm Des (2007); 13: 2248.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>2248</start></extent></part><relatedItem type="host"><titleInfo><title>Curr Pharm Des</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>2248</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit46"><titleInfo><title>The use of mood stabilizers during breastfeeding</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Stowe ZN. The use of mood stabilizers during breastfeeding. J Clin Psychiatry (2007); 68: 22.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>68</number></detail><extent unit="pages"><start>22</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Psychiatry</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>68</number></detail><extent unit="pages"><start>22</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit47"><titleInfo><title>Preclinical and clinical safety of monoclonal antibodies</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Tabrizi MA, Roskos LK. Preclinical and clinical safety of monoclonal antibodies. Drug Discov Today (2007); 12: 540.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>12</number></detail><extent unit="pages"><start>540</start></extent></part><relatedItem type="host"><titleInfo><title>Drug Discov Today</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>12</number></detail><extent unit="pages"><start>540</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit48"><titleInfo><title>Ocular toxicity of fluoroquinolones</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Thompson AM. Ocular toxicity of fluoroquinolones. Clin Exp Ophthalmol (2007); 35: 566.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>35</number></detail><extent unit="pages"><start>566</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Exp Ophthalmol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>35</number></detail><extent unit="pages"><start>566</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit49"><titleInfo><title>Systematic review of the incidence and characteristics of preventable adverse drug events in ambulatory care</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Thomsen LA, Winterstein AG, Sondergaard B, Haugbolle LS, Melander A. Systematic review of the incidence and characteristics of preventable adverse drug events in ambulatory care. Ann Pharmacother (2007); 41: 1411.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>1411</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Pharmacother</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>1411</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit50"><titleInfo><title>Teratogenicity and anticonvulsants: Lessons from neurology to psychiatry</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Viguera AC, Koukopoulos A, Muzina DJ, Baldessarini RJ. Teratogenicity and anticonvulsants: Lessons from neurology to psychiatry. J Clin Psychiatry (2007); 68: 29.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>68</number></detail><extent unit="pages"><start>29</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Psychiatry</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>68</number></detail><extent unit="pages"><start>29</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit51"><titleInfo><title>Drug‐induced thrombocytopenia</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Visentin GP, Liu CY. Drug‐induced thrombocytopenia. Hematol Oncol Clin North Am (2007); 21: 685.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>685</start></extent></part><relatedItem type="host"><titleInfo><title>Hematol Oncol Clin North Am</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>685</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit52"><titleInfo><title>Heparin‐induced thrombocytopenia</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Warkentin TE. Heparin‐induced thrombocytopenia. Hematol Oncol Clin North Am (2007); 21: 589.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>589</start></extent></part><relatedItem type="host"><titleInfo><title>Hematol Oncol Clin North Am</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>589</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit53"><titleInfo><title>Aminoglycosides, toxicity and cystic fibrosis</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Watson AR. Aminoglycosides, toxicity and cystic fibrosis. J R Soc Med (2007); 100: 24.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>100</number></detail><extent unit="pages"><start>24</start></extent></part><relatedItem type="host"><titleInfo><title>J R Soc Med</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>100</number></detail><extent unit="pages"><start>24</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit54"><titleInfo><title>Clozapine‐induced seizures: Recognition and treatment</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wong J, Delva N. Clozapine‐induced seizures: Recognition and treatment. Can J Psychiatry (2007); 52: 457.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>52</number></detail><extent unit="pages"><start>457</start></extent></part><relatedItem type="host"><titleInfo><title>Can J Psychiatry</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>52</number></detail><extent unit="pages"><start>457</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit55"><titleInfo><title>Cisplatin nephrotoxicity: A review</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Yao X, Panichpisal K, Kurtzman N, Nugent K. Cisplatin nephrotoxicity: A review. Am J Med Sci (2007); 334: 115.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>334</number></detail><extent unit="pages"><start>115</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Med Sci</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>334</number></detail><extent unit="pages"><start>115</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit56"><titleInfo><title>Global gastrointestinal safety profile of etoricoxib and lumiracoxib</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Yuan YH, Hunt RH. Global gastrointestinal safety profile of etoricoxib and lumiracoxib. Curr Pharm Des (2007); 13: 2237.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>2237</start></extent></part><relatedItem type="host"><titleInfo><title>Curr Pharm Des</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>2237</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit57"><titleInfo><title>2. General</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit58"><titleInfo><title>Lactation safety recommendations and reliability compared in 10 medication resources</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Akus M, Bartick M. Lactation safety recommendations and reliability compared in 10 medication resources. Ann Pharmacother (2007); 41: 1352.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>1352</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Pharmacother</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>1352</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit59"><titleInfo><title>Prescription to elderly patients: Reducing underuse and adverse drug reactions and improving adherence ‐ Disscussion (French)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Binet JL, Hollender L, Menkes CJ, Jaffiol C. Prescription to elderly patients: Reducing underuse and adverse drug reactions and improving adherence ‐ Disscussion (French). Bull Acad Natl Med (2007); 191: 269.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>191</number></detail><extent unit="pages"><start>269</start></extent></part><relatedItem type="host"><titleInfo><title>Bull Acad Natl Med</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>191</number></detail><extent unit="pages"><start>269</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit60"><titleInfo><title>Cardiovascular safety of drugs not intended for cardiovascular use: Need for a new conceptual basis for assessment and approval</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Borer JS, Pouleur H, Abadie E, Follath F, Wittes J, Pfeffer MA, Pitt B, Zannad F. Cardiovascular safety of drugs not intended for cardiovascular use: Need for a new conceptual basis for assessment and approval. Eur Heart J (2007); 28: 1904.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>1904</start></extent></part><relatedItem type="host"><titleInfo><title>Eur Heart J</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>1904</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit61"><titleInfo><title>Early detection of adverse drug events within population‐based health networks: Application of sequential testing methods</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Brown JS, Kulldorff M, Chan KA, Davis RL, Graham D, Pettus PT, Andrade SE, Raebel MA, Herrinton L, Roblin D, Boudreau D, Smith D, Gurwitz JH, Gunter MJ, Platt R. Early detection of adverse drug events within population‐based health networks: Application of sequential testing methods. Pharmacoepidemiol Drug Saf (2007); 16: 1275.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1275</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1275</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit62"><titleInfo><title>Prevention of adverse drug reactions in older patients (German, English Abstract)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Burkhardt H, Wehling M, Gladisch R. Prevention of adverse drug reactions in older patients (German, English Abstract). Z Gerontol Geriatr (2007); 40: 241.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>40</number></detail><extent unit="pages"><start>241</start></extent></part><relatedItem type="host"><titleInfo><title>Z Gerontol Geriatr</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>40</number></detail><extent unit="pages"><start>241</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit63"><titleInfo><title>Drug utilization study in a neonatology unit of a tertiary care hospital in eastern India</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Chatterjee S, Mandal A, Lyle N, Mukherjee S, Singh AK. Drug utilization study in a neonatology unit of a tertiary care hospital in eastern India. Pharmacoepidemiol Drug Saf (2007); 16: 1141.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1141</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1141</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit64"><titleInfo><title>The use of folic acid antagonists and the risk of colorectal cancer</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Coogan PF, Rosenberg L. The use of folic acid antagonists and the risk of colorectal cancer. Pharmacoepidemiol Drug Saf (2007); 16: 1111.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1111</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1111</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit65"><titleInfo><title>Distress with medication side effects among persons with severe mental illness</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Covell NH, Weissman EM, Schell B, McCorkle BH, Summerfelt WT, Weiden PJ, Essock SM. Distress with medication side effects among persons with severe mental illness. Adm Policy Ment Health (2007); 34: 435.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>34</number></detail><extent unit="pages"><start>435</start></extent></part><relatedItem type="host"><titleInfo><title>Adm Policy Ment Health</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>34</number></detail><extent unit="pages"><start>435</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit66"><titleInfo><title>Perception of risk of adverse drug reactions by medical students: Influence of a 1 year pharmacological course</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Durrieu G, Hurault C, Bongard V, Damase‐Michel C, Montastruc JL. Perception of risk of adverse drug reactions by medical students: Influence of a 1 year pharmacological course. Br J Clin Pharmacol (2007); 64: 233.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>64</number></detail><extent unit="pages"><start>233</start></extent></part><relatedItem type="host"><titleInfo><title>Br J Clin Pharmacol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>64</number></detail><extent unit="pages"><start>233</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit67"><titleInfo><title>Drug prescribing pattern at the medical outpatient clinic of a tertiary hospital in southwestern Nigeria</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Enwere OO, Falade CO, Salako BL. Drug prescribing pattern at the medical outpatient clinic of a tertiary hospital in southwestern Nigeria. Pharmacoepidemiol Drug Saf (2007); 16: 1244.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1244</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1244</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit68"><titleInfo><title>Contrasting time‐ and rate‐based approaches for the assessment of drug‐induced QT changes</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Extramiana F, Badilini F, Sarapa N, Leenhardt A, Maison‐Blanche P. Contrasting time‐ and rate‐based approaches for the assessment of drug‐induced QT changes. J Clin Pharmacol (2007); 47: 1129.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>47</number></detail><extent unit="pages"><start>1129</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Pharmacol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>47</number></detail><extent unit="pages"><start>1129</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit69"><titleInfo><title>Patient‐reporting of side effects may provide an important source of information in clinical practice (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Foster JM, Van der Molen T, De Jong‐van den Berg L. Patient‐reporting of side effects may provide an important source of information in clinical practice (Letter). Eur J Clin Pharmacol (2007); 63: 979.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>63</number></detail><extent unit="pages"><start>979</start></extent></part><relatedItem type="host"><titleInfo><title>Eur J Clin Pharmacol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>63</number></detail><extent unit="pages"><start>979</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit70"><titleInfo><title>What is the true risk of a pharmacokinetic drug‐drug interaction? (Editorial comment)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Fuhr U. What is the true risk of a pharmacokinetic drug‐drug interaction? (Editorial comment). Eur J Clin Pharmacol (2007); 63: 897.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>63</number></detail><extent unit="pages"><start>897</start></extent></part><relatedItem type="host"><titleInfo><title>Eur J Clin Pharmacol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>63</number></detail><extent unit="pages"><start>897</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit71"><titleInfo><title>Adherence to multiple drug therapies: Refill adherence to concomitant use of diabetes and asthma/COPD medication</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Krigsman K, Nilsson JLG, Ring L. Adherence to multiple drug therapies: Refill adherence to concomitant use of diabetes and asthma/COPD medication. Pharmacoepidemiol Drug Saf (2007); 16: 1120.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1120</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1120</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit72"><titleInfo><title>Patient‐reporting of side effects may provide an important source of information in clinical practice (Reply)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lampela P, Hartikainen S, Sulkava R, Huupponen R. Patient‐reporting of side effects may provide an important source of information in clinical practice (Reply). Eur J Clin Pharmacol (2007); 63: 981.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>63</number></detail><extent unit="pages"><start>981</start></extent></part><relatedItem type="host"><titleInfo><title>Eur J Clin Pharmacol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>63</number></detail><extent unit="pages"><start>981</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit73"><titleInfo><title>Prescription to elderly patients: Reducing underuse and adverse drug reactions and improving adherence (French, English Abstract)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Legrain S. Prescription to elderly patients: Reducing underuse and adverse drug reactions and improving adherence (French, English Abstract). Bull Acad Natl Med (2007); 191: 259.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>191</number></detail><extent unit="pages"><start>259</start></extent></part><relatedItem type="host"><titleInfo><title>Bull Acad Natl Med</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>191</number></detail><extent unit="pages"><start>259</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit74"><titleInfo><title>Drug‐drug interaction prediction: A Bayesian meta‐analysis approach</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Li L, Yul MG, Chin R, Lucksiri A, Flockhart DA, Hall SD. Drug‐drug interaction prediction: A Bayesian meta‐analysis approach. Stat Med (2007); 26: 3700.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>3700</start></extent></part><relatedItem type="host"><titleInfo><title>Stat Med</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>3700</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit75"><titleInfo><title>In clarification (re. Coronary heart disease outcomes in patients receiving antidiabetic agents. Pharmacoepidemiol Drug Saf 2007; 16: 711) (Reply to Editorial)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">McAfee AT, Walker AM. In clarification (re. Coronary heart disease outcomes in patients receiving antidiabetic agents. Pharmacoepidemiol Drug Saf 2007; 16: 711) (Reply to Editorial). Pharmacoepidemiol Drug Saf (2007); 16: 1063.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1063</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1063</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit76"><titleInfo><title>Serious adverse drug events reported to the Food and Drug Administration, 1998‐2005</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Moore TJ, Cohen MR, Furberg CD. Serious adverse drug events reported to the Food and Drug Administration, 1998‐2005. Arch Intern Med (2007); 167: 1752.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>167</number></detail><extent unit="pages"><start>1752</start></extent></part><relatedItem type="host"><titleInfo><title>Arch Intern Med</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>167</number></detail><extent unit="pages"><start>1752</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit77"><titleInfo><title>A quantitative approach to benefit‐risk assessment of medicines ‐ Part 2: The practical application of a new model. Pharmacoepidemiol Drug Saf 2007; 16: (Suppl 1) S16 (Retraction Notice)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mussen F, Salek S, Walker S. A quantitative approach to benefit‐risk assessment of medicines ‐ Part 2: The practical application of a new model. Pharmacoepidemiol Drug Saf 2007; 16: (Suppl 1) S16 (Retraction Notice). Pharmacoepidemiol Drug Saf (2007); 16: 1180.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1180</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1180</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit78"><titleInfo><title>A note on post‐marketing safety study design to characterise time‐dependent adverse events</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Narukawa M, Yafune A. A note on post‐marketing safety study design to characterise time‐dependent adverse events. Pharmacoepidemiol Drug Saf (2007); 16: 1146.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1146</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1146</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit79"><titleInfo><title>Adverse drug reactions in children. Identification and evaluation (German, English Abstract)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Neubert A, Rascher W. Adverse drug reactions in children. Identification and evaluation (German, English Abstract). Monatsschr Kinderheilk (2007); 155: 700.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>155</number></detail><extent unit="pages"><start>700</start></extent></part><relatedItem type="host"><titleInfo><title>Monatsschr Kinderheilk</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>155</number></detail><extent unit="pages"><start>700</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit80"><titleInfo><title>Optimizing safety of medicines by pharmacovigilance. What must be done? (German, English Abstract)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Rascher W, Mentzer D, Seyberth HW. Optimizing safety of medicines by pharmacovigilance. What must be done? (German, English Abstract). Monatsschr Kinderheilk (2007); 155: 692.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>155</number></detail><extent unit="pages"><start>692</start></extent></part><relatedItem type="host"><titleInfo><title>Monatsschr Kinderheilk</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>155</number></detail><extent unit="pages"><start>692</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit81"><titleInfo><title>Admissions to a medical intensive care unit related to adverse drug reactions</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Rivkin A. Admissions to a medical intensive care unit related to adverse drug reactions. Am J Health Syst Pharm (2007); 64: 1840.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>64</number></detail><extent unit="pages"><start>1840</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Health Syst Pharm</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>64</number></detail><extent unit="pages"><start>1840</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit82"><titleInfo><title>Multiple‐drug intolerance syndrome: Clinical findings and usefulness of challenge tests</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Schiavino D, Nucera E, Roncallo C, Pollastrini E, De Pasquale T, Lombardo C, Altomonte G, Buonomo A, Patriarca G. Multiple‐drug intolerance syndrome: Clinical findings and usefulness of challenge tests. Ann Allergy Asthma Immunol (2007); 99: 136.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>99</number></detail><extent unit="pages"><start>136</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Allergy Asthma Immunol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>99</number></detail><extent unit="pages"><start>136</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit83"><titleInfo><title>Applying quantitative methods for detecting new drug safety signals in pharmacovigilance national database</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Shalviri G, Mohammad K, Majdzadeh R, Gholami K. Applying quantitative methods for detecting new drug safety signals in pharmacovigilance national database. Pharmacoepidemiol Drug Saf (2007); 16: 1136.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1136</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1136</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit84"><titleInfo><title>A comparison of community pharmacists' views of over‐the‐counter omeprazole and simvastatin</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Stewart D, John D, Cunningham S, McCaig D, Hansford D. A comparison of community pharmacists' views of over‐the‐counter omeprazole and simvastatin. Pharmacoepidemiol Drug Saf (2007); 16: 1290.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1290</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1290</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit85"><titleInfo><title>Did thirst‐blockers like angiotensin‐converting‐enzyme inhibitors, sartans, serotonine‐re‐uptake‐inhibitors, dopamine agonists/antagonists, or atypical neuroleptics contribute to the exorbitant number of fatalities during the French 2003 heat wave? (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Stollberger C, Finsterer J. Did thirst‐blockers like angiotensin‐converting‐enzyme inhibitors, sartans, serotonine‐re‐uptake‐inhibitors, dopamine agonists/antagonists, or atypical neuroleptics contribute to the exorbitant number of fatalities during the French 2003 heat wave? (Letter). Pharmacoepidemiol Drug Saf (2007); 16: 1252.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1252</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1252</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit86"><titleInfo><title>In clarification (re. Coronary heart disease outcomes in patients receiving antidiabetic agents. Pharmacoepidemiol Drug Saf 2007; 16: 711) (Editorial)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Strom BL, Lewis JD. In clarification (re. Coronary heart disease outcomes in patients receiving antidiabetic agents. Pharmacoepidemiol Drug Saf 2007; 16: 711) (Editorial). Pharmacoepidemiol Drug Saf (2007); 16: 1063.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1063</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1063</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit87"><titleInfo><title>Access to up‐to‐date drug information in developing countries continues to pose problems: The case of Uganda (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Tumwikirize WA, Ogwal‐Okeng JW, Vernby A, Anokbonggo WW, Gustafsson LL, Lundborg CS. Access to up‐to‐date drug information in developing countries continues to pose problems: The case of Uganda (Letter). Pharmacoepidemiol Drug Saf (2007); 16: 1177.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1177</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1177</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit88"><titleInfo><title>Withdrawal of fall‐risk‐increasing drugs in older persons ‐ Effect on mobility test outcomes</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Van der Velde N, Stricker BHC, Pols HAP, Van der Cammen TJM. Withdrawal of fall‐risk‐increasing drugs in older persons ‐ Effect on mobility test outcomes. Drug Aging (2007); 24: 691.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>691</start></extent></part><relatedItem type="host"><titleInfo><title>Drug Aging</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>691</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit89"><titleInfo><title>Aversion to side effects in preventive medical treatment decisions</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Waters EA, Weinstein ND, Colditz GA, Emmons KM. Aversion to side effects in preventive medical treatment decisions. Br J Health Psychol (2007); 12: 383.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>12</number></detail><extent unit="pages"><start>383</start></extent></part><relatedItem type="host"><titleInfo><title>Br J Health Psychol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>12</number></detail><extent unit="pages"><start>383</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit90"><titleInfo><title>Population‐based drug‐related anaphylaxis in children and adolescents captured by South Carolina Emergency Room Hospital Discharge Database (SCERHDD) (2000‐2002)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">West SL, D'Aloisio AA, Ringel‐Kulka T, Waller AE, Bordley WC. Population‐based drug‐related anaphylaxis in children and adolescents captured by South Carolina Emergency Room Hospital Discharge Database (SCERHDD) (2000‐2002). Pharmacoepidemiol Drug Saf (2007); 16: 1255.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1255</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1255</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit91"><titleInfo><title>3. Anti‐infective Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit92"><titleInfo><title>Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Acosta EP, Kendall MA, Gerber JG, Alston‐Smith B, Koletar SL, Zolopa AR, Agarwala S, Child M, Bertz R, Hosey L, Haas DW. Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily. Antimicrob Agents Chemother (2007); 51: 3104.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>51</number></detail><extent unit="pages"><start>3104</start></extent></part><relatedItem type="host"><titleInfo><title>Antimicrob Agents Chemother</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>51</number></detail><extent unit="pages"><start>3104</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit93"><titleInfo><title>Safety of a trivalent meningococcal ACW135 vaccine among young children in Ethiopia</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Aseffa A, Bedru A, Yamuah L, Arga D, Worku A, Chandramohan D, Nelson CB, Engers HD. Safety of a trivalent meningococcal ACW135 vaccine among young children in Ethiopia. Vaccine (2007); 25: A79.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>A79</start></extent></part><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>A79</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit94"><titleInfo><title>Are disulfiram‐like reactions associated with abacavir‐containing antiretroviral regimens in clinical practice?</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Barber TJ, Marett B, Waldron S, Portsmouth S, Mackie NE, Weston R, Winston A. Are disulfiram‐like reactions associated with abacavir‐containing antiretroviral regimens in clinical practice?. AIDS (2007); 21: 1823.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>1823</start></extent></part><relatedItem type="host"><titleInfo><title>AIDS</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>1823</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit95"><titleInfo><title>Post licensure safety surveillance for Prevenar® (French, English Abstract)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bensouda‐Grimaldi L, Jonville‐Bera AP, Autret‐Leca E. Post licensure safety surveillance for Prevenar® (French, English Abstract). Arch Pediatr (2007); 14: 870.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><extent unit="pages"><start>870</start></extent></part><relatedItem type="host"><titleInfo><title>Arch Pediatr</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><extent unit="pages"><start>870</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit96"><titleInfo><title>Monitoring of adverse events during the 2003 mass vaccination campaign with a trivalent meningococcal A/C/W135 polysaccharide vaccine in Burkina Faso</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bentsi‐Enchill AD, Zongo I, Khamassi S, Pless R, Thombiano R, Tiendrebeogo S, Nelson CB, Duclos P. Monitoring of adverse events during the 2003 mass vaccination campaign with a trivalent meningococcal A/C/W135 polysaccharide vaccine in Burkina Faso. Vaccine (2007); 25: A72.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>A72</start></extent></part><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>A72</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit97"><titleInfo><title>Hair loss induced by lopinavir‐ritonavir</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Borras‐Blasco J, Belda A, Rosique‐Robles D, Castera E, Abad J, Amoros‐Quiles I. Hair loss induced by lopinavir‐ritonavir. Pharmacotherapy (2007); 27: 1215.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>1215</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacotherapy</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>1215</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit98"><titleInfo><title>Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Boulle A, Orrell C, Kaplan R, Van Cutsem G, McNally M, Hilderbrand K, Myer L, Egger M, Coetzee D, Maartens G, Wood R. Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort. Antivir Ther (2007); 12: 753.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>12</number></detail><extent unit="pages"><start>753</start></extent></part><relatedItem type="host"><titleInfo><title>Antivir Ther</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>12</number></detail><extent unit="pages"><start>753</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit99"><titleInfo><title>Self‐reported side‐effects of anti‐retroviral treatment among IDUs: A 7‐year longitudinal study (APROCO‐COPILOTE cohort ANRS CO‐8)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Carrieri MP, Villes V, Raffi F, Protopopescu C, Preau M, Salmon D, Taieb A, Lang JM, Verdon R, Chene G, Spire B. Self‐reported side‐effects of anti‐retroviral treatment among IDUs: A 7‐year longitudinal study (APROCO‐COPILOTE cohort ANRS CO‐8). Int J Drug Policy (2007); 18: 288.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>288</start></extent></part><relatedItem type="host"><titleInfo><title>Int J Drug Policy</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>288</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit100"><titleInfo><title>An evaluation of the immunogenicity and safety of a new trivalent meningococcal polysaccharide vaccine</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Chandramohan D, Hodgson A, Coleman P, Baiden R, Asante K, Awine E, Owusu‐Agyei S, Boutriau D, Nelson CB, Greenwood B. An evaluation of the immunogenicity and safety of a new trivalent meningococcal polysaccharide vaccine. Vaccine (2007); 25: A83.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>A83</start></extent></part><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>A83</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit101"><titleInfo><title>Clindamycin‐induced Sweet's syndrome</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Clark BM, Homeyer DC, Glass KR, D'Avignon LC. Clindamycin‐induced Sweet's syndrome. Pharmacotherapy (2007); 27: 1343.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>1343</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacotherapy</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>1343</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit102"><titleInfo><title>Cefiepime‐induced encephalopathy with triphasic waves in three Asian patients (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">De Silva DA, Pan ABS, Lim SH. Cefiepime‐induced encephalopathy with triphasic waves in three Asian patients (Letter). Ann Acad Med Singapore (2007); 36: 450.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>36</number></detail><extent unit="pages"><start>450</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Acad Med Singapore</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>36</number></detail><extent unit="pages"><start>450</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit103"><titleInfo><title>Drug‐drug interactions with systemic antifungals in clinical practice</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Depont F, Vargas F, Dutronc H, Giauque E, Ragnaud JM, Galperine T, Abouelfath A, Valentino R, Dupon M, Hebert G, Moore N. Drug‐drug interactions with systemic antifungals in clinical practice. Pharmacoepidemiol Drug Saf (2007); 16: 1227.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1227</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1227</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit104"><titleInfo><title>Lack of cross‐hepatotoxicity between voriconazole and posaconazole (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Foo H, Gottlieb T. Lack of cross‐hepatotoxicity between voriconazole and posaconazole (Letter). Clin Infect Dis (2007); 45: 803.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>803</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Infect Dis</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>803</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit105"><titleInfo><title>Pharmacological risk factors for amphotericin B nephrotoxicity in children</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Goldman RD, Ong M, Wolpin J, Doyle J, Parshuram C, Koren G. Pharmacological risk factors for amphotericin B nephrotoxicity in children. J Clin Pharmacol (2007); 47: 1049.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>47</number></detail><extent unit="pages"><start>1049</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Pharmacol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>47</number></detail><extent unit="pages"><start>1049</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit106"><titleInfo><title>Attitudes, beliefs and knowledge concerning antibiotic use and self‐medication: A comparative European study</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Grigoryan L, Burgerhof JGM, Degener JE, Deschepper R, Lundborg CS, Monnet DL, Scicluna EA, Birkin J, Haaijer‐Ruskamp. Attitudes, beliefs and knowledge concerning antibiotic use and self‐medication: A comparative European study. Pharmacoepidemiol Drug Saf (2007); 16: 1234.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1234</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1234</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit107"><titleInfo><title>Adverse skin reactions due to pegylated interferon α 2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hashimoto Y, Kanto H, Itoh M. Adverse skin reactions due to pegylated interferon α 2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus. J Dermatol (2007); 34: 577.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>34</number></detail><extent unit="pages"><start>577</start></extent></part><relatedItem type="host"><titleInfo><title>J Dermatol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>34</number></detail><extent unit="pages"><start>577</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit108"><titleInfo><title>Adverse events experienced by three children taking tenofovir and didanosine in combination (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hawkins S, Ball C. Adverse events experienced by three children taking tenofovir and didanosine in combination (Letter). HIV Med (2007); 8: 411.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>411</start></extent></part><relatedItem type="host"><titleInfo><title>HIV Med</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>411</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit109"><titleInfo><title>Interaction between lopinavir/ritonavir and warfarin</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hughes CA, Freitas A, Miedzinski LJ. Interaction between lopinavir/ritonavir and warfarin. Can Med Assoc J (2007); 177: 357.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>177</number></detail><extent unit="pages"><start>357</start></extent></part><relatedItem type="host"><titleInfo><title>Can Med Assoc J</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>177</number></detail><extent unit="pages"><start>357</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit110"><titleInfo><title>Probenecid‐induced membranous nephropathy (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Izzedine H, Brocheriou I, Becart J, Deray G. Probenecid‐induced membranous nephropathy (Letter). Nephrol Dial Transplant (2007); 22: 2405.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><extent unit="pages"><start>2405</start></extent></part><relatedItem type="host"><titleInfo><title>Nephrol Dial Transplant</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><extent unit="pages"><start>2405</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit111"><titleInfo><title>Adverse reactions of anti‐tuberculosis drugs in hospitalized patients: Incidence, severity and risk factors</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Javadi MR, Shalviri G, Gholami K, Salamzadeh J, Maghooli G, Mirsaeedi SM. Adverse reactions of anti‐tuberculosis drugs in hospitalized patients: Incidence, severity and risk factors. Pharmacoepidemiol Drug Saf (2007); 16: 1104.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1104</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1104</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit112"><titleInfo><title>Safety and efficacy of colistin compared with imipenem in the treatment of ventilator‐associated pneumonia: A matched case‐control study</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kallel H, Hergafi L, Bahloul M, Hakim A, Dammak H, Chelly H, Ben Hamida C, Chaari A, Rekik N, Bouaziz M. Safety and efficacy of colistin compared with imipenem in the treatment of ventilator‐associated pneumonia: A matched case‐control study. Intensive Care Med (2007); 33: 1162.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>33</number></detail><extent unit="pages"><start>1162</start></extent></part><relatedItem type="host"><titleInfo><title>Intensive Care Med</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>33</number></detail><extent unit="pages"><start>1162</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit113"><titleInfo><title>“Ciprofloxacin‐induced” bilateral rectus femoris tendon rupture</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Karistinos A, Paulos LE. “Ciprofloxacin‐induced” bilateral rectus femoris tendon rupture. Clin J Sport Med (2007); 17: 406.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>17</number></detail><extent unit="pages"><start>406</start></extent></part><relatedItem type="host"><titleInfo><title>Clin J Sport Med</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>17</number></detail><extent unit="pages"><start>406</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit114"><titleInfo><title>QT interval prolongation and torsades de pointes due to a coadministration of ciprofloxacin and azimilide in a patient with implantable cardioverter‐defibrillator</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kazmierczak J, Peregud‐Pogorzelska M, Rzeuski R. QT interval prolongation and torsades de pointes due to a coadministration of ciprofloxacin and azimilide in a patient with implantable cardioverter‐defibrillator. Pacing Clin Electrophysiol (2007); 30: 1043.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>30</number></detail><extent unit="pages"><start>1043</start></extent></part><relatedItem type="host"><titleInfo><title>Pacing Clin Electrophysiol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>30</number></detail><extent unit="pages"><start>1043</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit115"><titleInfo><title>Misperceptions regarding influenza vaccine safety for individuals with chronic medical illness</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kempe A, Daley MF, Crane LA, Barrow J, Chandrarnouli V, Beaty BL, Allred NJ, Bennan S. Misperceptions regarding influenza vaccine safety for individuals with chronic medical illness. Prev Med (2007); 45: 80.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>80</start></extent></part><relatedItem type="host"><titleInfo><title>Prev Med</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>80</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit116"><titleInfo><title>Drug‐drug interaction between itraconazole and efavirenz in a patient with AIDS and disseminated histoplasmosis</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Koo HL, Hamill RJ, Andrade RA. Drug‐drug interaction between itraconazole and efavirenz in a patient with AIDS and disseminated histoplasmosis. Clin Infect Dis (2007); 45: e77.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>e77</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Infect Dis</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>e77</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit117"><titleInfo><title>Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug‐resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Koomanachai P, Tiengrim S, Kiratisin P, Thamlikitkul V. Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug‐resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand. Int J Infect Dis (2007); 11: 402.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><extent unit="pages"><start>402</start></extent></part><relatedItem type="host"><titleInfo><title>Int J Infect Dis</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><extent unit="pages"><start>402</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit118"><titleInfo><title>Adverse effects during the treatment with pegylated interferon and ribavirin in children with chronic hepatitis C</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kowala‐Piaskowska A, Mozer‐Lisewska I, Figlerowicz M, Sluzewski W. Adverse effects during the treatment with pegylated interferon and ribavirin in children with chronic hepatitis C. Pharmacoepidemiol Drug Saf (2007); 16: 1095.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1095</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1095</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit119"><titleInfo><title>Safety, immunogenicity, and antibody persistence of a meningococcal group A conjugate vaccine in healthy Indian adults</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kshirsagar N, Mur N, Thatte U, Gogtay N, Viviani S, Preziosi MP, Elie C, Findlow H, Carlone G, Borrow R, Parulekar V, Plikaytis B, Kulkarni P, Imbault N, LaForce FM. Safety, immunogenicity, and antibody persistence of a meningococcal group A conjugate vaccine in healthy Indian adults. Vaccine (2007); 25: A101.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>A101</start></extent></part><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>A101</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit120"><titleInfo><title>Efficacy and safety of inhaled zanamivir in the prevention of influenza in community‐dwelling, high‐risk adult and adolescent subjects: A 28‐day, multicenter, randomized, double‐blind, placebo‐controlled trial</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">LaForce C, Man CY, Henderson FW, McElhaney JE, Hampel FC, Bettis R, Kudule L, Harris J, Yates P, Tisdale M, Webster A. Efficacy and safety of inhaled zanamivir in the prevention of influenza in community‐dwelling, high‐risk adult and adolescent subjects: A 28‐day, multicenter, randomized, double‐blind, placebo‐controlled trial. Clin Ther (2007); 29: 1579.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>1579</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Ther</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>1579</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit121"><titleInfo><title>Initiation of methamphetamine abuse during interferon treatment (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lampinen TM, Greatheart MS, Schilder AJ, Kowdley K. Initiation of methamphetamine abuse during interferon treatment (Letter). Am J Psychiatry (2007); 164: 1439.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>164</number></detail><extent unit="pages"><start>1439</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Psychiatry</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>164</number></detail><extent unit="pages"><start>1439</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit122"><titleInfo><title>Images in emergency medicine ‐ Diagnosis: Serum sickness‐like reaction to amoxicillin</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lin B, Strehlow M. Images in emergency medicine ‐ Diagnosis: Serum sickness‐like reaction to amoxicillin. Ann Emerg Med (2007); 50: 350.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>50</number></detail><extent unit="pages"><start>350</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Emerg Med</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>50</number></detail><extent unit="pages"><start>350</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit123"><titleInfo><title>Treatment of respiratory tract infections with moxifloxacin: Results of postmarketing surveillance in China</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Liu LY, Landen H. Treatment of respiratory tract infections with moxifloxacin: Results of postmarketing surveillance in China. Int J Clin Pract (2007); 61: 1509.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>61</number></detail><extent unit="pages"><start>1509</start></extent></part><relatedItem type="host"><titleInfo><title>Int J Clin Pract</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>61</number></detail><extent unit="pages"><start>1509</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit124"><titleInfo><title>Depression following pegylated interferon‐α: Characteristics and vunerability</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lotrich FE, Rabinovitz M, Gironda P, Pollock BG. Depression following pegylated interferon‐α: Characteristics and vunerability. J Psychosom Res (2007); 63: 131.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>63</number></detail><extent unit="pages"><start>131</start></extent></part><relatedItem type="host"><titleInfo><title>J Psychosom Res</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>63</number></detail><extent unit="pages"><start>131</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit125"><titleInfo><title>Association of saquinavir plasma concentrations with side effects but not with antiretroviral outcome in patients infected with protease inhibitor‐susceptible human immunodeficiency virus type 1</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lotsch J, Harder S, Sturmer M, Doerr HW, Geisslinger G, Staszewski S, Von Hentig N. Association of saquinavir plasma concentrations with side effects but not with antiretroviral outcome in patients infected with protease inhibitor‐susceptible human immunodeficiency virus type 1. Antimicrob Agents Chemother (2007); 51: 3264.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>51</number></detail><extent unit="pages"><start>3264</start></extent></part><relatedItem type="host"><titleInfo><title>Antimicrob Agents Chemother</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>51</number></detail><extent unit="pages"><start>3264</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit126"><titleInfo><title>Pure red blood cell aplasia and isoniazid use (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Loulergue P, Mir O, Dhote R. Pure red blood cell aplasia and isoniazid use (Letter). Emerg Infect Dis (2007); 13: 1427.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>1427</start></extent></part><relatedItem type="host"><titleInfo><title>Emerg Infect Dis</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>1427</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit127"><titleInfo><title>Immunogenicity and safety of a virosomal hepatitis A vaccine in HIV‐positive patients</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Loutan L, Bovier P, Herzog C. Immunogenicity and safety of a virosomal hepatitis A vaccine in HIV‐positive patients. Vaccine (2007); 25: 6310.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>6310</start></extent></part><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>6310</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit128"><titleInfo><title>A large prospective study assessing injection site reactions, quality of life and preference in patients using the Biojector® vs standard needles for enfuvirtide administration</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Loutfy MR, Harris M, Raboud JM, Antoniou T, Kovacs C, Shen S, Dufresne S, Smaill F, Rouleau D, Rachlis A, Gough K, Lalonde R, Tsoukas C, Trottier B, Walmsley SL, Montaner JS. A large prospective study assessing injection site reactions, quality of life and preference in patients using the Biojector® vs standard needles for enfuvirtide administration. HIV Med (2007); 8: 427.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>427</start></extent></part><relatedItem type="host"><titleInfo><title>HIV Med</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>427</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit129"><titleInfo><title>Assessment of adverse events associated with antiretroviral regimens for postexposure prophylaxis for occupational and nonoccupational exposures to prevent transmission of human immunodeficiency virus</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Luque A, Hulse S, Wang D, Shahzad U, Tanzman E, Antenozzi S, Smith B. Assessment of adverse events associated with antiretroviral regimens for postexposure prophylaxis for occupational and nonoccupational exposures to prevent transmission of human immunodeficiency virus. Infect Control Hosp Epidemiol (2007); 28: 695.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>695</start></extent></part><relatedItem type="host"><titleInfo><title>Infect Control Hosp Epidemiol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>695</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit130"><titleInfo><title>Life‐threatening, multiple hypersensitivity reactions induced by rifampicin in one patient with pulmonary tuberculosis (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Luzzati R, Giacomazzi D, Franchi F, Barcobello M, Vento S. Life‐threatening, multiple hypersensitivity reactions induced by rifampicin in one patient with pulmonary tuberculosis (Letter). South Med J (2007); 100: 854.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>100</number></detail><extent unit="pages"><start>854</start></extent></part><relatedItem type="host"><titleInfo><title>South Med J</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>100</number></detail><extent unit="pages"><start>854</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit131"><titleInfo><title>Calcified subcutaneous nodules: A long‐term complication of interferon β‐1 a therapy (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Macbeth AE, Kendall BR, Smith A, Saldanha G, Harman KE. Calcified subcutaneous nodules: A long‐term complication of interferon β‐1 a therapy (Letter). Br J Dermatol (2007); 157: 624.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>157</number></detail><extent unit="pages"><start>624</start></extent></part><relatedItem type="host"><titleInfo><title>Br J Dermatol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>157</number></detail><extent unit="pages"><start>624</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit132"><titleInfo><title>Safety and pharmacokinetics of bevirimat (PA‐457), a novel inhibitor of human immunodeficiency virus maturation, in healthy volunteers</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Martin DE, Blum R, Wilton J, Doto J, Galbraith H, Burgess GL, Smith PC, Ballow C. Safety and pharmacokinetics of bevirimat (PA‐457), a novel inhibitor of human immunodeficiency virus maturation, in healthy volunteers. Antimicrob Agents Chemother (2007); 51: 3063.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>51</number></detail><extent unit="pages"><start>3063</start></extent></part><relatedItem type="host"><titleInfo><title>Antimicrob Agents Chemother</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>51</number></detail><extent unit="pages"><start>3063</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit133"><titleInfo><title>Scleral and conjunctival pigmentation following minocycline therapy (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">McAllum P, Slomovic A. Scleral and conjunctival pigmentation following minocycline therapy (Letter). Can J Ophthalmol (2007); 42: 626.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>42</number></detail><extent unit="pages"><start>626</start></extent></part><relatedItem type="host"><titleInfo><title>Can J Ophthalmol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>42</number></detail><extent unit="pages"><start>626</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit134"><titleInfo><title>Reversible optic neuropathy due to metronidazole (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">McGrath NM, Kent‐Smith B, Sharp DM. Reversible optic neuropathy due to metronidazole (Letter). Clin Exp Ophthalmol (2007); 35: 585.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>35</number></detail><extent unit="pages"><start>585</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Exp Ophthalmol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>35</number></detail><extent unit="pages"><start>585</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit135"><titleInfo><title>Monitoring and evaluation of suspected complications of vaccination (German, English Abstract)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mentzer D, Weiber K, Keller‐Stanislawski B. Monitoring and evaluation of suspected complications of vaccination (German, English Abstract). Monatsschr Kinderheilk (2007); 155: 709.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>155</number></detail><extent unit="pages"><start>709</start></extent></part><relatedItem type="host"><titleInfo><title>Monatsschr Kinderheilk</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>155</number></detail><extent unit="pages"><start>709</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit136"><titleInfo><title>Single‐ and multiple‐dose administration of caspofungin in patients with hepatic insufficiency: Implications for safety and dosing recommendations</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mistry GC, Migoya E, Deutsch PJ, Winchell G, Hesney M, Li S, Bi S, Dilzer S, Lasseter KC, Stone JA. Single‐ and multiple‐dose administration of caspofungin in patients with hepatic insufficiency: Implications for safety and dosing recommendations. J Clin Pharmacol (2007); 47: 951.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>47</number></detail><extent unit="pages"><start>951</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Pharmacol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>47</number></detail><extent unit="pages"><start>951</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit137"><titleInfo><title>Electrocardiographic safety evaluation of dihydroartemisinin‐piperaquine in the treatment of uncomplicated falciparum malaria</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mytton OT, Ashley EA, Peto L, Price RN, La Y, Hae R, Singhasivanon P, White NJ, Nosten F. Electrocardiographic safety evaluation of dihydroartemisinin‐piperaquine in the treatment of uncomplicated falciparum malaria. Am J Trop Med Hyg (2007); 77: 447.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>77</number></detail><extent unit="pages"><start>447</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Trop Med Hyg</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>77</number></detail><extent unit="pages"><start>447</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit138"><titleInfo><title>Acute hepatitis attack after exposure to telithromycin</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Onur O, Guneysel O, Denizbasi A, Celikel C. Acute hepatitis attack after exposure to telithromycin. Clin Ther (2007); 29: 1725.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>1725</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Ther</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>1725</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit139"><titleInfo><title>Atazanavir‐associated menorrhagia (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Paparizos VA, Kourkounti S, Leuow K, Kyriakis KP, Botsi C, Katsambas AD. Atazanavir‐associated menorrhagia (Letter). Int J STD AIDS (2007); 18: 651.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>651</start></extent></part><relatedItem type="host"><titleInfo><title>Int J STD AIDS</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>651</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit140"><titleInfo><title>Outcomes of dosage adjustments used to manage antiretroviral drug interactions</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Park‐Wyllie LY, Levine MA, Holbrook A, Thabane L, Antoniou T, Yoong D, Kam D, Bayoumi AM. Outcomes of dosage adjustments used to manage antiretroviral drug interactions. Clin Infect Dis (2007); 45: 933.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>933</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Infect Dis</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>933</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit141"><titleInfo><title>Oral resiquimod in chronic HCV infection: Safety and efficacy in 2 placebo‐controlled, double blind phase IIa studies</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Pockros PJ, Guyader D, Patton H, Tong MJ, Wright T, McHutchison JG, Meng TC. Oral resiquimod in chronic HCV infection: Safety and efficacy in 2 placebo‐controlled, double blind phase IIa studies. J Hepatol (2007); 47: 174.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>47</number></detail><extent unit="pages"><start>174</start></extent></part><relatedItem type="host"><titleInfo><title>J Hepatol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>47</number></detail><extent unit="pages"><start>174</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit142"><titleInfo><title>High‐dose lopinavir/ritonavir in highly treatment‐experienced HIV‐1 patients: Efficacy, safety, and predictors of response</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Podzamczer D, King MS, Klein CE, Flexner C, Katlama C, Havlir DV, Letendre SL, Eron JJ, Brun SC, Bernstein B. High‐dose lopinavir/ritonavir in highly treatment‐experienced HIV‐1 patients: Efficacy, safety, and predictors of response. HIV Clin Trials (2007); 8: 193.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>193</start></extent></part><relatedItem type="host"><titleInfo><title>HIV Clin Trials</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>193</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit143"><titleInfo><title>Phase 3 safety comparisons for 1.0% azithromycin in polymeric mucoadhesive eye drops versus 0.3% tobramycin eye drops for bacterial conjunctivitis</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Protzko E, Bowman L, Abelson M, Shapiro A. Phase 3 safety comparisons for 1.0% azithromycin in polymeric mucoadhesive eye drops versus 0.3% tobramycin eye drops for bacterial conjunctivitis. Invest Ophthalmol Vis Sci (2007); 48: 3425.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>48</number></detail><extent unit="pages"><start>3425</start></extent></part><relatedItem type="host"><titleInfo><title>Invest Ophthalmol Vis Sci</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>48</number></detail><extent unit="pages"><start>3425</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit144"><titleInfo><title>Safety, tolerability, and efficacy of darunavir (TMC114) and low‐dose ritonavir in treatment‐experienced, hepatitis B or C co‐infected patients in POWER 1 and 3</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Rachlis A, Clotet B, Baxter J, Murphy R, Lefebvre E. Safety, tolerability, and efficacy of darunavir (TMC114) and low‐dose ritonavir in treatment‐experienced, hepatitis B or C co‐infected patients in POWER 1 and 3. HIV Clin Trials (2007); 8: 213.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>213</start></extent></part><relatedItem type="host"><titleInfo><title>HIV Clin Trials</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>213</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit145"><titleInfo><title>Safety and efficacy of oral HD‐03/ES given for six months in patients with chronic hepatitis B virus infection</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Rajkumar JS, Sekar MG, Mitra SK. Safety and efficacy of oral HD‐03/ES given for six months in patients with chronic hepatitis B virus infection. World J Gastroenterol (2007); 13: 4103.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>4103</start></extent></part><relatedItem type="host"><titleInfo><title>World J Gastroenterol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>4103</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit146"><titleInfo><title>Recognition by French courts of compensation for post‐vaccination multiple sclerosis: The consequences with regard to expert practice</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Rouge‐Maillart CI, Guillaume N, Jousset N, Penneau M. Recognition by French courts of compensation for post‐vaccination multiple sclerosis: The consequences with regard to expert practice. Med Sci Law (2007); 47: 185.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>47</number></detail><extent unit="pages"><start>185</start></extent></part><relatedItem type="host"><titleInfo><title>Med Sci Law</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>47</number></detail><extent unit="pages"><start>185</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit147"><titleInfo><title>Retinopathy in a multiple sclerosis patient undergoing interferon‐therapy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Saito H, Suzuki M, Asakowa T, Kato S. Retinopathy in a multiple sclerosis patient undergoing interferon‐therapy. Mult Scler (2007); 13: 939.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>939</start></extent></part><relatedItem type="host"><titleInfo><title>Mult Scler</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>939</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit148"><titleInfo><title>Amoxicillin‐associated linear IgA bullous dermatosis (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Santos‐Juanes J, Hernandez RC, Trapiella L, Caminal L, Del Rio JS, Soto J. Amoxicillin‐associated linear IgA bullous dermatosis (Letter). J Eur Acad Dermatol Venereol (2007); 21: 992.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>992</start></extent></part><relatedItem type="host"><titleInfo><title>J Eur Acad Dermatol Venereol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>992</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit149"><titleInfo><title>Acute pancreatitis in a patient treated with micafungin</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sato K, Hayashi M, Utsugi M, Ishizuka T, Takagi H, Mori M. Acute pancreatitis in a patient treated with micafungin. Clin Ther (2007); 29: 1468.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>1468</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Ther</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>1468</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit150"><titleInfo><title>Generalized lichen nitidus with involvement of the palms following interferon α treatment</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Scheler M, Proelss J, Brauninger W, Bieber T, Wenzel J. Generalized lichen nitidus with involvement of the palms following interferon α treatment. Dermatology (2007); 215: 236.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>215</number></detail><extent unit="pages"><start>236</start></extent></part><relatedItem type="host"><titleInfo><title>Dermatology</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>215</number></detail><extent unit="pages"><start>236</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit151"><titleInfo><title>Membranous nephropathy associated with fluconazole treatment</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Shin GT, Yim H, Park J, Kim H. Membranous nephropathy associated with fluconazole treatment. Am J Kidney Dis (2007); 49: 318.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>49</number></detail><extent unit="pages"><start>318</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Kidney Dis</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>49</number></detail><extent unit="pages"><start>318</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit152"><titleInfo><title>Ciprofloxacin crystal nephropathy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G. Ciprofloxacin crystal nephropathy. Am J Kidney Dis (2007); 50: 330.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>50</number></detail><extent unit="pages"><start>330</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Kidney Dis</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>50</number></detail><extent unit="pages"><start>330</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit153"><titleInfo><title>Epileptic myoclonus as ciprofloxacin‐associated adverse effect (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Striano P, Zara F, Coppola A, Ciampa C, Pezzella M, Striano S. Epileptic myoclonus as ciprofloxacin‐associated adverse effect (Letter). Mov Disord (2007); 22: 1675.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><extent unit="pages"><start>1675</start></extent></part><relatedItem type="host"><titleInfo><title>Mov Disord</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><extent unit="pages"><start>1675</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit154"><titleInfo><title>Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Thompson WW, Price C, Goodson B, Shay DK, Benson P, Hinrichsen VL, Lewis E, Eriksen E, Ray P, Marcy SM, Dunn J, Jackson LA, Lieu TA, Black S, Stewart G, Weintraub ES, Davis RL, DeStefano F. Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years. N Engl J Med (2007); 357: 1281.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>357</number></detail><extent unit="pages"><start>1281</start></extent></part><relatedItem type="host"><titleInfo><title>N Engl J Med</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>357</number></detail><extent unit="pages"><start>1281</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit155"><titleInfo><title>A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine ‐ ALVAC‐HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI‐DID) or bivalent gp120 (CM235/SF2) boost</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Thongcharoen P, Suriyanon V, Paris RM, Khamboonruang C, De Souza MS, Ratto‐Kim S, Karnasuta C, Polonis VR, Baglyos L, Habib RE, Gurunathan S, Barnett S, Brown AE, Birx DL, McNeil JG, Kim JH. A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine ‐ ALVAC‐HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI‐DID) or bivalent gp120 (CM235/SF2) boost. J Acquir Immune Defic Syndr Hum Retrovirol (2007); 46: 48.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>48</start></extent></part><relatedItem type="host"><titleInfo><title>J Acquir Immune Defic Syndr Hum Retrovirol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>48</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit156"><titleInfo><title>Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON™), an investigational synthetic Toll‐like receptor 9 agonist</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Vicari AP, Schmalbach T, Lekstrom‐Himes J, Morris ML, Al‐Adhami MJ, Lafromboise C, Leese P, Krieg AM, Efler SM, Davis HL. Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON™), an investigational synthetic Toll‐like receptor 9 agonist. Antivir Ther (2007); 12: 741.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>12</number></detail><extent unit="pages"><start>741</start></extent></part><relatedItem type="host"><titleInfo><title>Antivir Ther</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>12</number></detail><extent unit="pages"><start>741</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit157"><titleInfo><title>Renal safety of tenofovir in HIV‐infected children ‐ A prospective, 96‐week longitudinal study</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Vigano A, Zuccotti GV, Martelli L, Giacomet V, Cafarelli L, Borgonovo S, Beretta S, Rombola G, Mora S. Renal safety of tenofovir in HIV‐infected children ‐ A prospective, 96‐week longitudinal study. Clin Drug Invest (2007); 27: 573.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>573</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Drug Invest</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>573</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit158"><titleInfo><title>Maintenance of indinavir by dose adjustment in HIV‐1‐infected patients with indinavir‐related toxicity</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wasmuth JC, Lambertz I, Voigt E, Vogel M, Hoffmann C, Burger D, Rockstroh JK. Maintenance of indinavir by dose adjustment in HIV‐1‐infected patients with indinavir‐related toxicity. Eur J Clin Pharmacol (2007); 63: 901.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>63</number></detail><extent unit="pages"><start>901</start></extent></part><relatedItem type="host"><titleInfo><title>Eur J Clin Pharmacol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>63</number></detail><extent unit="pages"><start>901</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit159"><titleInfo><title>Developmental regression and autism reported to the Vaccine Adverse Event Reporting System</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Woo EJ, Ball R, Landa R, Zimmerman AW, Braun MM. Developmental regression and autism reported to the Vaccine Adverse Event Reporting System. Autism (2007); 11: 301.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><extent unit="pages"><start>301</start></extent></part><relatedItem type="host"><titleInfo><title>Autism</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><extent unit="pages"><start>301</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit160"><titleInfo><title>Pure pandysautonomia associated with interferon‐α therapy (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Yokote H, Saitou Y, Kanda T, Mizusawa H. Pure pandysautonomia associated with interferon‐α therapy (Letter). J Neurol (2007); 254: 961.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>254</number></detail><extent unit="pages"><start>961</start></extent></part><relatedItem type="host"><titleInfo><title>J Neurol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>254</number></detail><extent unit="pages"><start>961</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit161"><titleInfo><title>4. Cardiovascular System Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit162"><titleInfo><title>Hospitalization rates of generic metoprolol compared with the original β‐blocker in an epidemiological database study</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ahrens W, Hagemeier C, Muhlbauer B, Pigeot I, Puntmann I, Reineke A, Steinbach M, Timm J. Hospitalization rates of generic metoprolol compared with the original β‐blocker in an epidemiological database study. Pharmacoepidemiol Drug Saf (2007); 16: 1298.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1298</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1298</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit163"><titleInfo><title>Pegaptanib 1‐year systemic safety results from a safety‐pharmacokinetic trial in patients with neovascular age‐related macular degeneration</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Apte RS. Pegaptanib 1‐year systemic safety results from a safety‐pharmacokinetic trial in patients with neovascular age‐related macular degeneration. Ophthalmology (2007); 114: 1702.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>114</number></detail><extent unit="pages"><start>1702</start></extent></part><relatedItem type="host"><titleInfo><title>Ophthalmology</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>114</number></detail><extent unit="pages"><start>1702</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit164"><titleInfo><title>Amiodarone as cause of thyrotoxic hypopotasemic periodic paralysis (Reply) (Spanish)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Atienza Morales MP, Jimenez Garcia JA, Beato Perez JL, Aguilar Campos AJ. Amiodarone as cause of thyrotoxic hypopotasemic periodic paralysis (Reply) (Spanish). Rev Clin Espan (2007); 207: 378.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>207</number></detail><extent unit="pages"><start>378</start></extent></part><relatedItem type="host"><titleInfo><title>Rev Clin Espan</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>207</number></detail><extent unit="pages"><start>378</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit165"><titleInfo><title>Corneal oedema and acute anterior uveitis after two doses of travoprost (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Aydin S, Ozcura F. Corneal oedema and acute anterior uveitis after two doses of travoprost (Letter). Acta Ophthalmol Scand (2007); 85: 693.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>85</number></detail><extent unit="pages"><start>693</start></extent></part><relatedItem type="host"><titleInfo><title>Acta Ophthalmol Scand</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>85</number></detail><extent unit="pages"><start>693</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit166"><titleInfo><title>Pharmacokinetics and safety of intravenously administered citrulline in children undergoing congenital heart surgery: Potential therapy for postoperative pulmonary hypertension</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Barr FE, Tirona RG, Taylor MB, Rice G, Arnold J, Cunningham G, Smith HAB, Campbell A, Canter JA, Christian KG, Drinkwater DC, Scholl F, Kavanaugh‐McHugh A, Summar ML. Pharmacokinetics and safety of intravenously administered citrulline in children undergoing congenital heart surgery: Potential therapy for postoperative pulmonary hypertension. J Thorac Cardiovasc Surg (2007); 134: 319.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>134</number></detail><extent unit="pages"><start>319</start></extent></part><relatedItem type="host"><titleInfo><title>J Thorac Cardiovasc Surg</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>134</number></detail><extent unit="pages"><start>319</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit167"><titleInfo><title>Amiodarone as cause of thyrotoxic hypokalaemic periodic paralysis (Letter) (Spanish)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Blanco Jarava A, Moreno Rodriguez A, Cano Llorente V, Espinosa Magro P, Sanchez Castano A, Gonzalez Moraleja J. Amiodarone as cause of thyrotoxic hypokalaemic periodic paralysis (Letter) (Spanish). Rev Clin Espan (2007); 207: 377.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>207</number></detail><extent unit="pages"><start>377</start></extent></part><relatedItem type="host"><titleInfo><title>Rev Clin Espan</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>207</number></detail><extent unit="pages"><start>377</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit168"><titleInfo><title>Safety of amlodipine use in patients with acute intermittent porphyria (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Cinemre H, Korkmaz U, Alcelik A, Onder E, Gungor A. Safety of amlodipine use in patients with acute intermittent porphyria (Letter). Br J Clin Pharmacol (2007); 64: 246.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>64</number></detail><extent unit="pages"><start>246</start></extent></part><relatedItem type="host"><titleInfo><title>Br J Clin Pharmacol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>64</number></detail><extent unit="pages"><start>246</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit169"><titleInfo><title>Amlodipine‐induced bilateral upper extremity edema</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ganeshalingham A, Wong W. Amlodipine‐induced bilateral upper extremity edema. Ann Pharmacother (2007); 41: 1536.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>1536</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Pharmacother</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>1536</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit170"><titleInfo><title>Efficacy and safety of nifedipine GITS in Asians with hypertension ‐ Results of a post‐marketing surveillance study in China</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gao RL, Zhu JR, Liu GZ, Zhang WZ, Zhang TJ, Sun NL, Landen H. Efficacy and safety of nifedipine GITS in Asians with hypertension ‐ Results of a post‐marketing surveillance study in China. Clin Drug Invest (2007); 27: 565.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>565</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Drug Invest</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>565</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit171"><titleInfo><title>Potential link between HMG‐CoA reductase inhibitor (statin) use and interstitial lung disease (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Golomb BA, Evans MA. Potential link between HMG‐CoA reductase inhibitor (statin) use and interstitial lung disease (Letter). Med J Aust (2007); 187: 253.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>187</number></detail><extent unit="pages"><start>253</start></extent></part><relatedItem type="host"><titleInfo><title>Med J Aust</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>187</number></detail><extent unit="pages"><start>253</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit172"><titleInfo><title>Adverse events of blood‐pressure‐lowering drugs: Evidence of high incidence in a clinical setting</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Goncalves CBC, Moreira LB, Gus M, Fuchs FD. Adverse events of blood‐pressure‐lowering drugs: Evidence of high incidence in a clinical setting. Eur J Clin Pharmacol (2007); 63: 973.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>63</number></detail><extent unit="pages"><start>973</start></extent></part><relatedItem type="host"><titleInfo><title>Eur J Clin Pharmacol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>63</number></detail><extent unit="pages"><start>973</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit173"><titleInfo><title>The impact of pharmaceuticals on the decline of cardiovascular mortality in Germany</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Haussler B, Schiffhorst G, Gothe H, Hempel E. The impact of pharmaceuticals on the decline of cardiovascular mortality in Germany. Pharmacoepidemiol Drug Saf (2007); 16: 1167.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1167</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1167</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit174"><titleInfo><title>A double‐blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: The ERGO (Etomoxir for the Recovery of Glucose Oxidation) study</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Holubarsch CJF, Rohrbach M, Karrasch M, Boehm E, Polonski L, Ponikowski P, Rhein S. A double‐blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: The ERGO (Etomoxir for the Recovery of Glucose Oxidation) study. Clin Sci (2007); 113: 205.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>113</number></detail><extent unit="pages"><start>205</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Sci</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>113</number></detail><extent unit="pages"><start>205</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit175"><titleInfo><title>Results of European post‐marketing surveillance of bosentan in pulmonary hypertension</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Humbert M, Segal ES, Kiely DG, Carlsen J, Schwierin B, Hoeper MM. Results of European post‐marketing surveillance of bosentan in pulmonary hypertension. Eur Resp J (2007); 30: 338.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>30</number></detail><extent unit="pages"><start>338</start></extent></part><relatedItem type="host"><titleInfo><title>Eur Resp J</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>30</number></detail><extent unit="pages"><start>338</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit176"><titleInfo><title>Efficacy and safety of extended‐release fluvastatin in Turkish patients with hypercholesterolaemia: TULIPS (Turkish Lipid Study)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ilerigelen B, Uresin Y, San M, Kultusay H, Guneri S, Serdar OA, Gulec S, Pencedemir H. Efficacy and safety of extended‐release fluvastatin in Turkish patients with hypercholesterolaemia: TULIPS (Turkish Lipid Study). Curr Med Res Opin (2007); 23: 1093.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>1093</start></extent></part><relatedItem type="host"><titleInfo><title>Curr Med Res Opin</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>1093</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit177"><titleInfo><title>Intravitreal bevacizuman (Avastin) treatment is safe in terms of intraocular and blood pressure (Reply)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kernt M, Neubauer AS, Kampik A. Intravitreal bevacizuman (Avastin) treatment is safe in terms of intraocular and blood pressure (Reply). Acta Ophthalmol Scand (2007); 85: 574.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>85</number></detail><extent unit="pages"><start>574</start></extent></part><relatedItem type="host"><titleInfo><title>Acta Ophthalmol Scand</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>85</number></detail><extent unit="pages"><start>574</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit178"><titleInfo><title>Safety and efficacy of atorvastatin‐induced very low‐density lipoprotein cholesterol levels in patients with coronary heart disease (a post hoc analysis of the Treating to New Targets [TNT] study)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">LaRosa JC, Grundy SM, Kastelein JJP, Kostis JB, Greten H. Safety and efficacy of atorvastatin‐induced very low‐density lipoprotein cholesterol levels in patients with coronary heart disease (a post hoc analysis of the Treating to New Targets [TNT] study). Am J Cardiol (2007); 100: 747.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>100</number></detail><extent unit="pages"><start>747</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Cardiol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>100</number></detail><extent unit="pages"><start>747</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit179"><titleInfo><title>Rhabdomyolysis associated to combined ezetimibe‐statin treatment (Letter) (Spanish)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Leon MP, Unzueta MTG, Martinez MO, Senaris JAA. Rhabdomyolysis associated to combined ezetimibe‐statin treatment (Letter) (Spanish). Rev Clin Espan (2007); 207: 425.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>207</number></detail><extent unit="pages"><start>425</start></extent></part><relatedItem type="host"><titleInfo><title>Rev Clin Espan</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>207</number></detail><extent unit="pages"><start>425</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit180"><titleInfo><title>An instructive example of a long‐latency adverse drug reaction—sclerosing peritonitis due to practolol</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mann RD. An instructive example of a long‐latency adverse drug reaction—sclerosing peritonitis due to practolol. Pharmacoepidemiol Drug Saf (2007); 16: 1211.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1211</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1211</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit181"><titleInfo><title>Rebound effect after prostacyclin inhalation in pulmonary hypertension (Letter) (Spanish)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Moro JA, Almenar L, Morales P, Osa A. Rebound effect after prostacyclin inhalation in pulmonary hypertension (Letter) (Spanish). Med Clin (Barc) (2007); 129: 279.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>129</number></detail><extent unit="pages"><start>279</start></extent></part><relatedItem type="host"><titleInfo><title>Med Clin (Barc)</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>129</number></detail><extent unit="pages"><start>279</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit182"><titleInfo><title>Worsening of motor symptoms and gynecomastia during spironolactone treatment in a patient with Parkinson's disease and congestive heart failure (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Munhoz RP, Werneck LC. Worsening of motor symptoms and gynecomastia during spironolactone treatment in a patient with Parkinson's disease and congestive heart failure (Letter). Mov Disord (2007); 22: 1678.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><extent unit="pages"><start>1678</start></extent></part><relatedItem type="host"><titleInfo><title>Mov Disord</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><extent unit="pages"><start>1678</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit183"><titleInfo><title>Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Nichols GA, Koro CE. Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients. Clin Ther (2007); 29: 1761.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>1761</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Ther</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>1761</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit184"><titleInfo><title>A multi‐centre, randomised, double‐blind 14‐week extension study examining the long‐term safety and efficacy profile of the ezetimibe/simvastatin combination tablet</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ose L, Johnson‐Levonas A, Reyes R, Lin J, Shah A, Tribble D, Musliner T. A multi‐centre, randomised, double‐blind 14‐week extension study examining the long‐term safety and efficacy profile of the ezetimibe/simvastatin combination tablet. Int J Clin Pract (2007); 61: 1469.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>61</number></detail><extent unit="pages"><start>1469</start></extent></part><relatedItem type="host"><titleInfo><title>Int J Clin Pract</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>61</number></detail><extent unit="pages"><start>1469</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit185"><titleInfo><title>Cutaneous vasculitis induced by carvedilol (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Pavlovic M, Simic VD, Zolotarevski L, Zecevic RD, Vesic S. Cutaneous vasculitis induced by carvedilol (Letter). J Eur Acad Dermatol Venereol (2007); 21: 1004.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>1004</start></extent></part><relatedItem type="host"><titleInfo><title>J Eur Acad Dermatol Venereol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>1004</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit186"><titleInfo><title>Safety and efficacy of extended‐release ranolazine in patients aged 70 years or older with chronic stable angina pectoris</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Rich MW, Crager M, McKay CR. Safety and efficacy of extended‐release ranolazine in patients aged 70 years or older with chronic stable angina pectoris. Am J Geriatr Cardiol (2007); 16: 216.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>216</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Geriatr Cardiol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>216</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit187"><titleInfo><title>Hyponatremia induced by amiodarone therapy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Shavit E, Sherer Y. Hyponatremia induced by amiodarone therapy. Isr Med Assoc J (2007); 9: 564.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>564</start></extent></part><relatedItem type="host"><titleInfo><title>Isr Med Assoc J</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>564</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit188"><titleInfo><title>A postmarketing surveillance study of fasudil treatment after aneurysmal subarachnoid hemorrhage</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Suzuki Y, Shibuya M, Satoh SI, Sugimoto Y, Takakura K. A postmarketing surveillance study of fasudil treatment after aneurysmal subarachnoid hemorrhage. Surg Neurol (2007); 68: 126.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>68</number></detail><extent unit="pages"><start>126</start></extent></part><relatedItem type="host"><titleInfo><title>Surg Neurol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>68</number></detail><extent unit="pages"><start>126</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit189"><titleInfo><title>Myopathy associated with statin therapy (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wahl D, Petitpain N, Frederic M. Myopathy associated with statin therapy (Letter). Neuromuscul Disord (2007); 17: 661.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>17</number></detail><extent unit="pages"><start>661</start></extent></part><relatedItem type="host"><titleInfo><title>Neuromuscul Disord</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>17</number></detail><extent unit="pages"><start>661</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit190"><titleInfo><title>Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wolozin B, Wang SW, Li NC, Lee A, Lee TA, Kazis LE. Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med (2007); 5: 20.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>20</start></extent></part><relatedItem type="host"><titleInfo><title>BMC Med</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>20</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit191"><titleInfo><title>Cardiac memory induced by QRS widening due to propafenone toxicity</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wylie JV, Zimetbaum P, Josephson ME, Shivilkin A. Cardiac memory induced by QRS widening due to propafenone toxicity. Pacing Clin Electrophysiol (2007); 30: 1161.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>30</number></detail><extent unit="pages"><start>1161</start></extent></part><relatedItem type="host"><titleInfo><title>Pacing Clin Electrophysiol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>30</number></detail><extent unit="pages"><start>1161</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit192"><titleInfo><title>Evidence for the continued safety and tolerability of fixed‐dose isosorbide dinitrate/hydralazine in patients with chronic heart failure (the extension to African‐American Heart Failure Trial)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Yancy CW, Ghali JK, Braman VM, Sabolinski ML, Worcel M, Archambault WT, Franciosa JA. Evidence for the continued safety and tolerability of fixed‐dose isosorbide dinitrate/hydralazine in patients with chronic heart failure (the extension to African‐American Heart Failure Trial). Am J Cardiol (2007); 100: 684.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>100</number></detail><extent unit="pages"><start>684</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Cardiol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>100</number></detail><extent unit="pages"><start>684</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit193"><titleInfo><title>Intravitreous bevacizumab and blood pressure: Does ‘safe’ mean ‘safe enough’? (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ziemssen F, Folprecht G, Ziemssen T. Intravitreous bevacizumab and blood pressure: Does ‘safe’ mean ‘safe enough’? (Letter). Acta Ophthalmol Scand (2007); 85: 573.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>85</number></detail><extent unit="pages"><start>573</start></extent></part><relatedItem type="host"><titleInfo><title>Acta Ophthalmol Scand</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>85</number></detail><extent unit="pages"><start>573</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit194"><titleInfo><title>5. CNS Depressive Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit195"><titleInfo><title>A case of valproate‐induced hyperammonemic encephalopathy: Look beyond the liver</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Alqahtani S, Federico P, Myers RP. A case of valproate‐induced hyperammonemic encephalopathy: Look beyond the liver. Can Med Assoc J (2007); 177: 568.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>177</number></detail><extent unit="pages"><start>568</start></extent></part><relatedItem type="host"><titleInfo><title>Can Med Assoc J</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>177</number></detail><extent unit="pages"><start>568</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit196"><titleInfo><title>Valproic acid‐induced pancreatitis (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ben Salem C, Biour M, Hmouda H, Bouraoui K. Valproic acid‐induced pancreatitis (Letter). J Gastroenterol (2007); 42: 598.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>42</number></detail><extent unit="pages"><start>598</start></extent></part><relatedItem type="host"><titleInfo><title>J Gastroenterol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>42</number></detail><extent unit="pages"><start>598</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit197"><titleInfo><title>Multiple system atrophy due to prolonged valproic acid treatment (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Borroni B, Rosati A, Costanzi C, Zulli R, Mardighian D, Gasparotti R, Padovani A. Multiple system atrophy due to prolonged valproic acid treatment (Letter). Int Psychogeriatr (2007); 19: 780.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>780</start></extent></part><relatedItem type="host"><titleInfo><title>Int Psychogeriatr</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>780</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit198"><titleInfo><title>Does therapeutic use of acetaminophen cause acute liver failure?</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Dart RC, Bailley E. Does therapeutic use of acetaminophen cause acute liver failure?. Pharmacotherapy (2007); 27: 1219.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>1219</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacotherapy</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>1219</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit199"><titleInfo><title>Reversible hepatotoxicity, pancreatitis, coagulation disorder and simultaneous bone marrow suppression with valproate in a 2‐year‐old girl</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gerstner T, Bauer MO, Longin E, Bell N, Koenig SA. Reversible hepatotoxicity, pancreatitis, coagulation disorder and simultaneous bone marrow suppression with valproate in a 2‐year‐old girl. Seizure (2007); 16: 554.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>554</start></extent></part><relatedItem type="host"><titleInfo><title>Seizure</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>554</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit200"><titleInfo><title>An open‐label, multi‐dose efficacy and safety study of intramuscular tetrodotoxin in patients with severe cancer‐related pain</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hagen NA, Fisher KM, Lapointe B, Du Sotrch P, Chary S, Moulin D, Sellers E, Ngoc AH. An open‐label, multi‐dose efficacy and safety study of intramuscular tetrodotoxin in patients with severe cancer‐related pain. J Pain Symptom Manage (2007); 34: 171.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>34</number></detail><extent unit="pages"><start>171</start></extent></part><relatedItem type="host"><titleInfo><title>J Pain Symptom Manage</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>34</number></detail><extent unit="pages"><start>171</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit201"><titleInfo><title>Hypersensitivity to paracetamol in Asian children with early onset of nonsteroidal anti‐inflammatory drug allergy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kidon MI, Liew WK, Chiang WC, Lim SH, Goh A, Tang JPL, Chay OM. Hypersensitivity to paracetamol in Asian children with early onset of nonsteroidal anti‐inflammatory drug allergy. Int Arch Allergy Immunol (2007); 144: 51.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>144</number></detail><extent unit="pages"><start>51</start></extent></part><relatedItem type="host"><titleInfo><title>Int Arch Allergy Immunol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>144</number></detail><extent unit="pages"><start>51</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit202"><titleInfo><title>Clinical profile of oxcarbazepine‐related angioneurotic edema: Case report and review</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Knudsen JF, Flowers CM, Kortepeter C, Awaad Y. Clinical profile of oxcarbazepine‐related angioneurotic edema: Case report and review. Pediatr Neurol (2007); 37: 134.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>37</number></detail><extent unit="pages"><start>134</start></extent></part><relatedItem type="host"><titleInfo><title>Pediatr Neurol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>37</number></detail><extent unit="pages"><start>134</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit203"><titleInfo><title>Acute seizures in a patient receiving divalproex sodium after starting ertapenem therapy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lunde JL, Nelson RE, Storandt HE. Acute seizures in a patient receiving divalproex sodium after starting ertapenem therapy. Pharmacotherapy (2007); 27: 1202.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>1202</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacotherapy</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>1202</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit204"><titleInfo><title>Repetitive generalized seizure‐like activity during emergence from sevoflurane anesthesia</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mohanram A, Kumar V, Iqbal Z, Markan S, Pagel PS. Repetitive generalized seizure‐like activity during emergence from sevoflurane anesthesia. Can J Anaesth (2007); 54: 657.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>54</number></detail><extent unit="pages"><start>657</start></extent></part><relatedItem type="host"><titleInfo><title>Can J Anaesth</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>54</number></detail><extent unit="pages"><start>657</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit205"><titleInfo><title>Recurrent herpes simplex virus encephalitis secondary to carbamazapine induced hypogammaglobulinaemia (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Rice CM, Johnston SL, Unsworth DJ, Glover SC, Donati M, Renowden SA, Holloway J, Lhatoo SD. Recurrent herpes simplex virus encephalitis secondary to carbamazapine induced hypogammaglobulinaemia (Letter). J Neurol Neurosurg Psychiatry (2007); 78: 1011.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>78</number></detail><extent unit="pages"><start>1011</start></extent></part><relatedItem type="host"><titleInfo><title>J Neurol Neurosurg Psychiatry</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>78</number></detail><extent unit="pages"><start>1011</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit206"><titleInfo><title>Probable levetiracetam‐induced psychosis (Letter) (Spanish)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Roig J, Carreno MM, Parellada E. Probable levetiracetam‐induced psychosis (Letter) (Spanish). Med Clin (Barc) (2007); 129: 278.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>129</number></detail><extent unit="pages"><start>278</start></extent></part><relatedItem type="host"><titleInfo><title>Med Clin (Barc)</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>129</number></detail><extent unit="pages"><start>278</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit207"><titleInfo><title>Hemodynamic and cognitive effects of lofexidine and methadone coadministration: A pilot study</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Schroeder JR, Schmittner J, Bleiberg J, Epstein DH, Krantz MJ, Preston KL. Hemodynamic and cognitive effects of lofexidine and methadone coadministration: A pilot study. Pharmacotherapy (2007); 27: 1111.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>1111</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacotherapy</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>1111</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit208"><titleInfo><title>Dexmedetomidine related cardiac arrest in a patient with permanent pacemaker; A cautionary tale</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Shah AN, Koneru J, Nicoara A, Goldfeder LB, Thomas K, Ehlert FA. Dexmedetomidine related cardiac arrest in a patient with permanent pacemaker; A cautionary tale. Pacing Clin Electrophysiol (2007); 30: 1158.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>30</number></detail><extent unit="pages"><start>1158</start></extent></part><relatedItem type="host"><titleInfo><title>Pacing Clin Electrophysiol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>30</number></detail><extent unit="pages"><start>1158</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit209"><titleInfo><title>Antimuscarinic syndrome after propofol administration in the emergency department</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Snow KA, Clements EA, Eppert AJ, Judge BS. Antimuscarinic syndrome after propofol administration in the emergency department. J Emerg Med (2007); 33: 29.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>33</number></detail><extent unit="pages"><start>29</start></extent></part><relatedItem type="host"><titleInfo><title>J Emerg Med</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>33</number></detail><extent unit="pages"><start>29</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit210"><titleInfo><title>Benzocaine‐induced methemoglobinemia in two patients: Interdisciplinary collaboration, management, and near misses</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Throm MJ, Stevens MD, Hansen C. Benzocaine‐induced methemoglobinemia in two patients: Interdisciplinary collaboration, management, and near misses. Pharmacotherapy (2007); 27: 1206.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>1206</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacotherapy</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>1206</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit211"><titleInfo><title>Valproate‐associated hyperammonemic encephalopathy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wadzinski J, Francks R, Roane D, Bayard M. Valproate‐associated hyperammonemic encephalopathy. J Am Board Fam Med (2007); 20: 499.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>499</start></extent></part><relatedItem type="host"><titleInfo><title>J Am Board Fam Med</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>499</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit212"><titleInfo><title>Efficacy and safety evaluation of once‐daily OROS hydromorphone in patients with chronic low back pain: A pilot open‐label study (DO‐127)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wallace M, Skowronski R, Khanna S, Tudor LC, Thipphawong J. Efficacy and safety evaluation of once‐daily OROS hydromorphone in patients with chronic low back pain: A pilot open‐label study (DO‐127). Curr Med Res Opin (2007); 23: 981.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>981</start></extent></part><relatedItem type="host"><titleInfo><title>Curr Med Res Opin</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>981</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit213"><titleInfo><title>Alcoholic liver disease: Is acetaminophen safe? (Comment)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Worriax JD, Yates JE, Flake D, Saseen JJ. Alcoholic liver disease: Is acetaminophen safe? (Comment). J Fam Pract (2007); 56: 673.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>56</number></detail><extent unit="pages"><start>673</start></extent></part><relatedItem type="host"><titleInfo><title>J Fam Pract</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>56</number></detail><extent unit="pages"><start>673</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit214"><titleInfo><title>6. Non‐steroidal Anti‐inflammatory Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit215"><titleInfo><title>Does cardiovascular risk factor profile influence prescribing of non‐steroidal anti‐inflammatory drugs in a rheumatoid population? (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Armstrong DJ, Quinn AD, McCausland EM, Wright GD, Finch MB. Does cardiovascular risk factor profile influence prescribing of non‐steroidal anti‐inflammatory drugs in a rheumatoid population? (Letter). Rheumatology (2007); 46: 1209.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>1209</start></extent></part><relatedItem type="host"><titleInfo><title>Rheumatology</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>1209</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit216"><titleInfo><title>Controversies about postoperative nonsteroidal anti‐inflammatory drugs use (Editorial) (French)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Autret‐Leca E, Bensouda‐Grimaldi L, Goldwirt L, Jonville‐Bera AP. Controversies about postoperative nonsteroidal anti‐inflammatory drugs use (Editorial) (French). Arch Pediatr (2007); 14: 955.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><extent unit="pages"><start>955</start></extent></part><relatedItem type="host"><titleInfo><title>Arch Pediatr</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><extent unit="pages"><start>955</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit217"><titleInfo><title>What happened to the prescribing of other COX‐2 inhibitors, paracetamol and non‐steroidal anti‐inflammatory drugs when rofecoxib was withdrawn in Australia?</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Barozzi N, Tett SE. What happened to the prescribing of other COX‐2 inhibitors, paracetamol and non‐steroidal anti‐inflammatory drugs when rofecoxib was withdrawn in Australia?. Pharmacoepidemiol Drug Saf (2007); 16: 1184.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1184</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1184</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit218"><titleInfo><title>Case of corneal melting associated with the use of topical nepafenac</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bekendam PD, Narvaez J, Agarwal M. Case of corneal melting associated with the use of topical nepafenac. Cornea (2007); 26: 1002.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>1002</start></extent></part><relatedItem type="host"><titleInfo><title>Cornea</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>1002</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit219"><titleInfo><title>Reply: Adalimumab‐associated pulmonary fibrosis</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Collins K, Todd A, Rynne M, Hamilton J, Saravanan V, Kelly C. Reply: Adalimumab‐associated pulmonary fibrosis. Rheumatology (2007); 46: 1379.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>1379</start></extent></part><relatedItem type="host"><titleInfo><title>Rheumatology</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>1379</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit220"><titleInfo><title>Safety of etanercept therapy in rheumatoid patients undergoing surgery: Preliminary report</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Corrao S, Pistone G, Arnone S, Calvo L, Scaglione R, Licata G. Safety of etanercept therapy in rheumatoid patients undergoing surgery: Preliminary report. Clin Rheumatol (2007); 26: 1513.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>1513</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Rheumatol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>1513</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit221"><titleInfo><title>Acute generalized skin eruption due to adalimumab: Report of two cases (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Dalmau J, Roe E, Corella F, Garcia‐Navarro X, Peramiquel L, Alomar A. Acute generalized skin eruption due to adalimumab: Report of two cases (Letter). J Eur Acad Dermatol Venereol (2007); 21: 1105.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>1105</start></extent></part><relatedItem type="host"><titleInfo><title>J Eur Acad Dermatol Venereol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>1105</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit222"><titleInfo><title>Eradication of Helicobacter pylori does not reduce the incidence of gastroduodenal ulcers in patients on long‐term NSAID treatment: Double‐blind, randomized, placebo‐controlled trial</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">De Leest HTJI, Steen KSS, Lems WF, Bijlsma JWJ, Van de Laar MAFJ, Huisman AM, Vonkeman HE, Houben HHML, Kadir SW, Kostense PJ, Van Tulder MW, Kuipers EJ, Boers M, Dijkmans BA. Eradication of Helicobacter pylori does not reduce the incidence of gastroduodenal ulcers in patients on long‐term NSAID treatment: Double‐blind, randomized, placebo‐controlled trial. Helicobacter (2007); 12: 477.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>12</number></detail><extent unit="pages"><start>477</start></extent></part><relatedItem type="host"><titleInfo><title>Helicobacter</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>12</number></detail><extent unit="pages"><start>477</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit223"><titleInfo><title>Idiosyncratic toxic hepatitis secondary to single dose of naproxen</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Demirag MD, Ozenirler S, Goker B, Poyraz A, Haznedaroglu S, Ozturk MA. Idiosyncratic toxic hepatitis secondary to single dose of naproxen. Acta Gastroenterol Belg (2007); 70: 247.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>70</number></detail><extent unit="pages"><start>247</start></extent></part><relatedItem type="host"><titleInfo><title>Acta Gastroenterol Belg</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>70</number></detail><extent unit="pages"><start>247</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit224"><titleInfo><title>Hydroxychloroquine dosages should be calculated using lean body mass (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Elder M, Rahman AMA. Hydroxychloroquine dosages should be calculated using lean body mass (Letter). Arch Ophthalmol (2007); 125: 1304.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>125</number></detail><extent unit="pages"><start>1304</start></extent></part><relatedItem type="host"><titleInfo><title>Arch Ophthalmol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>125</number></detail><extent unit="pages"><start>1304</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit225"><titleInfo><title>Tuberculous uveitis after treatment with etanercept</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Fonollosa A, Segura A, Giralt J, Garcia‐Arumi J. Tuberculous uveitis after treatment with etanercept. Graefes Arch Clin Exp Ophthalmol (2007); 245: 1397.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>245</number></detail><extent unit="pages"><start>1397</start></extent></part><relatedItem type="host"><titleInfo><title>Graefes Arch Clin Exp Ophthalmol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>245</number></detail><extent unit="pages"><start>1397</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit226"><titleInfo><title>Adalimumab‐associated pulmonary fibrosis ‐ Reply</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Huggett MT, Armstrong R. Adalimumab‐associated pulmonary fibrosis ‐ Reply. Rheumatology (2007); 46: 1379.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>1379</start></extent></part><relatedItem type="host"><titleInfo><title>Rheumatology</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>1379</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit227"><titleInfo><title>Corneal melting and perforation in Stevens Johnson syndrome following topical bromfenac use</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Isawi H, Dhaliwal DK. Corneal melting and perforation in Stevens Johnson syndrome following topical bromfenac use. J Cataract Refract Surg (2007); 33: 1644.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>33</number></detail><extent unit="pages"><start>1644</start></extent></part><relatedItem type="host"><titleInfo><title>J Cataract Refract Surg</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>33</number></detail><extent unit="pages"><start>1644</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit228"><titleInfo><title>Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Krumbholz M, Pellkofer H, Gold R, Hoffmann LA, Hohlfeld R, Kumpfel T. Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies. Arch Neurol (2007); 64: 1331.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>64</number></detail><extent unit="pages"><start>1331</start></extent></part><relatedItem type="host"><titleInfo><title>Arch Neurol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>64</number></detail><extent unit="pages"><start>1331</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit229"><titleInfo><title>Aspirin withdrawal prior to invasive procedures (Reply)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Leitersdorf E. Aspirin withdrawal prior to invasive procedures (Reply). Isr Med Assoc J (2007); 9: 631.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>631</start></extent></part><relatedItem type="host"><titleInfo><title>Isr Med Assoc J</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>631</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit230"><titleInfo><title>Aspirin withdrawal prior to invasive procedures (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Liron M. Aspirin withdrawal prior to invasive procedures (Letter). Isr Med Assoc J (2007); 9: 631.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>631</start></extent></part><relatedItem type="host"><titleInfo><title>Isr Med Assoc J</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>631</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit231"><titleInfo><title>Long‐term effects of nonsteroidal anti‐inflammatory drugs and cyclooxygenase‐2 selective agents on the small bowel: A cross‐sectional capsule enteroscopy study</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Maiden L, Thjoleifsson B, Seigal A, Bjarnason II, Scott D, Birgisson S, Bjarnason I. Long‐term effects of nonsteroidal anti‐inflammatory drugs and cyclooxygenase‐2 selective agents on the small bowel: A cross‐sectional capsule enteroscopy study. Clin Gastroenterol Hepatol (2007); 5: 1040.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>1040</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Gastroenterol Hepatol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>1040</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit232"><titleInfo><title>Perioperative anti‐inflammatory drug use: Which evidences for their utility and safety? (French, English Abstract)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Marret E, Bonnet F. Perioperative anti‐inflammatory drug use: Which evidences for their utility and safety? (French, English Abstract). Ann Fr Anesth Reanim (2007); 26: 535.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>535</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Fr Anesth Reanim</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>535</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit233"><titleInfo><title>Severe, reversible dysphagia from chloroquine and hydroxychloroquine myopathy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mateen FJ, Keegan BM. Severe, reversible dysphagia from chloroquine and hydroxychloroquine myopathy. Can J Neurol Sci (2007); 34: 377.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>34</number></detail><extent unit="pages"><start>377</start></extent></part><relatedItem type="host"><titleInfo><title>Can J Neurol Sci</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>34</number></detail><extent unit="pages"><start>377</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit234"><titleInfo><title>Fever and headache in a patient in treatment with infliximab (Spanish)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Meilan Martinez A, Arguelles Garcia B, Anes Gonzalez G, Luyando LH. Fever and headache in a patient in treatment with infliximab (Spanish). Rev Clin Espan (2007); 207: 371.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>207</number></detail><extent unit="pages"><start>371</start></extent></part><relatedItem type="host"><titleInfo><title>Rev Clin Espan</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>207</number></detail><extent unit="pages"><start>371</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit235"><titleInfo><title>Cyclo‐oxygenase‐2 selective inhibitors and nonsteroidal anti‐inflammatory drugs: Balancing gastrointestinal and cardiovascular risk</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Moore RA, Derry S, McQuay HJ. Cyclo‐oxygenase‐2 selective inhibitors and nonsteroidal anti‐inflammatory drugs: Balancing gastrointestinal and cardiovascular risk. BMC Musculoskelet Disord (2007); 8: 73.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>73</start></extent></part><relatedItem type="host"><titleInfo><title>BMC Musculoskelet Disord</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>73</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit236"><titleInfo><title>Hydroxychloroquine dosages should be calculated using lean body mass (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Pautler SE. Hydroxychloroquine dosages should be calculated using lean body mass (Letter). Arch Ophthalmol (2007); 125: 1303.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>125</number></detail><extent unit="pages"><start>1303</start></extent></part><relatedItem type="host"><titleInfo><title>Arch Ophthalmol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>125</number></detail><extent unit="pages"><start>1303</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit237"><titleInfo><title>Chronic viral hepatitis and TNF‐α blockade (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Raftery G, Griffiths B, Kay L, Kane D. Chronic viral hepatitis and TNF‐α blockade (Letter). Rheumatology (2007); 46: 1381.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>1381</start></extent></part><relatedItem type="host"><titleInfo><title>Rheumatology</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>1381</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit238"><titleInfo><title>Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxibs</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ray WA, Chung CP, Stein CM, Smalley WE, Hall K, Arbogast PG, Griffin MR. Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxibs. Gastroenterology (2007); 133: 790.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>133</number></detail><extent unit="pages"><start>790</start></extent></part><relatedItem type="host"><titleInfo><title>Gastroenterology</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>133</number></detail><extent unit="pages"><start>790</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit239"><titleInfo><title>Reply: Safety of anti‐TNF‐α therapy in rheumatoid arthritis (RA) and spondylarthropathies (SA) with concurrent B or C chronic hepatitis (Reply)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Roux CH, Gelsii E, Brocq O, Euller‐Ziegler L. Reply: Safety of anti‐TNF‐α therapy in rheumatoid arthritis (RA) and spondylarthropathies (SA) with concurrent B or C chronic hepatitis (Reply). Rheumatology (2007); 46: 1381.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>1381</start></extent></part><relatedItem type="host"><titleInfo><title>Rheumatology</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>1381</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit240"><titleInfo><title>Re: Use of cyclo‐oxygenase 2 inhibitors (COX‐2) and prescription non‐steroidal anti‐inflammatory drugs (NSAIDS) in UK and USA populations: Implications for COX‐2 cardiovascular profile (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Van Staa TP, Parkinson J. Re: Use of cyclo‐oxygenase 2 inhibitors (COX‐2) and prescription non‐steroidal anti‐inflammatory drugs (NSAIDS) in UK and USA populations: Implications for COX‐2 cardiovascular profile (Letter). Pharmacoepidemiol Drug Saf (2007); 16: 1253.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1253</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1253</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit241"><titleInfo><title>Direct medical costs of serious gastrointestinal ulcers among users of NSAIDs</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Vonkeman HE, Klok RM, Postma MJ, Brouwers JRBJ, Van de Laar MAFJ. Direct medical costs of serious gastrointestinal ulcers among users of NSAIDs. Drug Aging (2007); 24: 681.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>681</start></extent></part><relatedItem type="host"><titleInfo><title>Drug Aging</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>681</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit242"><titleInfo><title>A placebo‐controlled, randomized, double‐blind study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Weisman MH, Paulus HE, Burch FX, Kivitz AJ, Fierer J, Dunn M, Kerr DR, Tsuji W, Baumgartner SW. A placebo‐controlled, randomized, double‐blind study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases. Rheumatology (2007); 46: 1122.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>1122</start></extent></part><relatedItem type="host"><titleInfo><title>Rheumatology</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>1122</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit243"><titleInfo><title>Should non‐steroidal anti‐inflammatory drugs be given to orthopaedic patients with fractures?</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Williams A. Should non‐steroidal anti‐inflammatory drugs be given to orthopaedic patients with fractures?. Br J Hosp Med (2007); 68: 452.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>68</number></detail><extent unit="pages"><start>452</start></extent></part><relatedItem type="host"><titleInfo><title>Br J Hosp Med</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>68</number></detail><extent unit="pages"><start>452</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit244"><titleInfo><title>Up‐to‐date information on gastric mucosal lesions from long‐term NSAID therapy in orthopedic outpatients: A study using logistic regression analysis</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Yajima H, Yamao J, Fukui H, Takakura Y. Up‐to‐date information on gastric mucosal lesions from long‐term NSAID therapy in orthopedic outpatients: A study using logistic regression analysis. J Orthop Sci (2007); 12: 341.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>12</number></detail><extent unit="pages"><start>341</start></extent></part><relatedItem type="host"><titleInfo><title>J Orthop Sci</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>12</number></detail><extent unit="pages"><start>341</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit245"><titleInfo><title>7. CNS Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit246"><titleInfo><title>Urticaria and angio‐oedema due to ziprasidone</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Akkaya C, Sarandol A, Aydogan K, Kirli S. Urticaria and angio‐oedema due to ziprasidone. J Psychopharmacol (2007); 21: 550.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>550</start></extent></part><relatedItem type="host"><titleInfo><title>J Psychopharmacol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>550</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit247"><titleInfo><title>A challenging case of syndrome of inappropriate secretion of antidiuretic hormone in an elderly patient secondary to quetiapine</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Atalay A, Turhan N, Aki OE. A challenging case of syndrome of inappropriate secretion of antidiuretic hormone in an elderly patient secondary to quetiapine. South Med J (2007); 100: 832.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>100</number></detail><extent unit="pages"><start>832</start></extent></part><relatedItem type="host"><titleInfo><title>South Med J</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>100</number></detail><extent unit="pages"><start>832</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit248"><titleInfo><title>Mortality in schizophrenia</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Auquier P, Lancon C, Rouillon F, Lader M. Mortality in schizophrenia. Pharmacoepidemiol Drug Saf (2007); 16: 1308.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1308</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1308</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit249"><titleInfo><title>Incidence of Brugada electrocardiographic pattern and outcomes of these patients after intentional tricyclic antidepressant ingestion</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bebarta VS, Phillips S, Eberhardt A, Calihan KJ, Waksman JC, Heard K. Incidence of Brugada electrocardiographic pattern and outcomes of these patients after intentional tricyclic antidepressant ingestion. Am J Cardiol (2007); 100: 656.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>100</number></detail><extent unit="pages"><start>656</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Cardiol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>100</number></detail><extent unit="pages"><start>656</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit250"><titleInfo><title>Tardive dyskinesia and glucid metabolism</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Brousse G, Meary A, Mouret J, Blanc O, Hueber T, Lemoine P, Llorca PM, Lachaux B. Tardive dyskinesia and glucid metabolism. Hum Psychopharmacol Clin Exp (2007); 22: 373.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><extent unit="pages"><start>373</start></extent></part><relatedItem type="host"><titleInfo><title>Hum Psychopharmacol Clin Exp</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><extent unit="pages"><start>373</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit251"><titleInfo><title>Subcutaneous midazolam as a cause of extrapyramidal side effects in a patient with prostate cancer (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Brown DJF, McArthnr D, Moulsdale H. Subcutaneous midazolam as a cause of extrapyramidal side effects in a patient with prostate cancer (Letter). J Pain Symptom Manage (2007); 34: 111.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>34</number></detail><extent unit="pages"><start>111</start></extent></part><relatedItem type="host"><titleInfo><title>J Pain Symptom Manage</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>34</number></detail><extent unit="pages"><start>111</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit252"><titleInfo><title>Malignant neuroleptic syndrome and serotoninergic syndrome: Two cases (Letter) (Spanish)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bruscas Alijarde MJ, De Benito Cordon L, Garcia Mateos D, Ruiz Clemente M, Hervas Laguna MJ. Malignant neuroleptic syndrome and serotoninergic syndrome: Two cases (Letter) (Spanish). Rev Clin Espan (2007); 207: 374.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>207</number></detail><extent unit="pages"><start>374</start></extent></part><relatedItem type="host"><titleInfo><title>Rev Clin Espan</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>207</number></detail><extent unit="pages"><start>374</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit253"><titleInfo><title>The efficacy and safety of drug treatments for chronic insomnia in adults: A meta‐analysis of RCTs</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Buscemi N, Vandermeer B, Friesen C, Bialy L, Tubman M, Ospina M, Klassen TP, Witmans M. The efficacy and safety of drug treatments for chronic insomnia in adults: A meta‐analysis of RCTs. J Gen Intern Med (2007); 22: 1335.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><extent unit="pages"><start>1335</start></extent></part><relatedItem type="host"><titleInfo><title>J Gen Intern Med</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><extent unit="pages"><start>1335</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit254"><titleInfo><title>“Atypical” neuroleptic malignant syndrome and the spectrum of malignant cerebrotoxic syndromes</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Choi‐Kain LW, Pope HG. “Atypical” neuroleptic malignant syndrome and the spectrum of malignant cerebrotoxic syndromes. Harv Rev Psychiatry (2007); 15: 181.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><extent unit="pages"><start>181</start></extent></part><relatedItem type="host"><titleInfo><title>Harv Rev Psychiatry</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><extent unit="pages"><start>181</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit255"><titleInfo><title>Antipsychotic polypharmacy at the University Psychiatric Hospital in Serbia (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Divac N, Jasovic‐Gasic M, Samardzic R, Lackovic M, Prostran M. Antipsychotic polypharmacy at the University Psychiatric Hospital in Serbia (Letter). Pharmacoepidemiol Drug Saf (2007); 16: 1250.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1250</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1250</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit256"><titleInfo><title>Aripiprazole‐induced tardive dyskinesia: The role of tamoxifen (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Evcimen YA, Evcimen H, Holland J. Aripiprazole‐induced tardive dyskinesia: The role of tamoxifen (Letter). Am J Psychiatry (2007); 164: 1436.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>164</number></detail><extent unit="pages"><start>1436</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Psychiatry</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>164</number></detail><extent unit="pages"><start>1436</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit257"><titleInfo><title>Cognitive facilitation and behavioral disinhibition with benzodiazepine: A case report (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gaillard R, Hemras A, Habert MO, Baup N, Naccache L, Gallarda T, Cohen L, Olle JP. Cognitive facilitation and behavioral disinhibition with benzodiazepine: A case report (Letter). J Clin Psychiatry (2007); 68: 1305.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>68</number></detail><extent unit="pages"><start>1305</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Psychiatry</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>68</number></detail><extent unit="pages"><start>1305</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit258"><titleInfo><title>Citalopram‐induced macropsia (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ghanizadeh A. Citalopram‐induced macropsia (Letter). Clin Neuropharmacol (2007); 30: 246.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>30</number></detail><extent unit="pages"><start>246</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Neuropharmacol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>30</number></detail><extent unit="pages"><start>246</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit259"><titleInfo><title>Clozapine‐induced non‐epileptic drop attacks: Report of two cases (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Giannakopoulou F, Andriopoulos I, Gourzis P, Argyriou AA, Dimitro‐Poulou C, Polychronopoulos P, Beratis S. Clozapine‐induced non‐epileptic drop attacks: Report of two cases (Letter). Eur J Neurol (2007); 14: e13.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><extent unit="pages"><start>e13</start></extent></part><relatedItem type="host"><titleInfo><title>Eur J Neurol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><extent unit="pages"><start>e13</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit260"><titleInfo><title>Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gibbons RD, Brown CH, Hur K, Marcus SM, Bhaurnik DK, Erkens JA, Herings RMC, Mann JJ. Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry (2007); 164: 1356.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>164</number></detail><extent unit="pages"><start>1356</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Psychiatry</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>164</number></detail><extent unit="pages"><start>1356</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit261"><titleInfo><title>Cognitive functioning and acute sedative effects of risperidone and quetiapine in patients with stable bipolar I disorder: A randomized, double‐blind, crossover study</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Harvey PD, Hassman H, Mao L, Gharabawi GM, Mahmoud RA, Engelhart LM. Cognitive functioning and acute sedative effects of risperidone and quetiapine in patients with stable bipolar I disorder: A randomized, double‐blind, crossover study. J Clin Psychiatry (2007); 68: 1186.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>68</number></detail><extent unit="pages"><start>1186</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Psychiatry</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>68</number></detail><extent unit="pages"><start>1186</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit262"><titleInfo><title>Observed association between antidepressant use and pneumonia risk was confounded by comorbidity measures</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hennessy S, Bilker WB, Leonard CE, Chittams J, Palumbo CM, Karlawish JH, Yang YX, Lautenbach E, Baine WB, Metlay JP. Observed association between antidepressant use and pneumonia risk was confounded by comorbidity measures. J Clin Epidemiol (2007); 60: 911.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>911</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Epidemiol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>911</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit263"><titleInfo><title>Relationship between cholinesterase inhibitors and pisa syndrome in a cohort of five French patients with Alzheimer's disease (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Huvent‐Grelle D, Roche J, Camus FE, Dewailly P, Puisieux F. Relationship between cholinesterase inhibitors and pisa syndrome in a cohort of five French patients with Alzheimer's disease (Letter). J Am Geriatr Soc (2007); 55: 1472.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>55</number></detail><extent unit="pages"><start>1472</start></extent></part><relatedItem type="host"><titleInfo><title>J Am Geriatr Soc</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>55</number></detail><extent unit="pages"><start>1472</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit264"><titleInfo><title>Cerebro‐ and cardiovascular conditions in adults with schizophrenia treated with antipsychotic medications</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Jerrell JM, McIntyre RS. Cerebro‐ and cardiovascular conditions in adults with schizophrenia treated with antipsychotic medications. Hum Psychopharmacol Clin Exp (2007); 22: 361.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><extent unit="pages"><start>361</start></extent></part><relatedItem type="host"><titleInfo><title>Hum Psychopharmacol Clin Exp</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><extent unit="pages"><start>361</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit265"><titleInfo><title>Aripiprazole‐induced psychosis: A case report of reexposure by stepwise up‐titration (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kapusta ND, Mossaheb N, Barnas C, Fischer P. Aripiprazole‐induced psychosis: A case report of reexposure by stepwise up‐titration (Letter). J Clin Psychiatry (2007); 68: 1445.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>68</number></detail><extent unit="pages"><start>1445</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Psychiatry</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>68</number></detail><extent unit="pages"><start>1445</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit266"><titleInfo><title>Paradoxical motor syndrome following a switch from atypical neuroleptics to aripiprazole (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Koener B, Emmanuel H, Maloteaux JM, Jean‐Jean A, Constant EL. Paradoxical motor syndrome following a switch from atypical neuroleptics to aripiprazole (Letter). Am J Psychiatry (2007); 164: 1437.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>164</number></detail><extent unit="pages"><start>1437</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Psychiatry</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>164</number></detail><extent unit="pages"><start>1437</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit267"><titleInfo><title>Varenicline‐induced manic episode in a patient with bipolar disorder (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kohen I, Kremen N. Varenicline‐induced manic episode in a patient with bipolar disorder (Letter). Am J Psychiatry (2007); 164: 1269.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>164</number></detail><extent unit="pages"><start>1269</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Psychiatry</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>164</number></detail><extent unit="pages"><start>1269</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit268"><titleInfo><title>Eosinophilia indicating subclinical clozapine‐induced pericarditis (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kortner K, Neuhaus AH, Schurer F, Dettling M. Eosinophilia indicating subclinical clozapine‐induced pericarditis (Letter). J Clin Psychiatry (2007); 68: 1147.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>68</number></detail><extent unit="pages"><start>1147</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Psychiatry</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>68</number></detail><extent unit="pages"><start>1147</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit269"><titleInfo><title>Charles Bonnet syndrome: Successful treatment of visual hallucinations due to vision loss with selective serotonin reuptake inhibitors</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lang UE, Stogowski D, Schuze D, Domula M, Schmidt E, Gallinat J, Tugtekin SM, Felber W. Charles Bonnet syndrome: Successful treatment of visual hallucinations due to vision loss with selective serotonin reuptake inhibitors. J Psychopharmacol (2007); 21: 553.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>553</start></extent></part><relatedItem type="host"><titleInfo><title>J Psychopharmacol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>553</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit270"><titleInfo><title>Brugada syndrome in a patient treated with lithium (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Laske C, Soekadar SR, Laszlo R, Plewnia C. Brugada syndrome in a patient treated with lithium (Letter). Am J Psychiatry (2007); 164: 1440.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>164</number></detail><extent unit="pages"><start>1440</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Psychiatry</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>164</number></detail><extent unit="pages"><start>1440</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit271"><titleInfo><title>Agitation associated with aripiprazole initiation</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lea JW, Stoner SC, LaFollette J. Agitation associated with aripiprazole initiation. Pharmacotherapy (2007); 27: 1339.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>1339</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacotherapy</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>1339</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit272"><titleInfo><title>A developmental perspective on the controversy surrounding the use of SSRIs to treat pediatric depression</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Leckman JF, King RA. A developmental perspective on the controversy surrounding the use of SSRIs to treat pediatric depression. Am J Psychiatry (2007); 164: 1304.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>164</number></detail><extent unit="pages"><start>1304</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Psychiatry</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>164</number></detail><extent unit="pages"><start>1304</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit273"><titleInfo><title>Antidepressants in adult suicides in New York City: 2001‐2004</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Leon AC, Marzuk PM, Tardiff K, Bucciarelli A, Stajic M, Piper TM, Galea S. Antidepressants in adult suicides in New York City: 2001‐2004. J Clin Psychiatry (2007); 68: 1399.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>68</number></detail><extent unit="pages"><start>1399</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Psychiatry</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>68</number></detail><extent unit="pages"><start>1399</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit274"><titleInfo><title>Clozapine‐related agranulocytosis associated with fever of unknown origin, protective hospitalisation, and multiple adverse events related to the administration of empiric antimicrobial treatment</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Manfredi R, Sabbatani S. Clozapine‐related agranulocytosis associated with fever of unknown origin, protective hospitalisation, and multiple adverse events related to the administration of empiric antimicrobial treatment. Pharmacoepidemiol Drug Saf (2007); 16: 1285.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1285</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1285</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit275"><titleInfo><title>New onset diabetes with ketoacidosis attributed to quetiapine</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Marlowe KF, Howard D, Chung A. New onset diabetes with ketoacidosis attributed to quetiapine. South Med J (2007); 100: 829.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>100</number></detail><extent unit="pages"><start>829</start></extent></part><relatedItem type="host"><titleInfo><title>South Med J</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>100</number></detail><extent unit="pages"><start>829</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit276"><titleInfo><title>A randomized, double‐blind, placebo‐controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">McEvoy JP, Daniel DG, Carson WH, McQuade RD, Marcus RN. A randomized, double‐blind, placebo‐controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. J Psychiatr Res (2007); 41: 895.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>895</start></extent></part><relatedItem type="host"><titleInfo><title>J Psychiatr Res</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>895</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit277"><titleInfo><title>Methylphenidate use in children and risk of cancer at 18 sites: Results of surveillance analyses</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Oestreicher N, Friedman GD, Jiang SF, Chan J, Quesenberry C, Habel LA. Methylphenidate use in children and risk of cancer at 18 sites: Results of surveillance analyses. Pharmacoepidemiol Drug Saf (2007); 16: 1268.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1268</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1268</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit278"><titleInfo><title>Au audit of the association between the use of antipsychotic medication and bone density measurement in female patients within a special (high security) hospital</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Orr J, Jamieson L. Au audit of the association between the use of antipsychotic medication and bone density measurement in female patients within a special (high security) hospital. J Forensic Psychiatry Psychol (2007); 18: 317.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>317</start></extent></part><relatedItem type="host"><titleInfo><title>J Forensic Psychiatry Psychol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>317</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit279"><titleInfo><title>Neuroleptic malignant syndrome due to amisulpride in a patient with solvent‐induced chronic toxic encephalopathy (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Peritogiannis V, Tsouli S, Pappas D, Mavreas V, Konitsiotis S. Neuroleptic malignant syndrome due to amisulpride in a patient with solvent‐induced chronic toxic encephalopathy (Letter). Clin Neuropharmacol (2007); 30: 245.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>30</number></detail><extent unit="pages"><start>245</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Neuropharmacol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>30</number></detail><extent unit="pages"><start>245</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit280"><titleInfo><title>Changes in neuroendocrine and metabolic hormones induced by atypical antipsychotics in normal‐weight patients with schizophrenia</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Popovic V, Doknic M, Maric N, Pekic S, Damjanovic A, Miljic D, Popovic S, Miljic N, Djurovic M, Jasovic‐Gasic M, Dieguez C, Casanueva FF. Changes in neuroendocrine and metabolic hormones induced by atypical antipsychotics in normal‐weight patients with schizophrenia. Neuroendocrinology (2007); 85: 249.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>85</number></detail><extent unit="pages"><start>249</start></extent></part><relatedItem type="host"><titleInfo><title>Neuroendocrinology</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>85</number></detail><extent unit="pages"><start>249</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit281"><titleInfo><title>Changes in serum lipids, independent of weight, are associated with changes in symptoms during long‐term clozapine treatment</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Procyshyn RM, Wasan KM, Thornton AE, Barr AM, Chen EYH, Pomarol‐Clotet E, Stip E, Williams R, MacEwan GW, Birmingham CL, Honer WG. Changes in serum lipids, independent of weight, are associated with changes in symptoms during long‐term clozapine treatment. J Psychiatry Neurosci (2007); 32: 331.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>32</number></detail><extent unit="pages"><start>331</start></extent></part><relatedItem type="host"><titleInfo><title>J Psychiatry Neurosci</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>32</number></detail><extent unit="pages"><start>331</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit282"><titleInfo><title>Focal craniofacial hyperhidrosis associated with selective serotonin reuptake inhibitors (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Rajaratnam R, Mehmi M, Lim SPR, Lewis H. Focal craniofacial hyperhidrosis associated with selective serotonin reuptake inhibitors (Letter). Clin Exp Dermatol (2007); 32: 587.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>32</number></detail><extent unit="pages"><start>587</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Exp Dermatol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>32</number></detail><extent unit="pages"><start>587</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit283"><titleInfo><title>Clozapine‐induced effuso‐constrictive pericarditis</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Rathore S, Masani ND, Callaghan PO. Clozapine‐induced effuso‐constrictive pericarditis. Cardiology (2007); 108: 183.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>108</number></detail><extent unit="pages"><start>183</start></extent></part><relatedItem type="host"><titleInfo><title>Cardiology</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>108</number></detail><extent unit="pages"><start>183</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit284"><titleInfo><title>A 2‐night, 3‐period, crossover study of ramelteon's efficacy and safety in older adults with chronic insomnia</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Roth T, Seiden D, Wang‐Weigand S, Zhang J. A 2‐night, 3‐period, crossover study of ramelteon's efficacy and safety in older adults with chronic insomnia. Curr Med Res Opin (2007); 23: 1005.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>1005</start></extent></part><relatedItem type="host"><titleInfo><title>Curr Med Res Opin</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>1005</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit285"><titleInfo><title>Metabolic syndrome in drug‐naive first‐episode psychosis treated with atypical antipsychotics (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sahoo S, Ameen S, Akhtar S. Metabolic syndrome in drug‐naive first‐episode psychosis treated with atypical antipsychotics (Letter). Aust N Z J Psychiatry (2007); 41: 629.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>629</start></extent></part><relatedItem type="host"><titleInfo><title>Aust N Z J Psychiatry</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>629</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit286"><titleInfo><title>Interaction of clozapine and ciprofloxacin: A case report (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sambhi RS, Puri R, Jones G. Interaction of clozapine and ciprofloxacin: A case report (Letter). Eur J Clin Pharmacol (2007); 63: 895.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>63</number></detail><extent unit="pages"><start>895</start></extent></part><relatedItem type="host"><titleInfo><title>Eur J Clin Pharmacol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>63</number></detail><extent unit="pages"><start>895</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit287"><titleInfo><title>Olanzapine and blepharoclonus (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sofia‐Gabrion CK, Yahia YA, Holzer L. Olanzapine and blepharoclonus (Letter). J Clin Psychiatry (2007); 68: 1443.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>68</number></detail><extent unit="pages"><start>1443</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Psychiatry</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>68</number></detail><extent unit="pages"><start>1443</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit288"><titleInfo><title>Branch retinal artery occlusion after injection of a long‐acting risperidone preparation (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Tang J, Weiter JJ. Branch retinal artery occlusion after injection of a long‐acting risperidone preparation (Letter). Ann Intern Med (2007); 147: 283.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>147</number></detail><extent unit="pages"><start>283</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Intern Med</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>147</number></detail><extent unit="pages"><start>283</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit289"><titleInfo><title>Renal tubular dysfunction in schizophrenic patients treated with antipsychotic drugs</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Tutor‐Crespo MJ, Paz E, Hermida J, Tutor JC. Renal tubular dysfunction in schizophrenic patients treated with antipsychotic drugs. Clin Lab (2007); 53: 433.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>53</number></detail><extent unit="pages"><start>433</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Lab</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>53</number></detail><extent unit="pages"><start>433</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit290"><titleInfo><title>Patterns and prevalence of antidepressant drug use in the German state of Baden‐Wuerttemberg: A prescription‐based analysis</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ufer M, Meyer SA, Junge O, Selke G, Volz HP, Hedderich J, Gleiter CH. Patterns and prevalence of antidepressant drug use in the German state of Baden‐Wuerttemberg: A prescription‐based analysis. Pharmacoepidemiol Drug Saf (2007); 16: 1153.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1153</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1153</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit291"><titleInfo><title>Intraoperative floppy‐iris syndrome associated with chronic use of chlorpromazine (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Unal M, Yucel I, Tenlik A. Intraoperative floppy‐iris syndrome associated with chronic use of chlorpromazine (Letter). Eye (2007); 21: 1241.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>1241</start></extent></part><relatedItem type="host"><titleInfo><title>Eye</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>1241</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit292"><titleInfo><title>Photodistributed eruptive telangiectasia: An uncommon adverse drug reaction to venlafaxine (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Vaccaro M, Borgia F, Barbuzza O, Guarneri B. Photodistributed eruptive telangiectasia: An uncommon adverse drug reaction to venlafaxine (Letter). Br J Dermatol (2007); 157: 822.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>157</number></detail><extent unit="pages"><start>822</start></extent></part><relatedItem type="host"><titleInfo><title>Br J Dermatol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>157</number></detail><extent unit="pages"><start>822</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit293"><titleInfo><title>Spillover effects on treatment of adult depression in primary care after FDA advisory on risk of pediatric suicidality with SSRIs</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Valuck RJ, Libby AM, Orton HD, Morrato EH, Allen R, Baldessarini RJ. Spillover effects on treatment of adult depression in primary care after FDA advisory on risk of pediatric suicidality with SSRIs. Am J Psychiatry (2007); 164: 1198.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>164</number></detail><extent unit="pages"><start>1198</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Psychiatry</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>164</number></detail><extent unit="pages"><start>1198</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit294"><titleInfo><title>Tricyclic antidepressants and the risk of reflux esophagitis</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Van Soest EM, Dieleman JP, Siersema PD, Schoof L, Sturkenboom MCJM, Kuipers EJ. Tricyclic antidepressants and the risk of reflux esophagitis. Am J Gastroenterol (2007); 102: 1870.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>102</number></detail><extent unit="pages"><start>1870</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Gastroenterol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>102</number></detail><extent unit="pages"><start>1870</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit295"><titleInfo><title>Recalcitrant lithium‐induced psoriasis in a suicidal patient alleviated by tumour necrosis factor‐α inhibition (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wachter T, Murach WM, Broecker EB, Schoen MP. Recalcitrant lithium‐induced psoriasis in a suicidal patient alleviated by tumour necrosis factor‐α inhibition (Letter). Br J Dermatol (2007); 157: 627.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>157</number></detail><extent unit="pages"><start>627</start></extent></part><relatedItem type="host"><titleInfo><title>Br J Dermatol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>157</number></detail><extent unit="pages"><start>627</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit296"><titleInfo><title>Antipsychotic drugs and the acute respiratory distress syndrome (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wilson H, Ridley S. Antipsychotic drugs and the acute respiratory distress syndrome (Letter). Br J Anaesth (2007); 99: 301.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>99</number></detail><extent unit="pages"><start>301</start></extent></part><relatedItem type="host"><titleInfo><title>Br J Anaesth</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>99</number></detail><extent unit="pages"><start>301</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit297"><titleInfo><title>The impact of environmental temperature on lithium serum levels</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wilting I, Fase S, Martens EP, Heerdink ER, Nolen WA, Egberts ACG. The impact of environmental temperature on lithium serum levels. Bipolar Disord (2007); 9: 603.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>603</start></extent></part><relatedItem type="host"><titleInfo><title>Bipolar Disord</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>603</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit298"><titleInfo><title>Metabolic effects of the atypical antipsychotics (Editorial comment)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wooton J. Metabolic effects of the atypical antipsychotics (Editorial comment). South Med J (2007); 100: 771.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>100</number></detail><extent unit="pages"><start>771</start></extent></part><relatedItem type="host"><titleInfo><title>South Med J</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>100</number></detail><extent unit="pages"><start>771</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit299"><titleInfo><title>Risperidone‐and quetiapine‐induced cholestasis</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wright TM, Vandenberg AM. Risperidone‐and quetiapine‐induced cholestasis. Ann Pharmacother (2007); 41: 1518.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>1518</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Pharmacother</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>1518</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit300"><titleInfo><title>Is there a connection between methylphenidate and cancer in youth? (Commentary)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Zito JM, Safer DJ. Is there a connection between methylphenidate and cancer in youth? (Commentary). Pharmacoepidemiol Drug Saf (2007); 16: 1273.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1273</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1273</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit301"><titleInfo><title>8. Anti‐neoplastic Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit302"><titleInfo><title>Safety and activity of trastuzumab‐containing therapies for the treatment of metastatic breast cancer: Our long‐term clinical experience (GOIM study)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Adamo V, Franchina T, Adamo B, Ferraro G, Rossello R, Sacca MM, Scibilia C, Valerio MR, Russo A. Safety and activity of trastuzumab‐containing therapies for the treatment of metastatic breast cancer: Our long‐term clinical experience (GOIM study). Ann Oncol (2007); 18: 11.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>11</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Oncol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>11</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit303"><titleInfo><title>Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2‐overexpressing metastatic breast cancer</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Andreopoulou E, Gaiotti D, Kim E, Volm M, Oratz R, Freedberg R, Downey A, Vogel CL, Chia S, Muggia F. Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2‐overexpressing metastatic breast cancer. Clin Breast Cancer (2007); 7: 690.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>690</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Breast Cancer</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>690</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit304"><titleInfo><title>Congestive heart failure is a rare event in patients receiving imatinib therapy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Atallah E, Durand JB, Kantarjian H, Cortes J. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood (2007); 110: 1233.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>110</number></detail><extent unit="pages"><start>1233</start></extent></part><relatedItem type="host"><titleInfo><title>Blood</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>110</number></detail><extent unit="pages"><start>1233</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit305"><titleInfo><title>Exfoliative eruption secondary to gefitinib (ZD1839) (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Becuwe C, Dalle S, Arpin D, Balme B, Thomas L. Exfoliative eruption secondary to gefitinib (ZD1839) (Letter). Dermatology (2007); 215: 266.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>215</number></detail><extent unit="pages"><start>266</start></extent></part><relatedItem type="host"><titleInfo><title>Dermatology</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>215</number></detail><extent unit="pages"><start>266</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit306"><titleInfo><title>Renal safety and pharmacokinetics of ibandronate in multiple myeloma patients with or without impaired renal function</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bergner R, Henrich DM, Hoffmann M, Honecker A, Mikus G, Nauth B, Nagel D, Uppenkamp M. Renal safety and pharmacokinetics of ibandronate in multiple myeloma patients with or without impaired renal function. J Clin Pharmacol (2007); 47: 942.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>47</number></detail><extent unit="pages"><start>942</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Pharmacol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>47</number></detail><extent unit="pages"><start>942</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit307"><titleInfo><title>Macrocytosis due to treatment with sunitinib (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Billemont B, Izzedine H, Rixe O. Macrocytosis due to treatment with sunitinib (Letter). N Engl J Med (2007); 357: 1351.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>357</number></detail><extent unit="pages"><start>1351</start></extent></part><relatedItem type="host"><titleInfo><title>N Engl J Med</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>357</number></detail><extent unit="pages"><start>1351</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit308"><titleInfo><title>Focal segmental glomerulosclerosis associated with long‐term treatment with zoledronate in a myeloma patient</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bodmer M, Anu P, Mihatsch MJ, Haschke M, Kummer O, Krahenbuhl S, Mayr M. Focal segmental glomerulosclerosis associated with long‐term treatment with zoledronate in a myeloma patient. Nephrol Dial Transplant (2007); 22: 2366.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><extent unit="pages"><start>2366</start></extent></part><relatedItem type="host"><titleInfo><title>Nephrol Dial Transplant</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><extent unit="pages"><start>2366</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit309"><titleInfo><title>Aromatase inhibitors and arthralgias: A new frontier in symptom management for breast cancer survivors (Editorial comment)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Burstein HJ, Winer EP. Aromatase inhibitors and arthralgias: A new frontier in symptom management for breast cancer survivors (Editorial comment). J Clin Oncol (2007); 25: 3797.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>3797</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Oncol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>3797</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit310"><titleInfo><title>Drug safety in paediatric oncology. The contribution of therapeutic trials to pharmacovigilance (German, English Abstract)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Butterfab‐Bahloul T, Boos J. Drug safety in paediatric oncology. The contribution of therapeutic trials to pharmacovigilance (German, English Abstract). Monatsschr Kinderheilk (2007); 155: 716.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>155</number></detail><extent unit="pages"><start>716</start></extent></part><relatedItem type="host"><titleInfo><title>Monatsschr Kinderheilk</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>155</number></detail><extent unit="pages"><start>716</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit311"><titleInfo><title>Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high‐dose methotrexate and cytarabine to patients with acute lymphocytic leukemia (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Chamberlain MC, Glamtz MJ. Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high‐dose methotrexate and cytarabine to patients with acute lymphocytic leukemia (Letter). Blood (2007); 110: 1698.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>110</number></detail><extent unit="pages"><start>1698</start></extent></part><relatedItem type="host"><titleInfo><title>Blood</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>110</number></detail><extent unit="pages"><start>1698</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit312"><titleInfo><title>Estrogen‐dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Confavreux CB, Fontana A, Guastalla JP, Munoz F, Brun J, Delmas PD. Estrogen‐dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. Bone (2007); 41: 346.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>346</start></extent></part><relatedItem type="host"><titleInfo><title>Bone</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>346</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit313"><titleInfo><title>Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early‐stage breast cancer</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Crew KD, Greenlee H, Capodice J, Raptis G, Brafman L, Fuentes D, Sierra A, Hershman DL. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early‐stage breast cancer. J Clin Oncol (2007); 25: 3877.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>3877</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Oncol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>3877</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit314"><titleInfo><title>Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin ‐ A retrospective review of the MD Anderson experience</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Dawood S, Gonzalez‐Angulo AM, Peintinger F, Broglio K, Symmans WF, Kau SW, Islam R, Hortobagyi GN, Buzdar AU. Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin ‐ A retrospective review of the MD Anderson experience. Cancer (2007); 110: 1195.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>110</number></detail><extent unit="pages"><start>1195</start></extent></part><relatedItem type="host"><titleInfo><title>Cancer</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>110</number></detail><extent unit="pages"><start>1195</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit315"><titleInfo><title>Capecitabine‐induced diffuse palmoplantar keratoderma: Is it a sequential event of hand‐foot syndrome?</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Do JE, Kim YC. Capecitabine‐induced diffuse palmoplantar keratoderma: Is it a sequential event of hand‐foot syndrome?. Clin Exp Dermatol (2007); 32: 519.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>32</number></detail><extent unit="pages"><start>519</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Exp Dermatol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>32</number></detail><extent unit="pages"><start>519</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit316"><titleInfo><title>Severe epidermal necrolysis after bortezomib treatment for multiple myeloma</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Fang BJ, Song YP, Ma J, Zhao RC. Severe epidermal necrolysis after bortezomib treatment for multiple myeloma. Acta Haematol (2007); 118: 65.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>118</number></detail><extent unit="pages"><start>65</start></extent></part><relatedItem type="host"><titleInfo><title>Acta Haematol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>118</number></detail><extent unit="pages"><start>65</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit317"><titleInfo><title>Necrotizing vasculitis due to gefitinib (Iressa®) (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Fernandez‐Guarino M, Ryan AM, Perez‐Garcia B, Gonzalez‐Lopez C, Olasolo PJ. Necrotizing vasculitis due to gefitinib (Iressa®) (Letter). Int J Dermatol (2007); 46: 890.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>890</start></extent></part><relatedItem type="host"><titleInfo><title>Int J Dermatol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>890</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit318"><titleInfo><title>Erlotinib (Tarceva®) induced severe exanthema (Letter) (Spanish)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Fernandez‐Guarino M, Garrido‐Lopez P, Gonzalez‐Garcia C, Jaen P. Erlotinib (Tarceva®) induced severe exanthema (Letter) (Spanish). Rev Clin Espan (2007); 207: 422.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>207</number></detail><extent unit="pages"><start>422</start></extent></part><relatedItem type="host"><titleInfo><title>Rev Clin Espan</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>207</number></detail><extent unit="pages"><start>422</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit319"><titleInfo><title>Bortezomib‐associated cutaneous vasculitis (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Garcia‐Navarro X, Puig L, Fernandez‐Figueras MT, Dalmau J, Roe E, Alomar A. Bortezomib‐associated cutaneous vasculitis (Letter). Br J Dermatol (2007); 157: 799.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>157</number></detail><extent unit="pages"><start>799</start></extent></part><relatedItem type="host"><titleInfo><title>Br J Dermatol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>157</number></detail><extent unit="pages"><start>799</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit320"><titleInfo><title>Second‐line chemotherapy in advanced pancreatic carcinoma: A multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gebbia V, Maiello E, Giuliani F, Borsellino N, Caruso M, Di Maggio G, Ferrau F, Bordonaro R, Verderame F, Tralongo P, Di Cristina L, Agueli R, Russo P, Colucci G. Second‐line chemotherapy in advanced pancreatic carcinoma: A multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice. Ann Oncol (2007); 18: 124.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>124</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Oncol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>124</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit321"><titleInfo><title>Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Goldstein D, Van Hazel G, Walpole E, Underhill C, Kotasek D, Michael M, Shapiro J, Davies T, Reece W, Harvey J, Spry N. Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer. Br J Cancer (2007); 97: 464.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>97</number></detail><extent unit="pages"><start>464</start></extent></part><relatedItem type="host"><titleInfo><title>Br J Cancer</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>97</number></detail><extent unit="pages"><start>464</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit322"><titleInfo><title>Macrocytosis due to treatment with sunitinib (Reply)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Graf L, Gillessen S, Korte W. Macrocytosis due to treatment with sunitinib (Reply). N Engl J Med (2007); 357: 1352.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>357</number></detail><extent unit="pages"><start>1352</start></extent></part><relatedItem type="host"><titleInfo><title>N Engl J Med</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>357</number></detail><extent unit="pages"><start>1352</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit323"><titleInfo><title>Severe spontaneous cases of bisphosphonate‐related osteonecrosis of the jaws</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Herbozo PJ, Briones DL, Ferres AJ, Torrealba RL. Severe spontaneous cases of bisphosphonate‐related osteonecrosis of the jaws. J Oral Maxillofac Surg (2007); 65: 1650.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>65</number></detail><extent unit="pages"><start>1650</start></extent></part><relatedItem type="host"><titleInfo><title>J Oral Maxillofac Surg</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>65</number></detail><extent unit="pages"><start>1650</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit324"><titleInfo><title>Noninvasive evaluation of late anthracycline cardiac toxicity in childhood cancer survivors</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hudson MM, Rai SN, Nunez C, Merchant TE, Marina NM, Zalamea N, Cox C, Phipps S, Pompeu R, Rosenthal D. Noninvasive evaluation of late anthracycline cardiac toxicity in childhood cancer survivors. J Clin Oncol (2007); 25: 3635.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>3635</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Oncol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>3635</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit325"><titleInfo><title>Interstitital nephritis in a patient taking sorafenib (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Izzedine H, Brocheriou I, Rixe O, Deray G. Interstitital nephritis in a patient taking sorafenib (Letter). Nephrol Dial Transplant (2007); 22: 2411.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><extent unit="pages"><start>2411</start></extent></part><relatedItem type="host"><titleInfo><title>Nephrol Dial Transplant</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><extent unit="pages"><start>2411</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit326"><titleInfo><title>Adverse hypersensitivity reactions to mesna as adjunctive therapy for cyclophosphamide</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Khaw SL, Downie PA, Waters KD, Ashley DM, Heath JA. Adverse hypersensitivity reactions to mesna as adjunctive therapy for cyclophosphamide. Pediatr Blood Cancer (2007); 49: 341.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>49</number></detail><extent unit="pages"><start>341</start></extent></part><relatedItem type="host"><titleInfo><title>Pediatr Blood Cancer</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>49</number></detail><extent unit="pages"><start>341</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit327"><titleInfo><title>Predicting asparaginase‐associated pancreatitis</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Knoderer HM, Robarge J, Flockhart DA. Predicting asparaginase‐associated pancreatitis. Pediatr Blood Cancer (2007); 49: 634.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>49</number></detail><extent unit="pages"><start>634</start></extent></part><relatedItem type="host"><titleInfo><title>Pediatr Blood Cancer</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>49</number></detail><extent unit="pages"><start>634</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit328"><titleInfo><title>Toxicity of dose‐dense docetaxel followed by doxorubicin with cyclophosphamide as adjuvant therapy for breast cancer in a phase II study</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lambert‐Falls R, Modugno S. Toxicity of dose‐dense docetaxel followed by doxorubicin with cyclophosphamide as adjuvant therapy for breast cancer in a phase II study. Clin Breast Cancer (2007); 7: 697.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>697</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Breast Cancer</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>697</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit329"><titleInfo><title>Fulminant hepatic failure secondary to erlotinib</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Liu WT, Makrauer FL, Qamar AA, Janne PA, Odze RD. Fulminant hepatic failure secondary to erlotinib. Clin Gastroenterol Hepatol (2007); 5: 917.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>917</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Gastroenterol Hepatol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>917</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit330"><titleInfo><title>Dihydropyrimidine dehydrogenase activity and the IVS14+1G>A mutation in patients developing 5FU‐related toxicity</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Magne N, Etienne‐Grimaldi MC, Cals L, Renee N, Formento JL, Francoual M, Milano G. Dihydropyrimidine dehydrogenase activity and the IVS14+1G>A mutation in patients developing 5FU‐related toxicity. Br J Clin Pharmacol (2007); 64: 237.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>64</number></detail><extent unit="pages"><start>237</start></extent></part><relatedItem type="host"><titleInfo><title>Br J Clin Pharmacol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>64</number></detail><extent unit="pages"><start>237</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit331"><titleInfo><title>Hydroxyurea therapy: A rare cause of reversible azoospermia</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Masood J, Hafeez A, Hughes A, Barua JM. Hydroxyurea therapy: A rare cause of reversible azoospermia. Int Urol Nephrol (2007); 39: 905.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>905</start></extent></part><relatedItem type="host"><titleInfo><title>Int Urol Nephrol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>905</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit332"><titleInfo><title>Imatinib‐induced erythroderma (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mathew T, Chandrashekar L, Pulimood S, Srivastava A. Imatinib‐induced erythroderma (Letter). Australas J Dermatol (2007); 48: 193.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>48</number></detail><extent unit="pages"><start>193</start></extent></part><relatedItem type="host"><titleInfo><title>Australas J Dermatol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>48</number></detail><extent unit="pages"><start>193</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit333"><titleInfo><title>Eye complications of cetuximab therapy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Melichar B, Nemcova I. Eye complications of cetuximab therapy. Eur J Cancer Care (Engl) (2007); 16: 439.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>439</start></extent></part><relatedItem type="host"><titleInfo><title>Eur J Cancer Care (Engl)</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>439</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit334"><titleInfo><title>Ocular effects of imiquimod with treatment of eyelid melanoma in situ</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Murchison AP, Washington CV, Soloman AR, Bernardino CR. Ocular effects of imiquimod with treatment of eyelid melanoma in situ. Dermatol Surg (2007); 33: 1136.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>33</number></detail><extent unit="pages"><start>1136</start></extent></part><relatedItem type="host"><titleInfo><title>Dermatol Surg</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>33</number></detail><extent unit="pages"><start>1136</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit335"><titleInfo><title>Pilot study evaluating the efficacy and toxicity of irinotecan plus oral etoposide for platinum‐ and taxane‐resistant epithelial ovarian cancer</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Nishio S, Sugiyama T, Shouji T, Yoshizaki A, Kitagawa R, Ushijima K, Kamura T. Pilot study evaluating the efficacy and toxicity of irinotecan plus oral etoposide for platinum‐ and taxane‐resistant epithelial ovarian cancer. Gynecol Oncol (2007); 106: 342.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>106</number></detail><extent unit="pages"><start>342</start></extent></part><relatedItem type="host"><titleInfo><title>Gynecol Oncol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>106</number></detail><extent unit="pages"><start>342</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit336"><titleInfo><title>Exposure‐toxicity relationships for tipifarnib in cancer patients</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Perez‐Ruixo JJ, Chen W, Zhang S, Hayes S, Chow A. Exposure‐toxicity relationships for tipifarnib in cancer patients. Br J Clin Pharmacol (2007); 64: 219.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>64</number></detail><extent unit="pages"><start>219</start></extent></part><relatedItem type="host"><titleInfo><title>Br J Clin Pharmacol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>64</number></detail><extent unit="pages"><start>219</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit337"><titleInfo><title>Isolated thrombocytopenia induced by thalidomide in a patient with multiple myeloma: Case report and review of literature</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Prasad HK, Kaushal V, Mehta P. Isolated thrombocytopenia induced by thalidomide in a patient with multiple myeloma: Case report and review of literature. Am J Hematol (2007); 82: 855.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>82</number></detail><extent unit="pages"><start>855</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Hematol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>82</number></detail><extent unit="pages"><start>855</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit338"><titleInfo><title>Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Quintas‐Cardama A, Kantarjian H, O'Brien S, Borthakur G, Bruzzi J, Munden R, Cortes J. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol (2007); 25: 3908.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>3908</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Oncol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>3908</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit339"><titleInfo><title>Cisplatin nephropathy: Is cytotoxicity avoidable? (Editorial comment)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Razzaque MS. Cisplatin nephropathy: Is cytotoxicity avoidable? (Editorial comment). Nephrol Dial Transplant (2007); 22: 2112.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><extent unit="pages"><start>2112</start></extent></part><relatedItem type="host"><titleInfo><title>Nephrol Dial Transplant</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><extent unit="pages"><start>2112</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit340"><titleInfo><title>Can sorafenib cause hyperthyroidism? (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Robinson SI, Hobday TJ, Sathanathan A, Morris JC, McWilliams RR. Can sorafenib cause hyperthyroidism? (Letter). J Chemother (2007); 19: 352.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>352</start></extent></part><relatedItem type="host"><titleInfo><title>J Chemother</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>352</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit341"><titleInfo><title>Eccrine squamous syringometaplasia associated with sunitinib therapy (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sheen YS, Huang CL, Chu CY. Eccrine squamous syringometaplasia associated with sunitinib therapy (Letter). J Eur Acad Dermatol Venereol (2007); 21: 1136.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>1136</start></extent></part><relatedItem type="host"><titleInfo><title>J Eur Acad Dermatol Venereol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>1136</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit342"><titleInfo><title>Adverse reaction caused by excipients in mercaptopurine tablets (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sims‐McCallum RP. Adverse reaction caused by excipients in mercaptopurine tablets (Letter). Ann Pharmacother (2007); 41: 1548.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>1548</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Pharmacother</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>1548</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit343"><titleInfo><title>Trastuzumab‐associated cardiac adverse effects in the herceptin adjuvant trial</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Suter TM, Procter M, Van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, Perren T, Passalacqua R, Bighin C, Klijn JGM, Ageev FT, Hitre E, Groetz J, Iwata H, Knap M, Gnant M, Muehlbauer S, Spence A, Gelber RD, Piccart‐Gebhart MJ. Trastuzumab‐associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol (2007); 25: 3859.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>3859</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Oncol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>3859</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit344"><titleInfo><title>Neurologic toxicity of intrathecal liposomal cytarabine when used for CNS prophylaxis in conjunction with the hyper‐CVAD regimen (Reply)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Thomas DA, Jabbour E, Kantarjian H, O'Brien S. Neurologic toxicity of intrathecal liposomal cytarabine when used for CNS prophylaxis in conjunction with the hyper‐CVAD regimen (Reply). Blood (2007); 110: 1698.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>110</number></detail><extent unit="pages"><start>1698</start></extent></part><relatedItem type="host"><titleInfo><title>Blood</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>110</number></detail><extent unit="pages"><start>1698</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit345"><titleInfo><title>Leuprolide acetate‐induced leukocytoclastic vasculitis</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Turk BG, Dereli T, Dereli D, Akalin T. Leuprolide acetate‐induced leukocytoclastic vasculitis. Acta Obstet Gynecol Scand (2007); 86: 892.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>86</number></detail><extent unit="pages"><start>892</start></extent></part><relatedItem type="host"><titleInfo><title>Acta Obstet Gynecol Scand</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>86</number></detail><extent unit="pages"><start>892</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit346"><titleInfo><title>Sclerodermiform aspect of arm lymphoedema after treatment with docetaxel for breast cancer (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Vignes S, Lebrun‐Vignes B. Sclerodermiform aspect of arm lymphoedema after treatment with docetaxel for breast cancer (Letter). J Eur Acad Dermatol Venereol (2007); 21: 1131.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>1131</start></extent></part><relatedItem type="host"><titleInfo><title>J Eur Acad Dermatol Venereol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>1131</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit347"><titleInfo><title>Risk factors of ototoxicity after cisplatin‐based chemoirradiation in patients with locally advanced head‐and‐neck cancer: A multivariate analysis</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Zuur CL, Simis YJ, Lansdaal PE, Hart AA, Rasch CR, Schornagel JH, Dreschler WA, Balm AJ. Risk factors of ototoxicity after cisplatin‐based chemoirradiation in patients with locally advanced head‐and‐neck cancer: A multivariate analysis. Int J Radiat Oncol Biol Phys (2007); 68: 1320.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>68</number></detail><extent unit="pages"><start>1320</start></extent></part><relatedItem type="host"><titleInfo><title>Int J Radiat Oncol Biol Phys</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>68</number></detail><extent unit="pages"><start>1320</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit348"><titleInfo><title>9. Haematological Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit349"><titleInfo><title>Safety of intravitreal injections in patients receiving warfarin anticoagulation</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Dayani PN, Siddiqi OK, Holekamp NM. Safety of intravitreal injections in patients receiving warfarin anticoagulation. Am J Ophthalmol (2007); 144: 451.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>144</number></detail><extent unit="pages"><start>451</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Ophthalmol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>144</number></detail><extent unit="pages"><start>451</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit350"><titleInfo><title>Drug‐drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Delaney JA, Opatrny L, Brophy JM, Suissa S. Drug‐drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. Can Med Assoc J (2007); 177: 347.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>177</number></detail><extent unit="pages"><start>347</start></extent></part><relatedItem type="host"><titleInfo><title>Can Med Assoc J</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>177</number></detail><extent unit="pages"><start>347</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit351"><titleInfo><title>Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non‐ST‐segment elevation acute coronary syndromes</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Fox KAA, Bassand JP, Mehta SR, Wallentin L, Theroux P, Piegas LS, Valentin V, Moccetti T, Chrolavicius S, Afzal R, Yusuf S. Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non‐ST‐segment elevation acute coronary syndromes. Ann Intern Med (2007); 147: 304.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>147</number></detail><extent unit="pages"><start>304</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Intern Med</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>147</number></detail><extent unit="pages"><start>304</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit352"><titleInfo><title>Cardiac tamponade secondary to haemopericardium in a patient on warfarin</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hong YC, Chen YG, Hsiao CT, Kuan JT, Chiu TF, Chen JC. Cardiac tamponade secondary to haemopericardium in a patient on warfarin. Emerg Med J (2007); 24: 679.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>679</start></extent></part><relatedItem type="host"><titleInfo><title>Emerg Med J</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>679</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit353"><titleInfo><title>Dyspnoea and antiplatelet agents: Revisited (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Husted S, Van Giezen JJJ. Dyspnoea and antiplatelet agents: Revisited (Letter). Int J Clin Pract (2007); 61: 1590.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>61</number></detail><extent unit="pages"><start>1590</start></extent></part><relatedItem type="host"><titleInfo><title>Int J Clin Pract</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>61</number></detail><extent unit="pages"><start>1590</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit354"><titleInfo><title>Drug interactions with warfarin: What clinicians need to know (Comment)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Juurlink DN. Drug interactions with warfarin: What clinicians need to know (Comment). Can Med Assoc J (2007); 177: 369.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>177</number></detail><extent unit="pages"><start>369</start></extent></part><relatedItem type="host"><titleInfo><title>Can Med Assoc J</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>177</number></detail><extent unit="pages"><start>369</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit355"><titleInfo><title>Safety and efficiency of recombinant activated factor VII in postcardiotomy massive hemorrhage</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lamarche Y, Demers P, Poirier NC, Robitaille D, Cartier R. Safety and efficiency of recombinant activated factor VII in postcardiotomy massive hemorrhage. Can J Cardiol (2007); 23: 809.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>809</start></extent></part><relatedItem type="host"><titleInfo><title>Can J Cardiol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>809</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit356"><titleInfo><title>Early edema in warfarin‐related intracerebal hemorrhage</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Levine JM, Snider R, Finkelstein D, Gurol ME, Chanderraj R, Smith EE, Greenberg SM, Rosand J. Early edema in warfarin‐related intracerebal hemorrhage. Neurocrit Care (2007); 7: 58.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>58</start></extent></part><relatedItem type="host"><titleInfo><title>Neurocrit Care</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>58</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit357"><titleInfo><title>Interaction between warfarin and cranberry juice</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Paeng CH, Sprague M, Jackevicius CA. Interaction between warfarin and cranberry juice. Clin Ther (2007); 29: 1730.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>1730</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Ther</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>1730</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit358"><titleInfo><title>Heparin‐induced thrombocytopenia: A frequent complication after cardiac surgery (French, English Abstract)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Pouplard C, Regina S, May MA, Gruel Y. Heparin‐induced thrombocytopenia: A frequent complication after cardiac surgery (French, English Abstract). Arch Mal Coeur Vaiss (2007); 100: 563.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>100</number></detail><extent unit="pages"><start>563</start></extent></part><relatedItem type="host"><titleInfo><title>Arch Mal Coeur Vaiss</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>100</number></detail><extent unit="pages"><start>563</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit359"><titleInfo><title>Dyspnoea after AZD 6140: Blaming the messenger (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Serebruany VL, Stebbing J. Dyspnoea after AZD 6140: Blaming the messenger (Letter). Int J Clin Pract (2007); 61: 1591.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>61</number></detail><extent unit="pages"><start>1591</start></extent></part><relatedItem type="host"><titleInfo><title>Int J Clin Pract</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>61</number></detail><extent unit="pages"><start>1591</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit360"><titleInfo><title>Meta‐analysis: The utility and safety of heparin in the treatment of active ulcerative colitis</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Shen J, Ran ZH, Tong JL, Xiao SD. Meta‐analysis: The utility and safety of heparin in the treatment of active ulcerative colitis. Aliment Pharmacol Ther (2007); 26: 653.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>653</start></extent></part><relatedItem type="host"><titleInfo><title>Aliment Pharmacol Ther</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>653</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit361"><titleInfo><title>Pegfilgrastin‐induced hyperleukocytosis</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Snyder RL, Stringham DJ. Pegfilgrastin‐induced hyperleukocytosis. Ann Pharmacother (2007); 41: 1524.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>1524</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Pharmacother</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>1524</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit362"><titleInfo><title>10. Neuroregulator‐Blocking Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit363"><titleInfo><title>Safety of levocetirizine treatment in young atopic children: An 18‐month study</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Estelle F, Simons R. Safety of levocetirizine treatment in young atopic children: An 18‐month study. Pediatr Allergy Immunol (2007); 18: 535.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>535</start></extent></part><relatedItem type="host"><titleInfo><title>Pediatr Allergy Immunol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>535</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit364"><titleInfo><title>Sibutramine usage in New Zealand: An analysis of prescription data by the Intensive Medicines Monitoring Programme</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hill GR, Ashton J, Harrison‐Woolrych M. Sibutramine usage in New Zealand: An analysis of prescription data by the Intensive Medicines Monitoring Programme. Pharmacoepidemiol Drug Saf (2007); 16: 1217.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1217</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1217</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit365"><titleInfo><title>Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Zeltser D, Rosansky S, Van Rensburg H, Verbalis JG, Smith N. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol (2007); 27: 447.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>447</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Nephrol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>447</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit366"><titleInfo><title>11. Dermatological Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit367"><titleInfo><title>A double, blinded, randomized, vehicle‐controlled, multicenter, parallel‐group study to assess the safety and efficacy of tretinoin gel microsphere 0.04% in the treatment of acne vulgaris in adults</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Berger R, Barba A, Fleischer A, Leyden JJ, Lucky A, Pariser D, Rafal E, Thiboutot D, Wilson D, Grossman R, Nighland M. A double, blinded, randomized, vehicle‐controlled, multicenter, parallel‐group study to assess the safety and efficacy of tretinoin gel microsphere 0.04% in the treatment of acne vulgaris in adults. Cutis (2007); 80: 152.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>80</number></detail><extent unit="pages"><start>152</start></extent></part><relatedItem type="host"><titleInfo><title>Cutis</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>80</number></detail><extent unit="pages"><start>152</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit368"><titleInfo><title>A simple intervention to improve safety in methotrexate prescribing (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Birnie AJ, Littlewood SM. A simple intervention to improve safety in methotrexate prescribing (Letter). Australas J Dermatol (2007); 48: 134.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>48</number></detail><extent unit="pages"><start>134</start></extent></part><relatedItem type="host"><titleInfo><title>Australas J Dermatol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>48</number></detail><extent unit="pages"><start>134</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit369"><titleInfo><title>Monitoring people treated with isotretinoin for depression</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Brasic JR. Monitoring people treated with isotretinoin for depression. Psychol Rep (2007); 100: 1312.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>100</number></detail><extent unit="pages"><start>1312</start></extent></part><relatedItem type="host"><titleInfo><title>Psychol Rep</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>100</number></detail><extent unit="pages"><start>1312</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit370"><titleInfo><title>Acute myopia while on oral isotretinoin treatment (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Martinez‐Gonzalez MC, Garcia‐Silva J, Sanchez MA, Castineiras I, Del Pozo J, Capdevila EF. Acute myopia while on oral isotretinoin treatment (Letter). J Eur Acad Dermatol Venereol (2007); 21: 977.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>977</start></extent></part><relatedItem type="host"><titleInfo><title>J Eur Acad Dermatol Venereol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>977</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit371"><titleInfo><title>12. Immunosuppressive Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit372"><titleInfo><title>Thalidomide‐induced hypothyroidism (Letter) (Spanish)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bermudez Rodriguez A, Palazuelos Blanco LR, Gonzalez Diaz CI, Amado Senaris JA. Thalidomide‐induced hypothyroidism (Letter) (Spanish). Med Clin (Barc) (2007); 129: 318.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>129</number></detail><extent unit="pages"><start>318</start></extent></part><relatedItem type="host"><titleInfo><title>Med Clin (Barc)</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>129</number></detail><extent unit="pages"><start>318</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit373"><titleInfo><title>Sirolimus therapy of focal segmental glomerulosclerosis is associated with nephrotoxicity</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Cho ME, Hurley JK, Kopp JB. Sirolimus therapy of focal segmental glomerulosclerosis is associated with nephrotoxicity. Am J Kidney Dis (2007); 49: 310.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>49</number></detail><extent unit="pages"><start>310</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Kidney Dis</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>49</number></detail><extent unit="pages"><start>310</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit374"><titleInfo><title>Development of psoriasis after B cell depletion with rituximab</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Dass S, Vital EM, Emery P. Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum (2007); 56: 2715.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>56</number></detail><extent unit="pages"><start>2715</start></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheum</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>56</number></detail><extent unit="pages"><start>2715</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit375"><titleInfo><title>Hypersensitivity pneumonitis associated with leflunomide therapy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Martin N, Innes JA, Lambert CM, Turnbull CM, Wallace WAH. Hypersensitivity pneumonitis associated with leflunomide therapy. J Rheumatol (2007); 34: 1934.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>34</number></detail><extent unit="pages"><start>1934</start></extent></part><relatedItem type="host"><titleInfo><title>J Rheumatol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>34</number></detail><extent unit="pages"><start>1934</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit376"><titleInfo><title>Fatal Pseudomonas pneumonia following rituximab therapy in a patient with epidermolysis bullosa acquisita (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mercader P, Rodenas JM, Pena A, Mascaro JM. Fatal Pseudomonas pneumonia following rituximab therapy in a patient with epidermolysis bullosa acquisita (Letter). J Eur Acad Dermatol Venereol (2007); 21: 1141.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>1141</start></extent></part><relatedItem type="host"><titleInfo><title>J Eur Acad Dermatol Venereol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>1141</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit377"><titleInfo><title>Lenalidomide‐induced myelosuppression is associated with renal dysfunction: Adverse events evaluation of treatment‐naive patients undergoing front‐line lenalidomide and dexamethasone therapy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Niesvizky R, Naib T, Christos PJ, Jayabalan D, Furst JR, Jalbrzikowski J, Zafar F, Mark T, Lent R, Pearse RN, Ely S, Leonard JP, Mazumdar M, Chen‐Kiang S, Coleman M. Lenalidomide‐induced myelosuppression is associated with renal dysfunction: Adverse events evaluation of treatment‐naive patients undergoing front‐line lenalidomide and dexamethasone therapy. Br J Haematol (2007); 138: 640.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>138</number></detail><extent unit="pages"><start>640</start></extent></part><relatedItem type="host"><titleInfo><title>Br J Haematol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>138</number></detail><extent unit="pages"><start>640</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit378"><titleInfo><title>Should we test TPMT enzyme levels before starting azathioprine?</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Richard VS, Al‐Ismail D, Salamat A. Should we test TPMT enzyme levels before starting azathioprine?. Hematology (2007); 12: 359.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>12</number></detail><extent unit="pages"><start>359</start></extent></part><relatedItem type="host"><titleInfo><title>Hematology</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>12</number></detail><extent unit="pages"><start>359</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit379"><titleInfo><title>Pancytopenia related to low‐dose methotrexate: Study of five cases and review of the literature</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Serraj K, Federici L, Maloisel F, Alt M, Andres E. Pancytopenia related to low‐dose methotrexate: Study of five cases and review of the literature. Rev Med Interne (2007); 28: 584.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>584</start></extent></part><relatedItem type="host"><titleInfo><title>Rev Med Interne</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>584</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit380"><titleInfo><title>Optimizing drug safety by drug monitoring. Example of immunosuppressive therapy in pediatric nephrology (German, English Abstract)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Weber LT. Optimizing drug safety by drug monitoring. Example of immunosuppressive therapy in pediatric nephrology (German, English Abstract). Monatsschr Kinderheilk (2007); 155: 724.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>155</number></detail><extent unit="pages"><start>724</start></extent></part><relatedItem type="host"><titleInfo><title>Monatsschr Kinderheilk</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>155</number></detail><extent unit="pages"><start>724</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit381"><titleInfo><title>13. Autonomic Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit382"><titleInfo><title>Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome (Reply)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Abrams P, Cardozo L, Chapple C, Serdarevic D, Hargreaves K, Khullar V. Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome (Reply). Int J Urol (2007); 14: 670.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><extent unit="pages"><start>670</start></extent></part><relatedItem type="host"><titleInfo><title>Int J Urol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><extent unit="pages"><start>670</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit383"><titleInfo><title>Memantine‐induced decompensation in a patient with Lewy body dementia (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Alisky JM. Memantine‐induced decompensation in a patient with Lewy body dementia (Letter). Ann Acad Med Singapore (2007); 36: 707.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>36</number></detail><extent unit="pages"><start>707</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Acad Med Singapore</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>36</number></detail><extent unit="pages"><start>707</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit384"><titleInfo><title>New onset heightened interest or drive for gambling, shopping, eating or sexual activity in patients with Parkinson's disease: The rote of dopamine agonist treatment and age at motor symptoms onset</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Giladi N, Weitzman N, Schreiber S, Shabati H, Peretz C. New onset heightened interest or drive for gambling, shopping, eating or sexual activity in patients with Parkinson's disease: The rote of dopamine agonist treatment and age at motor symptoms onset. J Psychopharmacol (2007); 21: 501.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>501</start></extent></part><relatedItem type="host"><titleInfo><title>J Psychopharmacol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>501</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit385"><titleInfo><title>Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: A meta‐analysis of randomised controlled trials</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: A meta‐analysis of randomised controlled trials. Lancet Neurol (2007); 6: 782.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>6</number></detail><extent unit="pages"><start>782</start></extent></part><relatedItem type="host"><titleInfo><title>Lancet Neurol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>6</number></detail><extent unit="pages"><start>782</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit386"><titleInfo><title>Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson's disease</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lees AJ, Ratziu V, Tolosa E, Oertel WH. Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson's disease. J Neurol Neurosurg Psychiatry (2007); 78: 944.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>78</number></detail><extent unit="pages"><start>944</start></extent></part><relatedItem type="host"><titleInfo><title>J Neurol Neurosurg Psychiatry</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>78</number></detail><extent unit="pages"><start>944</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit387"><titleInfo><title>Atropine fever ‐ An anesthetic dilemma (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Rewari V, Trikha A. Atropine fever ‐ An anesthetic dilemma (Letter). Pediatr Anaesth (2007); 17: 901.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>17</number></detail><extent unit="pages"><start>901</start></extent></part><relatedItem type="host"><titleInfo><title>Pediatr Anaesth</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>17</number></detail><extent unit="pages"><start>901</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit388"><titleInfo><title>A randomized double‐blind placebo‐controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Robinson D, Cardozo L, Terpstra G, Bolodeoku J. A randomized double‐blind placebo‐controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome. BJU Int (2007); 100: 840.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>100</number></detail><extent unit="pages"><start>840</start></extent></part><relatedItem type="host"><titleInfo><title>BJU Int</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>100</number></detail><extent unit="pages"><start>840</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit389"><titleInfo><title>Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Schaefer W. Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome (Letter). Int J Urol (2007); 14: 670.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><extent unit="pages"><start>670</start></extent></part><relatedItem type="host"><titleInfo><title>Int J Urol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><extent unit="pages"><start>670</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit390"><titleInfo><title>Drug related problems with antiparkinsonian agents: Consumer Internet reports versus published data</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Schroder S, Zollner YF, Schaefer M. Drug related problems with antiparkinsonian agents: Consumer Internet reports versus published data. Pharmacoepidemiol Drug Saf (2007); 16: 1161.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1161</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1161</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit391"><titleInfo><title>14. Respiratory System Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit392"><titleInfo><title>A randomized, double‐blind, parallel‐group study to compare the efficacy and safety of a once‐daily loratadine‐pseudoephedrine combination with that of a twice‐daily loratadine‐pseudoephedrine combination in the treatment of allergic rhinitis</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Chen YA, Chang KP, Lin YS, Hao SP. A randomized, double‐blind, parallel‐group study to compare the efficacy and safety of a once‐daily loratadine‐pseudoephedrine combination with that of a twice‐daily loratadine‐pseudoephedrine combination in the treatment of allergic rhinitis. Eur Arch Otorhinolaryngol (2007); 264: 1019.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>264</number></detail><extent unit="pages"><start>1019</start></extent></part><relatedItem type="host"><titleInfo><title>Eur Arch Otorhinolaryngol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>264</number></detail><extent unit="pages"><start>1019</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit393"><titleInfo><title>Inhaled corticosteroids and the risk of fracture in chronic obstructive pulmonary disease</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Pujades‐Rodriguez M, Smith QP, Hubbard RB. Inhaled corticosteroids and the risk of fracture in chronic obstructive pulmonary disease. Q J Med (2007); 100: 509.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>100</number></detail><extent unit="pages"><start>509</start></extent></part><relatedItem type="host"><titleInfo><title>Q J Med</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>100</number></detail><extent unit="pages"><start>509</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit394"><titleInfo><title>Long‐term safety of fluticasone furoate nasal spray in adults and adolescents with perennial allergic rhinitis</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Rosenblut A, Bardin PG, Muller B, Faris MA, Wu WW, Caldwell MF, Fokkens WJ. Long‐term safety of fluticasone furoate nasal spray in adults and adolescents with perennial allergic rhinitis. Allergy (2007); 62: 1071.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>62</number></detail><extent unit="pages"><start>1071</start></extent></part><relatedItem type="host"><titleInfo><title>Allergy</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>62</number></detail><extent unit="pages"><start>1071</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit395"><titleInfo><title>15. Neuromuscular Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit396"><titleInfo><title>Carisoprodol use and abuse in Norway. A pharmacoepidemiological study</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bramness JG, Furu K, Engeland A, Skurtveit S. Carisoprodol use and abuse in Norway. A pharmacoepidemiological study. Br J Clin Pharmacol (2007); 64: 210.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>64</number></detail><extent unit="pages"><start>210</start></extent></part><relatedItem type="host"><titleInfo><title>Br J Clin Pharmacol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>64</number></detail><extent unit="pages"><start>210</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit397"><titleInfo><title>Reversal of rocuronium‐induced (1.2 mg/kg) profound neuromuscular block by sugammadex ‐ A multicenter, dosefinding and safety study</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">De Boer HD, Driessen JJ, Marcus MAE, Kerkkamp H, Heeringa M, Klimek M. Reversal of rocuronium‐induced (1.2 mg/kg) profound neuromuscular block by sugammadex ‐ A multicenter, dosefinding and safety study. Anesthesiology (2007); 107: 239.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>107</number></detail><extent unit="pages"><start>239</start></extent></part><relatedItem type="host"><titleInfo><title>Anesthesiology</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>107</number></detail><extent unit="pages"><start>239</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit398"><titleInfo><title>Re: Masseter spasm after succinylcholine administration (Reply)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gill M, Graeme K, Guenterberg K. Re: Masseter spasm after succinylcholine administration (Reply). J Emerg Med (2007); 33: 76.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>33</number></detail><extent unit="pages"><start>76</start></extent></part><relatedItem type="host"><titleInfo><title>J Emerg Med</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>33</number></detail><extent unit="pages"><start>76</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit399"><titleInfo><title>Re: Masseter spasm after succinylcholine administration (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Girard T, Ummenhofer W. Re: Masseter spasm after succinylcholine administration (Letter). J Emerg Med (2007); 33: 75.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>33</number></detail><extent unit="pages"><start>75</start></extent></part><relatedItem type="host"><titleInfo><title>J Emerg Med</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>33</number></detail><extent unit="pages"><start>75</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit400"><titleInfo><title>Severe anaphylactic reactions due to relaxants: From hazard to risk‐taking? (Letter) (French)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Leclerc C. Severe anaphylactic reactions due to relaxants: From hazard to risk‐taking? (Letter) (French). Ann Fr Anesth Reanim (2007); 26: 616.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>616</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Fr Anesth Reanim</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>616</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit401"><titleInfo><title>Skin reactions to intradermal neuromuscular blocking agent injections ‐ A randomized multicenter trial in healthy volunteers</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mertes PM, Moneret‐Vautrin DA, Leynadier F, Laxenaire MC. Skin reactions to intradermal neuromuscular blocking agent injections ‐ A randomized multicenter trial in healthy volunteers. Anesthesiology (2007); 107: 245.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>107</number></detail><extent unit="pages"><start>245</start></extent></part><relatedItem type="host"><titleInfo><title>Anesthesiology</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>107</number></detail><extent unit="pages"><start>245</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit402"><titleInfo><title>Cutaneous reactions secondary with anaesthetic induction with mivacurium (Letter) (French)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Miloudi Y, El Harrar N, Bensaid A, Hussein MA. Cutaneous reactions secondary with anaesthetic induction with mivacurium (Letter) (French). Ann Fr Anesth Reanim (2007); 26: 717.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>717</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Fr Anesth Reanim</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>717</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit403"><titleInfo><title>Prevention of withdrawal movement associated with injection of rocuronium in children: Comparison of remifentanil, alfentanil and fentanyl</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Oh AY, Seo KS, Goo EK, Park YO, Kim SJ, Kim JH. Prevention of withdrawal movement associated with injection of rocuronium in children: Comparison of remifentanil, alfentanil and fentanyl. Acta Anaesthesiol Scand (2007); 51: 1190.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>51</number></detail><extent unit="pages"><start>1190</start></extent></part><relatedItem type="host"><titleInfo><title>Acta Anaesthesiol Scand</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>51</number></detail><extent unit="pages"><start>1190</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit404"><titleInfo><title>16. Reproductive System Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit405"><titleInfo><title>Encephalopathy and psychosis following administration of the combined oral contraceptive pill in an 11‐year‐old female</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Busby G, Bancroft K. Encephalopathy and psychosis following administration of the combined oral contraceptive pill in an 11‐year‐old female. Gynecol Endocrinol (2007); 23: 361.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>361</start></extent></part><relatedItem type="host"><titleInfo><title>Gynecol Endocrinol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>361</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit406"><titleInfo><title>Retinal venous occlusion associated with depot medroxyprogesterone acetate (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Deen BF, Shuler RK, Fekrat S. Retinal venous occlusion associated with depot medroxyprogesterone acetate (Letter). Br J Ophthalmol (2007); 91: 1254.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>91</number></detail><extent unit="pages"><start>1254</start></extent></part><relatedItem type="host"><titleInfo><title>Br J Ophthalmol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>91</number></detail><extent unit="pages"><start>1254</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit407"><titleInfo><title>Three cases of endometrial cancer associated with “bioidentical” hormone replacement therapy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Eden JA, Hacker NF, Fortune M. Three cases of endometrial cancer associated with “bioidentical” hormone replacement therapy. Med J Aust (2007); 187: 244.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>187</number></detail><extent unit="pages"><start>244</start></extent></part><relatedItem type="host"><titleInfo><title>Med J Aust</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>187</number></detail><extent unit="pages"><start>244</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit408"><titleInfo><title>Cancer risk among users of oral contraceptives: Cohort data from the Royal College of General Practitioners' oral contraception study</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hannaford PC, Selvaraj S, Elliott AM, Angus V, Iversen L, Lee AJ. Cancer risk among users of oral contraceptives: Cohort data from the Royal College of General Practitioners' oral contraception study. Br Med J (2007); 335: 651.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>335</number></detail><extent unit="pages"><start>651</start></extent></part><relatedItem type="host"><titleInfo><title>Br Med J</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>335</number></detail><extent unit="pages"><start>651</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit409"><titleInfo><title>Risk of cancer and the oral contraceptive pill (Editorial comment)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Meirik O, Farley TMM. Risk of cancer and the oral contraceptive pill (Editorial comment). Br Med J (2007); 335: 621.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>335</number></detail><extent unit="pages"><start>621</start></extent></part><relatedItem type="host"><titleInfo><title>Br Med J</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>335</number></detail><extent unit="pages"><start>621</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit410"><titleInfo><title>Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Seeger JD, Loughlin J, Eng PM, Clifford CR, Cutone J, Walker AM. Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives. Obstet Gynecol (2007); 110: 587.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>110</number></detail><extent unit="pages"><start>587</start></extent></part><relatedItem type="host"><titleInfo><title>Obstet Gynecol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>110</number></detail><extent unit="pages"><start>587</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit411"><titleInfo><title>A case report of recurrent endometriosis following tibolone hormone replacement therapy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sundar SS, Gornall RJ, Kerr‐Wilson R, Swingler GR, Kinder RB, McCarthy K. A case report of recurrent endometriosis following tibolone hormone replacement therapy. J Obstet & Gynaecol (2007); 27: 433.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>433</start></extent></part><relatedItem type="host"><titleInfo><title>J Obstet & Gynaecol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>433</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit412"><titleInfo><title>17. Gastrointestinal System Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit413"><titleInfo><title>Severe pulmonary toxicity after azathioprine/6‐mercaptopurine initiation for the treatment of inflammatory bowel disease</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ananthakrishnan AN, Attila T, Otterson MF, Lipchik RJ, Massey BT, Komorowski RA, Binion DG. Severe pulmonary toxicity after azathioprine/6‐mercaptopurine initiation for the treatment of inflammatory bowel disease. J Clin Gastroenterol (2007); 41: 682.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>682</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Gastroenterol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>682</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit414"><titleInfo><title>Another paradox on Crohn's disease: New onset of psoriasis in a patient receiving tumour necrosis factor‐α antagonist (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Angelucci E, Cocco A, Viscido A, Vernia P, Caprilli R. Another paradox on Crohn's disease: New onset of psoriasis in a patient receiving tumour necrosis factor‐α antagonist (Letter). Inflamm Bowel Dis (2007); 13: 1059.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>1059</start></extent></part><relatedItem type="host"><titleInfo><title>Inflamm Bowel Dis</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>1059</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit415"><titleInfo><title>Methotrexate‐induced pneumonitis in a woman with Crohn's disease (German, English Abstract)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Brechmann T, Heyer C, Schmiegel W. Methotrexate‐induced pneumonitis in a woman with Crohn's disease (German, English Abstract). Dtsch Med Wochenschr (2007); 132: 1759.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>132</number></detail><extent unit="pages"><start>1759</start></extent></part><relatedItem type="host"><titleInfo><title>Dtsch Med Wochenschr</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>132</number></detail><extent unit="pages"><start>1759</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit416"><titleInfo><title>Toxic epidermal necrosis associated with mesalamine in a patient with ulcerative colitis (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Fukunaga K, Ohda Y, Inoue T, Kono T, Miwa H, Matsumoto T. Toxic epidermal necrosis associated with mesalamine in a patient with ulcerative colitis (Letter). Inflamm Bowel Dis (2007); 13: 1055.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>1055</start></extent></part><relatedItem type="host"><titleInfo><title>Inflamm Bowel Dis</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>1055</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit417"><titleInfo><title>Crohn's disease patients' risk‐benefit preferences: Serious adverse event risks versus treatment efficacy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Johnson FR, Ozdemir S, Mansfield C, Hass S, Miller DW, Siegel CA, Sands BE. Crohn's disease patients' risk‐benefit preferences: Serious adverse event risks versus treatment efficacy. Gastroenterology (2007); 133: 769.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>133</number></detail><extent unit="pages"><start>769</start></extent></part><relatedItem type="host"><titleInfo><title>Gastroenterology</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>133</number></detail><extent unit="pages"><start>769</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit418"><titleInfo><title>Meta‐analysis: Inosine triphosphate pyrophosphatase polymorphisms and thiopurine toxicity in the treatment of inflammatory bowel disease</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Van Dieren JM, Hansen BE, Kuipers EJ, Nieuwenhuis EES, Van der Woude CJ. Meta‐analysis: Inosine triphosphate pyrophosphatase polymorphisms and thiopurine toxicity in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther (2007); 26: 643.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>643</start></extent></part><relatedItem type="host"><titleInfo><title>Aliment Pharmacol Ther</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>643</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit419"><titleInfo><title>18. Anti‐inflammatory Agents ‐ Steroidal</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit420"><titleInfo><title>Safety and efficacy of intraoperative intravitreal injection of triamcinolone acetonide injection after phacoemulsification in cases of uveitic cataract</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Dada T, Dhawan M, Garg S, Nair S, Mandal S. Safety and efficacy of intraoperative intravitreal injection of triamcinolone acetonide injection after phacoemulsification in cases of uveitic cataract. J Cataract Refract Surg (2007); 33: 1613.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>33</number></detail><extent unit="pages"><start>1613</start></extent></part><relatedItem type="host"><titleInfo><title>J Cataract Refract Surg</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>33</number></detail><extent unit="pages"><start>1613</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit421"><titleInfo><title>Corticosteroid‐induced lipodystrophy is associated with features of the metabolic syndrome</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Fardet L, Cabane J, Kettaneh A, Lebbe C, Flahault A. Corticosteroid‐induced lipodystrophy is associated with features of the metabolic syndrome. Rheumatology (2007); 46: 1102.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>1102</start></extent></part><relatedItem type="host"><titleInfo><title>Rheumatology</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>1102</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit422"><titleInfo><title>Repeated pseudoendophthalmitis after combined photodynamic therapy and intravitreal triamcinolone (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Marticorena J, Gomez‐Ulla F, Romano MR, Luna I. Repeated pseudoendophthalmitis after combined photodynamic therapy and intravitreal triamcinolone (Letter). Graefes Arch Clin Exp Ophthalmol (2007); 245: 1403.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>245</number></detail><extent unit="pages"><start>1403</start></extent></part><relatedItem type="host"><titleInfo><title>Graefes Arch Clin Exp Ophthalmol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>245</number></detail><extent unit="pages"><start>1403</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit423"><titleInfo><title>Withdrawal acute psychosis after corticosteroid discontinuation (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mercadante S, Villari P, Intravaia G. Withdrawal acute psychosis after corticosteroid discontinuation (Letter). J Pain Symptom Manage (2007); 34: 118.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>34</number></detail><extent unit="pages"><start>118</start></extent></part><relatedItem type="host"><titleInfo><title>J Pain Symptom Manage</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>34</number></detail><extent unit="pages"><start>118</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit424"><titleInfo><title>Type IV‐allergy due to corticosteroids (German, English Abstract)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Plaza T, Nist G, Den Driesch PV. Type IV‐allergy due to corticosteroids (German, English Abstract). Dtsch Med Wochenschr (2007); 132: 1692.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>132</number></detail><extent unit="pages"><start>1692</start></extent></part><relatedItem type="host"><titleInfo><title>Dtsch Med Wochenschr</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>132</number></detail><extent unit="pages"><start>1692</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit425"><titleInfo><title>19. Teratogens/fetal exposure</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit426"><titleInfo><title>Gold therapy in women planning pregnancy: Outcomes in one center</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Almarzouqi M, Scarsbrook D, Klinkhoff A. Gold therapy in women planning pregnancy: Outcomes in one center. J Rheumatol (2007); 34: 1827.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>34</number></detail><extent unit="pages"><start>1827</start></extent></part><relatedItem type="host"><titleInfo><title>J Rheumatol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>34</number></detail><extent unit="pages"><start>1827</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit427"><titleInfo><title>Promise and pitfalls of administrative data in evaluating pregnancy outcomes (Commentary)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Andrews EB, Tennis P. Promise and pitfalls of administrative data in evaluating pregnancy outcomes (Commentary). Pharmacoepidemiol Drug Saf (2007); 16: 1181.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1181</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1181</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit428"><titleInfo><title>Antenatal betamethasone during pregnancy with severe diabetes: Is better worse than good? (French, English Abstract)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Barondiot C, Morel O, Vieux R, Sery GA, Floriot M, Hascoet JM. Antenatal betamethasone during pregnancy with severe diabetes: Is better worse than good? (French, English Abstract). Arch Pediatr (2007); 14: 989.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><extent unit="pages"><start>989</start></extent></part><relatedItem type="host"><titleInfo><title>Arch Pediatr</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><extent unit="pages"><start>989</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit429"><titleInfo><title>Treatment of acromegaly with pegvisomant during pregnancy: Maternal and fetal effects</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Brian SR, Bidlingmaier M, Wajnrajch MP, Weinzimer SA, Inzucchi SE. Treatment of acromegaly with pegvisomant during pregnancy: Maternal and fetal effects. J Clin Endocrinol Metab (2007); 92: 3374.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>92</number></detail><extent unit="pages"><start>3374</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Endocrinol Metab</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>92</number></detail><extent unit="pages"><start>3374</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit430"><titleInfo><title>Paroxetine in the first trimester and the prevalence of congenital malformations</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Cole JA, Ephross SA, Cosmatos IS, Walker AM. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf (2007); 16: 1075.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1075</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1075</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit431"><titleInfo><title>Fetal anticonvulsant syndromes and polymorphisms in MTHFR, MTR, and MTRR</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Dean J, Robertson Z, Reid V, Wang QD, Hailey H, Moore S, Rasalam AD, Turnpenny P, Lloyd D, Cardy A, Shaw D, Little J. Fetal anticonvulsant syndromes and polymorphisms in MTHFR, MTR, and MTRR. Am J Med Genet (2007); 143A: 2303.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>143A</number></detail><extent unit="pages"><start>2303</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Med Genet</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>143A</number></detail><extent unit="pages"><start>2303</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit432"><titleInfo><title>Olanzapine exposure during pregnancy (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Dervaux A, Ichou P, Pierron G, Devianne F, Bavoux F. Olanzapine exposure during pregnancy (Letter). Aust N Z J Psychiatry (2007); 41: 706.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>706</start></extent></part><relatedItem type="host"><titleInfo><title>Aust N Z J Psychiatry</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>706</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit433"><titleInfo><title>Pregnancy after liver transplantation with tacrolimus (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ducarme G, Theron‐Gerard L, Duvoux C, Uzan M, Poncelet C. Pregnancy after liver transplantation with tacrolimus (Letter). Eur J Obstet Gynecol Reprod Biol (2007); 133: 249.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>133</number></detail><extent unit="pages"><start>249</start></extent></part><relatedItem type="host"><titleInfo><title>Eur J Obstet Gynecol Reprod Biol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>133</number></detail><extent unit="pages"><start>249</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit434"><titleInfo><title>Angiotensin‐converting enzyme inhibitor fetopathy: Long‐term outcome</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Laube GF, Kemper MJ, Schubiger G, Neuhaus TJ. Angiotensin‐converting enzyme inhibitor fetopathy: Long‐term outcome. Arch Dis Child Fetal Neonatal Ed (2007); 92: F402.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>92</number></detail><extent unit="pages"><start>F402</start></extent></part><relatedItem type="host"><titleInfo><title>Arch Dis Child Fetal Neonatal Ed</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>92</number></detail><extent unit="pages"><start>F402</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit435"><titleInfo><title>Atypical antipsychotic administration during late pregnancy: Placental passage and obstetrical outcomes</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Newport DJ, Calarnaras MR, DeVane CL, Donovan J, Beach AJ, Winn S, Knight BT, Gibson BB, Viguera AC, Owens MJ, Nemeroff CB, Stowe ZN. Atypical antipsychotic administration during late pregnancy: Placental passage and obstetrical outcomes. Am J Psychiatry (2007); 164: 1214.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>164</number></detail><extent unit="pages"><start>1214</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Psychiatry</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>164</number></detail><extent unit="pages"><start>1214</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit436"><titleInfo><title>Birth outcomes following prenatal exposure to antidepressants</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Pearson KH, Nonacs RM, Vigueya AC, Heller VL, Petrillo LF, Brandes M, Hennen J, Cohen LS. Birth outcomes following prenatal exposure to antidepressants. J Clin Psychiatry (2007); 68: 1284.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>68</number></detail><extent unit="pages"><start>1284</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Psychiatry</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>68</number></detail><extent unit="pages"><start>1284</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit437"><titleInfo><title>The treatment of Hodgkin's and non‐Hodgkin's lymphoma in pregnancy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Pereg D, Koren G, Lishner M. The treatment of Hodgkin's and non‐Hodgkin's lymphoma in pregnancy. Haematologica (2007); 92: 1230.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>92</number></detail><extent unit="pages"><start>1230</start></extent></part><relatedItem type="host"><titleInfo><title>Haematologica</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>92</number></detail><extent unit="pages"><start>1230</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit438"><titleInfo><title>Adriamycin and cyclophosphamide chemotherapy in advanced breast cancer in pregnancy (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Skrablin S, Matkovic V, Matkovi V. Adriamycin and cyclophosphamide chemotherapy in advanced breast cancer in pregnancy (Letter). Eur J Obstet Gynecol Reprod Biol (2007); 133: 251.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>133</number></detail><extent unit="pages"><start>251</start></extent></part><relatedItem type="host"><titleInfo><title>Eur J Obstet Gynecol Reprod Biol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>133</number></detail><extent unit="pages"><start>251</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit439"><titleInfo><title>Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Suri R, Altshuler L, Hellemann G, Burt VK, Aquino A, Mintz J. Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth. Am J Psychiatry (2007); 164: 1206.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>164</number></detail><extent unit="pages"><start>1206</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Psychiatry</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>164</number></detail><extent unit="pages"><start>1206</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit440"><titleInfo><title>The contribution of fetal drug exposure to temperament: Potential teratogenic effects on neuropsychiatric risk</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Weiss SJ, Jonn‐Seed MS, Harris‐Muchell C. The contribution of fetal drug exposure to temperament: Potential teratogenic effects on neuropsychiatric risk. J Child Psychol Psychiatry (2007); 48: 773.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>48</number></detail><extent unit="pages"><start>773</start></extent></part><relatedItem type="host"><titleInfo><title>J Child Psychol Psychiatry</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>48</number></detail><extent unit="pages"><start>773</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit441"><titleInfo><title>Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: Neonatal outcome and congenital malformations</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wikner BN, Stiller CO, Bergman U, Asker C, Kallen B. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: Neonatal outcome and congenital malformations. Pharmacoepidemiol Drug Saf (2007); 16: 1203.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1203</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1203</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit442"><titleInfo><title>Secondary sex ratio among women exposed to diethylstilbestrol in utero</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wise LA, Palmer JR, Hatch EE, Troisi R, Titus‐Ernstoff L, Herbst AL, Kautman R, Noller KL, Hoover RN. Secondary sex ratio among women exposed to diethylstilbestrol in utero. Environ Health Perspect (2007); 115: 1314.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>115</number></detail><extent unit="pages"><start>1314</start></extent></part><relatedItem type="host"><titleInfo><title>Environ Health Perspect</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>115</number></detail><extent unit="pages"><start>1314</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit443"><titleInfo><title>20. Others</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit444"><titleInfo><title>Granulomatous reaction to injectable hyaluronic acid (Restylane) diagnosed by fine needle biopsy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Al‐Shraim M, Jaragh M, Geddie W. Granulomatous reaction to injectable hyaluronic acid (Restylane) diagnosed by fine needle biopsy. J Clin Pathol (2007); 60: 1060.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>1060</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Pathol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>1060</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit445"><titleInfo><title>Rosiglitazone and myocardial infarction: Cause for concern or misleading meta‐analysis? (Editorial)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bilous RW. Rosiglitazone and myocardial infarction: Cause for concern or misleading meta‐analysis? (Editorial). Diabet Med (2007); 24: 931.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>931</start></extent></part><relatedItem type="host"><titleInfo><title>Diabet Med</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>931</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit446"><titleInfo><title>Renal insufficiency following contrast media administration trial (REMEDIAL): A Randomized comparison of 3 preventive strategies (Reply)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Briguori C, D'Andrea D, Focaccio A, Ricciardelli B, Airoldi F, Morici N, Michev I, Montorfano M, Carlino M, Cosgrave J et al. Renal insufficiency following contrast media administration trial (REMEDIAL): A Randomized comparison of 3 preventive strategies (Reply). Circulation (2007); 116: e311.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>116</number></detail><extent unit="pages"><start>e311</start></extent></part><relatedItem type="host"><titleInfo><title>Circulation</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>116</number></detail><extent unit="pages"><start>e311</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit447"><titleInfo><title>A comment on ‘the risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy’ (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Chang Y, Choi NK, Hahn S, Park BJ. A comment on ‘the risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy’ (Letter). Pharmacoepidemiol Drug Saf (2007); 16: 1072.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1072</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1072</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit448"><titleInfo><title>Adverse reactions to contrast media: An analysis from spontaneous reporting data</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Cutroneo P, Polimeni G, Curcuruto R, Calapai G, Caputi AP. Adverse reactions to contrast media: An analysis from spontaneous reporting data. Pharmacol Res (2007); 56: 35.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>56</number></detail><extent unit="pages"><start>35</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacol Res</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>56</number></detail><extent unit="pages"><start>35</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit449"><titleInfo><title>Thromboembolic events during continuous vasopressin infusions: A retrospective evaluation</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Doepker BA, Lucarelli MR, Lehman A, Shirk MB. Thromboembolic events during continuous vasopressin infusions: A retrospective evaluation. Ann Pharmacother (2007); 41: 1383.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>1383</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Pharmacother</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>1383</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit450"><titleInfo><title>A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gerrits CM, Bhattacharya M, Manthena S, Baran R, Perez A, Kupfer S. A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. Pharmacoepidemiol Drug Saf (2007); 16: 1065.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1065</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1065</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit451"><titleInfo><title>A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gerrits CM, Bhattacharya M, Manthena S, Baran R, Perez A, Kupfer S. A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes (Letter). Pharmacoepidemiol Drug Saf (2007); 16: 1314.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1314</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1314</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit452"><titleInfo><title>Adverse effects of incretin therapy for type 2 diabetes (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Grouzmann E, Monod M, Landis BN, Lacroix JS. Adverse effects of incretin therapy for type 2 diabetes (Letter). JAMA (2007); 298: 1759.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>298</number></detail><extent unit="pages"><start>1759</start></extent></part><relatedItem type="host"><titleInfo><title>JAMA</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>298</number></detail><extent unit="pages"><start>1759</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit453"><titleInfo><title>Efficacy and safety of the dipeptidase‐4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P. Efficacy and safety of the dipeptidase‐4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab (2007); 9: 733.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>733</start></extent></part><relatedItem type="host"><titleInfo><title>Diabetes Obes Metab</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>733</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit454"><titleInfo><title>Response to a comment on ‘the risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy’ (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Johannes CB, Seeger JD, Koro CE, Cutone JA, Quinn SG. Response to a comment on ‘the risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy’ (Letter). Pharmacoepidemiol Drug Saf (2007); 16: 1073.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1073</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1073</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit455"><titleInfo><title>Anaphylaxis to gadobenate dimeglumine (Multihance®): A case report</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kalogeromitros DC, Makris MP, Aggelides XS, Spanoudaki N, Gregoriou SG, Avgerinou G, Rigopoulos DG. Anaphylaxis to gadobenate dimeglumine (Multihance®): A case report. Int Arch Allergy Immunol (2007); 144: 150.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>144</number></detail><extent unit="pages"><start>150</start></extent></part><relatedItem type="host"><titleInfo><title>Int Arch Allergy Immunol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>144</number></detail><extent unit="pages"><start>150</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit456"><titleInfo><title>High incidence of reduced plasma HDL cholesterol in diabetic patients treated with rosiglitazone and fibrate</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Keidar S, Guttmann H, Stam T, Fishman I, Shapira C. High incidence of reduced plasma HDL cholesterol in diabetic patients treated with rosiglitazone and fibrate. Pharmacoepidemiol Drug Saf (2007); 16: 1192.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1192</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1192</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit457"><titleInfo><title>Delayed‐type hypersensitivity reaction to the meta‐cresol component of insulin</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kim D, Baraniuk J. Delayed‐type hypersensitivity reaction to the meta‐cresol component of insulin. Ann Allergy Asthma Immunol (2007); 99: 194.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>99</number></detail><extent unit="pages"><start>194</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Allergy Asthma Immunol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>99</number></detail><extent unit="pages"><start>194</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit458"><titleInfo><title>Medical therapy for diabetes is associated with increased use of lower endoscopy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lewis JD, Capra AM, Achacoso NS, Ferrara A, Levin TR, Quesenberry CP, Habel LA. Medical therapy for diabetes is associated with increased use of lower endoscopy. Pharmacoepidemiol Drug Saf (2007); 16: 1195.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1195</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1195</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit459"><titleInfo><title>Response to: Safety risks with gadolinium‐based contrast agents</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Maki JH, Prince MR. Response to: Safety risks with gadolinium‐based contrast agents. J Magn Reson Imaging (2007); 26: 817.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>817</start></extent></part><relatedItem type="host"><titleInfo><title>J Magn Reson Imaging</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>817</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit460"><titleInfo><title>Oral bisphosphonate associated osteonecrosis of the jaws: Three case reports</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Malden NJ, Pai AY. Oral bisphosphonate associated osteonecrosis of the jaws: Three case reports. Br Dent J (2007); 203: 93.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>203</number></detail><extent unit="pages"><start>93</start></extent></part><relatedItem type="host"><titleInfo><title>Br Dent J</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>203</number></detail><extent unit="pages"><start>93</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit461"><titleInfo><title>A comparison of the safety and intraocular pressure lowering of bimatoprost/timolol fixed combination versus latanoprost/timolol fixed combination in patients with open‐angle glaucoma</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Martinez A, Sanchez M. A comparison of the safety and intraocular pressure lowering of bimatoprost/timolol fixed combination versus latanoprost/timolol fixed combination in patients with open‐angle glaucoma. Curr Med Res Opin (2007); 23: 1025.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>1025</start></extent></part><relatedItem type="host"><titleInfo><title>Curr Med Res Opin</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>1025</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit462"><titleInfo><title>Safety risks with gadolinium‐based contrast agents (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Marzella L, Blank M, Gelperin K, Johann‐Liang R. Safety risks with gadolinium‐based contrast agents (Letter). J Magn Reson Imaging (2007); 26: 816.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>816</start></extent></part><relatedItem type="host"><titleInfo><title>J Magn Reson Imaging</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>816</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit463"><titleInfo><title>Comparison of usefulness of sodium bicarbonate versus sodium chloride to prevent contrast‐induced nephropathy in patients undergoing an emergent coronary procedure</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Masuda M, Yamada T, Mine T, Morita T, Tamaki S, Tsukamoto Y, Okuda K, Iwasaki Y, Hori M, Fukunami M. Comparison of usefulness of sodium bicarbonate versus sodium chloride to prevent contrast‐induced nephropathy in patients undergoing an emergent coronary procedure. Am J Cardiol (2007); 100: 781.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>100</number></detail><extent unit="pages"><start>781</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Cardiol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>100</number></detail><extent unit="pages"><start>781</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit464"><titleInfo><title>Acute phase response and mineral status following low dose intravenous zoledronic acid in children</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Munns CF, Rajab MH, Hong J, Briody J, Hogler W, McQuade M, Little DG, Cowell CT. Acute phase response and mineral status following low dose intravenous zoledronic acid in children. Bone (2007); 41: 366.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>366</start></extent></part><relatedItem type="host"><titleInfo><title>Bone</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>366</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit465"><titleInfo><title>Bisphosphonate induced osteochemonecrosis of the jaw mimicking a tumour</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Pancholi M, Edwards A, Langton S. Bisphosphonate induced osteochemonecrosis of the jaw mimicking a tumour. Br Dent J (2007); 203: 87.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>203</number></detail><extent unit="pages"><start>87</start></extent></part><relatedItem type="host"><titleInfo><title>Br Dent J</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>203</number></detail><extent unit="pages"><start>87</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit466"><titleInfo><title>Safety and pharmacokinetics of agalsidase α in patients with Fabry disease and end‐stage renal disease</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Pastores GM, Boyd E, Crandall K, Whelan A, Piersall L, Barnett N. Safety and pharmacokinetics of agalsidase α in patients with Fabry disease and end‐stage renal disease. Nephrol Dial Transplant (2007); 22: 1920.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><extent unit="pages"><start>1920</start></extent></part><relatedItem type="host"><titleInfo><title>Nephrol Dial Transplant</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><extent unit="pages"><start>1920</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit467"><titleInfo><title>Risk factors for developing gadolinium‐induced nephrogenic systemic fibrosis</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Peak AS, Sheller A. Risk factors for developing gadolinium‐induced nephrogenic systemic fibrosis. Ann Pharmacother (2007); 41: 1481.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>1481</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Pharmacother</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>1481</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit468"><titleInfo><title>Adverse effects of incretin therapy for type 2 diabetes (Reply)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Pittas AG, Amori RE, Lau J. Adverse effects of incretin therapy for type 2 diabetes (Reply). JAMA (2007); 298: 1760.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>298</number></detail><extent unit="pages"><start>1760</start></extent></part><relatedItem type="host"><titleInfo><title>JAMA</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>298</number></detail><extent unit="pages"><start>1760</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit469"><titleInfo><title>Secondary failure of glycemic control for patients adding thiazolidinedione or sulfonylurea therapy to a metformin regimen</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Riedel AA, Heien H, Wogen J, Plauschinat CA. Secondary failure of glycemic control for patients adding thiazolidinedione or sulfonylurea therapy to a metformin regimen. Am J Managed Care (2007); 13: 457.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>457</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Managed Care</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>457</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit470"><titleInfo><title>Does rosiglitazone adversely affect bone formation and bone mineral density in postmenopausal women? (Practice point)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Schwartz AV, Cummings SR. Does rosiglitazone adversely affect bone formation and bone mineral density in postmenopausal women? (Practice point). Nat Clin Pract Endocrinol Metab (2007); 3: 622.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>3</number></detail><extent unit="pages"><start>622</start></extent></part><relatedItem type="host"><titleInfo><title>Nat Clin Pract Endocrinol Metab</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>3</number></detail><extent unit="pages"><start>622</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit471"><titleInfo><title>Bisphosphonates and osteonecrosis of the jaw (Editoral)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Shenker NG, Jawad ASM. Bisphosphonates and osteonecrosis of the jaw (Editoral). Rheumatology (2007); 46: 1049.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>1049</start></extent></part><relatedItem type="host"><titleInfo><title>Rheumatology</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>1049</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit472"><titleInfo><title>Prevention of contrast‐induced nephropathy in the emergency department</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sinert R, Doty CI. Prevention of contrast‐induced nephropathy in the emergency department. Ann Emerg Med (2007); 50: 335.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>50</number></detail><extent unit="pages"><start>335</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Emerg Med</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>50</number></detail><extent unit="pages"><start>335</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit473"><titleInfo><title>Contrast media nephropathy ‐ How to diagnose and how to prevent?</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Solomon R. Contrast media nephropathy ‐ How to diagnose and how to prevent?. Nephrol Dial Transplant (2007); 22: 1812.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><extent unit="pages"><start>1812</start></extent></part><relatedItem type="host"><titleInfo><title>Nephrol Dial Transplant</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><extent unit="pages"><start>1812</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit474"><titleInfo><title>Orofacial pain ‐ A presenting symptom of bisphosphonate associated with osteonecrosis of the jaws</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Srinivasan D, Shetty S, Ashworth D, Grew N, Millar B. Orofacial pain ‐ A presenting symptom of bisphosphonate associated with osteonecrosis of the jaws. Br Dent J (2007); 203: 91.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>203</number></detail><extent unit="pages"><start>91</start></extent></part><relatedItem type="host"><titleInfo><title>Br Dent J</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>203</number></detail><extent unit="pages"><start>91</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit475"><titleInfo><title>Studies of diabetes, thiazolidinediones, and coronary heart disease (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Walker AM, McAfee AT, Koro C. Studies of diabetes, thiazolidinediones, and coronary heart disease (Letter). Pharmacoepidemiol Drug Saf (2007); 16: 1313.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1313</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacoepidemiol Drug Saf</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1313</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit476"><titleInfo><title>Renal insufficiency following contrast media administration trial (REMEDIAL): A Randomized comparison of 3 preventive strategies (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wetzels JFM. Renal insufficiency following contrast media administration trial (REMEDIAL): A Randomized comparison of 3 preventive strategies (Letter). Circulation (2007); 116: e310.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>116</number></detail><extent unit="pages"><start>e310</start></extent></part><relatedItem type="host"><titleInfo><title>Circulation</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>116</number></detail><extent unit="pages"><start>e310</start></extent></part></relatedItem></relatedItem><identifier type="istex">EC2952E26CD15CA219654F0C5AB72A0C4E7223DD</identifier><identifier type="ark">ark:/67375/WNG-M51NF9R3-6</identifier><identifier type="DOI">10.1002/pds.1485</identifier><identifier type="ArticleID">PDS1485</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2008 John Wiley & Sons, Ltd.</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-L0C46X92-X">wiley</recordContentSource><recordOrigin>Converted from (version ) to MODS version 3.6.</recordOrigin><recordCreationDate encoding="w3cdtf">2019-11-16</recordCreationDate></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-M51NF9R3-6/record.json</uri></json:item></metadata><author></author><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002792 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 002792 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:EC2952E26CD15CA219654F0C5AB72A0C4E7223DD
|texte= Current awareness: Pharmacoepidemiology and drug safety
}}
| This area was generated with Dilib version V0.6.33. |  |